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Plasticity in developmental programming has evolved in order to provide the best chances of survival and repro-
ductive success to the organism under changing environments. Environmental conditions that are experienced in
early life can profoundly influence human biology and long-term health. Developmental origins of health and
disease and life-history transitions are purported to use placental, nutritional, and endocrine cues for setting long-
term biological, mental, and behavioral strategies in response to local ecological and/or social conditions. The
window of developmental plasticity extends from preconception to early childhood and involves epigenetic re-
sponses to environmental changes, which exert their effects during life-history phase transitions. These epigenetic
responses influence development, cell- and tissue-specific gene expression, and sexual dimorphism, and, in excep-
tionalcases,couldbetransmittedtransgenerationally.Translationalepigeneticresearchinchildhealthisareiterative
process that rangesfromresearch inthebasic sciences,preclinical research,andpediatric clinical research. Identifying
the epigenetic consequences of fetal programming creates potential applications in clinical practice: the develop-
ment of epigenetic biomarkers for early diagnosis of disease, the ability to identify susceptible individuals at risk for
adult diseases, and the development of novel preventive and curativemeasures that are based ondiet and/or novel
epigenetic drugs. (Endocrine Reviews 32: 159–224, 2011)
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Abbreviations: ART, Assisted reproductive technology; ASM, allele-specific methylation;
BMI, bodymass index; BWS, Beckwith-Wiedemann syndrome; CpG, cytosine and guanine
linked by a phosphate moiety; CYP, cytochrome P450 enzyme; DNase, DNA nuclease;
DNMT, DNAmethyltransferase; DOHaD, developmental origins of health and disease; DZ,
dizygotic; E, embryonic day; EDC, endocrine-disrupting chemical; ESC, embryonic stem
cell; F1, first generation; F2, second generation; GOM, gain of methylation; GR, gluco-
corticoid receptor; GRB10, growth factor receptor-binding protein 10; GWAS, genome-
wide association study or studies; HAT, histone acetyltransferase; HC, high-carbohydrate;
HDAC, histone deacetylase; HFD, high-fat diet; HLA, human leukocyte antigen; HNF, he-
patocyte nuclear factor; HP1, heterochromatin protein 1; HPA, hypothalamic-pituitary-
adrenal; IAP, intracisternal particle; ICR, imprinting control region; ICT, infancy-childhood
transition; IUGR, intrauterine growth restriction; IVF, in vitro fertilization; lncRNA, long
ncRNA; LOM, loss of methylation; m5C, DNA cytosine methylation; miRNA, microRNA;
Momme, modifier of murine metastable epiallele; MSA, methylation-specific amplifica-
tion; MZ, monozygotic; ncRNA, noncoding RNA; NF-B, nuclear factor-B; NIMA, nonin-
heritedmaternal antigen; NIPA, noninherited paternal antigen; NR, nuclear receptor; PcG,
polycomb group (proteins); PEV, position effect variegation; PGC, primordial germ cell;
piRNA, PIWI-interacting RNA; PIWI, P-element-induced wimpy testes; PPAR, peroxisome
proliferator-activated receptor; PRC, polycomb repressive complex; RE, response element;
RNAi, RNA interference; RXR, retinoid X receptor; SAM, S-adenosyl methionine; SFN,
sulforaphane; SGA, small-for-gestational age; SNP, single nucleotide polymorphism; SRS,
Silver-Russell syndrome; STAT5b, signal transducer and activator of transcription 5b; T1D,
type 1 diabetes mellitus; T2D, type 2 diabetes mellitus; TGE, transgenerational effect; TS,
Turner syndrome; Xa, active X-chromosome; Xi, inactive X-chromosome; XIC, X-inactiva-
tion center; Xist, X inactive-specific transcript (gene); Xm, maternal X-chromosome; Xp,
paternal X-chromosome.
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I. Introduction
Each livingorganismhas twohistories thatdetermine itsbiology: an evolutionary historywhose duration is in
the hundreds of thousands of years, and a developmental
history that starts at the time of its conception. Develop-
mental history of an organism is associated with the ap-
pearance of new structures that cannot be explained in
terms of its developmental programming. The ability of
the genotype to produce different phenotypes in response
to different environments is termed “plasticity.” The time
of maximal plasticity appears to be during development.
However, heritable phenotypic variation at a later stage is
also possible because of the individual’s capability to re-
spond to environmental cues. This ability of the organism
to facilitate change is termed “adaptability” (1), and the
expressions of suites of genes, particularly during devel-
opment or life-history transitions, probably underlie the
fundamental plasticity of an organism (2).
Trait variability, irrespective of whether it is molecular,
cellular, physiological, morphological, or behavioral, is the
leading edge of evolution. Plasticity in developmental pro-
gramminghasevolved toprovide thebest chancesof survival
and reproductive success to the organism. It was recently
appreciated that the life-history evolutionary theory is a
powerful tool for understanding child growth and develop-
ment from an evolutionary perspective (3) (Fig. 1). By ap-
plying this theory to developmental data, adaptive growth-
andmetabolic-related strategies for transition from one life-
history phase to the next and the timing of such transitions
(inherent adaptive plasticity) have evolved.
The environmental conditions that are experienced in
early life can profoundly influence human biology and
long-termhealth. Early-life nutrition and stress are among
the best documented examples of such conditions because
they influence the adult risk of developing metabolic dis-
eases, such as type 2 diabetes mellitus (T2D), and cardio-
vascular diseases (4). Individuals who are born small-
for-gestational age (SGA) have an increased risk of
cardiovascular morbidity and mortality when they are
adults (4–7). This epidemiological evidence is now sup-
ported by an extensive experimental literature in animals
[see Gluckman et al. (8)]. Accordingly, cardiovascular
morbidity can now be considered to be, in part, a prenatal
and pediatric disease. Evidence on the importance of pre-
natal and early postnatal growth for later morbidity sug-
gests the existence of a link between developmental re-
sponses to early environments and adult biology. These
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FIG. 1. Preadult periods of adaptive plasticity in the transition
between life-history phases (double arrows). Prenatal growth affects
adult health and disease. The transition from infancy to childhood
confers a predictive adaptive response that determines adult height.
The transition from childhood to juvenility bestows an adaptive
response that resolves adult body composition and metabolic
consequences. The transition from juvenility to adolescence establishes
longevity and the age of reproduction and fecundity. IC, Infancy-
childhood (transition).
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associations are grounded in functional relationships and
are broadly consistent with life-history evolution theory.
Moreover, they complement current research on the im-
pact of early-life environments on disease occurrence and
susceptibility in later life.
A. Developmental origins of health and
disease (DOHaD)
Interest in developmental plasticity and its relationship
to human health arose from the results of early epidemi-
ological and subsequent clinical and experimental studies
that identified a relationship between early cues (often
measured using birth weight as the surrogate marker) and
the later risk of developing metabolic and other diseases
(5, 7, 9–16). This relationship is the basis of the DOHaD
phenomenon, and the inevitable association between im-
mediate and predictive adaptive responses bestmodels the
original birth weight-disease relationships (7). There is a
growing consensus that this association is broader than
that of grossly disturbed early growth. Indeed, the rela-
tionships between thematernal state and later phenotypic
changes of pathophysiological relevance can be indepen-
dent of the birth weight (17).
The DOHaD phenomenon is an example of develop-
mental plasticity, through which alternative phenotypes
(morphs) are generated from a specific genotype by ad-
justing the developmental program in response to persis-
tent environmental cues (8, 18–24). Such phenotypic vari-
ation is considered to be anticipatory of later conditions
and is termed a “predictive adaptive response” that the
organism induceswith the expectation of a future (fitness)
benefit. The recognition that environmental cues can pro-
foundly influence development encourages the appear-
ance of functional morphs in the population (a postgen-
omic interpretation of phenotype). Two examples of such
developmental plasticity are often cited: the appearance of
the“helmeted”morph in the freshwater crustaceanDaph-
nia in response to an increased presence of predators (25),
and themarked shifts inmorphology and behavior of des-
ert locusts in response to increased population density
(26). In mammals, such adaptive plasticity is typified by
the fetal meadow vole, which determines the thickness of
its postnatal coat in utero in response to maternally de-
rived signals of day length, which are used as an indicator
of the season (27). The DOHaD phenomenon challenges
the simplistic interpretation of phenotype as a determin-
istic fixed outcome of the genotype, an interpretation that
has dominated much of developmental and evolutionary
biology thinking in the 20th century. When phenotype is
viewed as “the expression of a given genotype under its
particular environmental influences” (28), the arguments
of the early evolutionary biologists, such as Schmalhausen
(564) andWaddington (565), are reignited. The DOHaD
phenomenon also sits comfortably with emerging notions
in modern molecular biology.
Mismatch arises when our evolution as a species and
our development as an individual do not leave us well-
matched toan“evolutionarilynovel”world (20,23).Met-
abolic disease is an example of a mismatch (Fig. 2). The
FIG. 2. The match-mismatch paradigm of metabolic disease. The developing organism senses maternally transmitted environmental cues, such as
undernutrition, during prenatal and early postnatal life. Developmental plasticity in response to these cues modifies the default trajectory defined
by the inherited fetal genome and epigenome according to whether the environment is perceived as adequate (dark background) or deprived
(light background), resulting in adjustment of metabolic set points. If the eventual mature environment, whether adequate or deprived, matches
the prediction, then the risk of metabolic disease in later life is low. If there is a mismatch between the predicted and actual mature environments,
particularly if the mature environment is richer than anticipated, then the risk of metabolic disease is enhanced. [Reproduced from P. D. Gluckman
et al.: Am J Hum Biol 19:1–19, 2007 (23). © 2006 Wiley-Liss, Inc.; reprinted with permission from John Wiley & Sons, Inc.]
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individual variation in the sensitivity of mismatch can be
explained in part by genomic variation, and in part by
developmental plasticity. Although we have yet to fully
understand the overnutrition pathway, medicine is reen-
gaging with development. As a result, a new developmen-
tal synthesis is evolving where the weights of genetics,
development, and the ancestral, intergenerational, and
current environments in disease causation are more bal-
anced than previously thought.
B. Plasticity in developmental programming
Environments change continuously, and a species
adapts its phenotype to the prevailing environment, even
when the environmental change is disruptive or even cat-
astrophic. A species is considered to be well adapted and
fit in evolutionary terms when it can survive to reproduce
and display relative phenotypic consistency across many
generations. Phenotype stability is most likely to occur
when the species has adapted to a normative range of
environments that remains relatively stable on genera-
tional time scales. Numerous plants and animals utilize
phenotypic variation as a means to maintain fitness (re-
productive success) under the challenge of a changing en-
vironment, and phenotypic variations might occur on a
rapid time basis, such as in acclimatization, or over many
generations, such as in natural selection.
Almost all organisms exist within an environment that
can change rapidly, and those species with a relatively
fixed phenotype may not be able to respond sufficiently
quickly to survive an unexpected environmental change.
Maintaining this flexibility results in polyphenisms (alter-
native phenotypes in different environments, such as in
metamorphosis). Adaptive plasticity enables a species to
respond to an environmental change to survive and re-
produce and may manifest itself as polyphenism or as a
continuous variation in traits. In evolutionary terms, plas-
tic and developmental responses in early life enable an
organism to adjust its phenotype so that it can survive in
the environment in which it will grow and reproduce.
However, not all developmental responses to environmen-
tal cues have an adaptive basis. When the cue is severe or
novel, the outcome may be disruptive and may result in
teratogenesis, disease, or death (23, 24).
The time scale and persistence of an environmental
change can impact upon the phenotype because both can
trigger phenotypic shifts. These shifts are also adaptive
responses and have survival and/or reproductive value.
Many organisms maintain a degree of phenotypic plastic-
ity to live their life to its full potential in a constantly
changing environment. The predictability of environmen-
tal changes is also an important determinant of the degree
of adaptive flexibility of a species. In some instances, the
environmental change is highly predictable, and an
adapted species exists as a limited range of subtle but dis-
tinct and definable phenotypes. Adaptive plasticity of an
organism is associatedwith immediate adaptive responses
(forecasting or predicting), which are concerned with its
immediate survival with no consideration for the long-
term consequences. These adaptive responses adjust the
developmental phenotype and comprise a set of processes
that can be triggered by a wide range of environmental
cues to promote lifetime fitness. Recognition of an envi-
ronmental cue often occurs during sensitive periods in the
life span of a species, namely the prenatal period and/or
during transitions between life-history phases. Recogni-
tion of an environmental cue also enables the organism to
adapt or acclimatize to an environment change and creates
future trajectories in its development. Adaptive responses
override the canalization of development and the inheri-
tance of acquired characteristics (the constancy of the
wild-type phenotype under varying developmental condi-
tions) (29) to maintain developmental robustness (23).
The resultant adaptive advantage depends on the fidelity
of the cue about the future state of the environment.High-
fidelity cues enable the organism to optimize its adapta-
tion or fit to the anticipated environment. Low-fidelity
cues carry a fitness disadvantage, although the impactwill
depend on the extent of mismatch between the predicted
and actual future environment. According to the Darwin-
ian theory of natural selection, the surviving phenotypes
are better adapted to the prevailing conditions than the
alternative forms (morphs)—postdevelopmental determi-
nation of the best-fit phenotype. One such cue is the
energy/nutrition supply, which can cause a shift in the
growth trajectory of subsequent generations (maternal
prediction). Another example is population density,
which is sometimes used as a surrogate indicator and pre-
dictor of future nutritional supply.
Two types of adaptive responses or plasticity exist (23).
The first type is the anticipatory or predictive adaptive
responses, where the developing organism forecasts the
future environment and then adjusts its phenotypic tra-
jectory accordingly. The second type is the immediate
adaptive responses that promote short-term maternal or
fetal survival with some advantages in later life (develop-
mental plasticity). Because these two types of adaptive
responses come with a significant cost, individual mem-
bers of a species make a cost-benefit analysis to determine
the true valueof an adaptive response.Within the adaptive
responses, theorganismmayengage ina trade-off between
phenotypic changes to ensure its short-term survival at the
expense of a long-termadvantage.Hence, trade-offs occur
because energy needs to be allocated to meet the different
metabolic and physiological demands of a developing or-
ganism. Therefore, trade-offs can often manifest them-
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selves as longevity, as an alternative to reduced survival of
the juveniles. Such is the consequence of embryonic fetal
development when it occurs in a deprived intrauterine en-
vironment as a result of a limited transplacental nutrient
supply. In response, the fetus protects the development of
its heart and brain at the expense of other organs, and
somatic growth is retarded. Underlying developmental
plasticity is the fundamental premise that the physiology
of an individual is driven by the induction of a particular
developmental program, which is influenced by the pre-
vailing environmentduring critical developmental periods
(18). To improve the chances of survival at birth, the off-
spring are small and have high rates of morbidity and
mortality. Intrauterine growth restriction (IUGR) is an
example of an immediate cryptically maladaptive re-
sponse to the environment (19, 20, 22). Under severe sit-
uations in polytocous species, which produce numerous
offspring in a single birth, adaptation may be driven by
maternal interests that compromise some of the offspring.
However, this adaptation seems unlikely to happen in
slow-reproducing, single-offspring species (8, 23, 24).
When the environmental cue is subtle in early life, often
no immediate adaptive responses occur because the cue is
interpreted as a surrogate predictor of the later reproduc-
tive environment. Because developmental plasticity is lim-
ited by temporal constraints, the interpretation of this re-
sponse can create a situation where it is evolutionarily
advantageous for the fetus to adjust its phenotypic devel-
opment to create a “better-matched” postnatal pheno-
type. Although such processes are robustly selected across
taxa, there is a high risk of low fidelity of the prediction in
mammals. In fitness terms, suchadjustmentsmaynot have
much impact because health and fitness are distinct con-
cepts. However, for humans who live beyond the peak
reproduction period, the health consequences, rather than
the reproductive consequences, become the primary con-
cern. For example, the occurrence of metabolic disease is
more likely to occur when the nutritional status in adult-
hood differs markedly from that experienced and pre-
dicted during development and the expectation of a poor
environment is not subsequently met. Life-history theory
argues that energy- and stress-related cues experienced
by the mother are likely to be the primary environmen-
tal triggers of developmental plastic responses (30). The
predictive responses are primarily induced by subtle
cues, and the immediate adaptive responses are induced
by more obvious cues. However, both types of re-
sponses could coexist when the immediate adaptive re-
sponses are induced.
C. Plasticity in phase transitions of human life history
The secular trends in child growth and puberty are daz-
zling examples of such adaptation (31). Europeanmen are
now 13 cm taller than they were 150 yr ago. This range of
plasticity in growth over approximately six generations is
not long enough to result from changes in the DNA se-
quence. Over the same six generations, the age of men-
arche in Western countries has decreased by 4 yr. This
reduction has a fitness advantage on the fecundity span in
an environment that is rich in energy resources and dem-
onstrates plasticity in thematurationof the hypothalamic-
pituitary-gonadal axis. As a consequence of constantly
changing life conditions and environment, today’s chil-
dren may be stunted in growth or be tall, adapt their body
composition and energy metabolism, and modulate their
longevity, fertility, and fecundity. The signals of energy
balance thatmodulate this plasticity are both intrinsic (in-
ternal) and extrinsic (environmental). The internal signals
include leptin, the GH-IGF-I axis, ghrelin, thyroid hor-
mones, insulin, and the cortisone-cortisol shuttle (11-
hydroxysteroid dehydrogenases), whereas the environ-
mental signals include prenatal and postnatal nutrition,
stressors, endocrine-disrupting chemicals (EDCs), and
light.
Human growth and development are orchestrated pro-
cesses of well-recognized and predictable events with five
overlapping, yet distinct, preadult life-history phases: the
prenatal, infantile, childhood, juvenile, and pubertal
growth phases (Fig. 1). The transition periods between
these phases are sensitivewindows of developmental plas-
ticity, and there is now some evidence that the features of
transition from one phase to the next are transmitted
transgenerationally (32). With decreasing sensitivity, the
transitions between phases are periods of adaptive plas-
ticity, and the multifactorial regulation of growth during
each phase mirrors the interplay between genetic, hor-
monal, environmental, and psychosocial factors.
Four adaptive processes influence human phenotype,
and each operates on a different time scale (33). The first
process involves changes in gene sequence and frequency
in a population or species, and this process occurs over
several hundred thousand years. The second process is
modification of homozygosity of the population, and this
process occurs over several hundred years and numerous
generations. The third process is adaptive phenotypic
plasticity, and this process occurs over the entire life span
of the individual, and may be carried forward for three to
four generations. The fourth process is short-term accli-
matization that can last several months or years. In re-
sponse to environmental cues, especially those that relate
to energy resources, a life-history phase can be added or
deleted and canhave its duration, intensity, andonset time
altered (3). Thus, the timing of infancy-childhood transi-
tion (ICT) adaptively adjusts an individual’s size to the
prevailing environment in response to environmental cues
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(3). Hochberg and Albertsson-Wikland (34) have previ-
ously reported that the ICT is amajor determinant of final
adult height and a delayed ICT is the most common cause
of idiopathic short stature. The transition from juvenility
to adolescent-related puberty and the growth spurt is a
function of maturation of the hypothalamic-pituitary-go-
nadal axis. Poor quality of life during this transitiondelays
fecundity and increases longevity (35). Hence, a series of
control mechanisms must exist to enable 1) the GH-IGF-I
axis to dominate as the child transits into childhood; 2)
adrenarche at the onset of juvenility; and 3) an abrupt
increase in sex hormones at initiation of puberty (3).
As already noted, an organism distributes its energy
resources during its life by timed allocations toward
growth, self-maintenance, reproduction, and raising off-
spring to independence to avoid death (33, 36). Whereas
the environment at any one geographical location may
vary slowly, nutritional conditions may change rapidly.
Evolutionhasprovidedorganismswith themechanisms to
adapt to such extremes. Humans can also use sociocul-
tural adjustments to fill the gaps when the changes occur
faster than the evolutionary time scale. This can be seen
when one examines the evolution of hominid life history
from Australopithecus afarensis to Homo sapiens. In hu-
mans, the duration of infancy has been shortened and that
of childhoodhasbeenprolonged, and these twophases are
followed by a relatively short juvenility and late adoles-
cence to increase fitness (36–38). The overall result of this
strategy is increased body size and longevity, and repro-
duction at a later age, comparedwith other primates. This
strategy has been very successful for humans, who can
thrive and propagate in extremely diverse environments
that encompass the entire range of geographic latitudes
and altitudes.
An important environmental cue for infants and young
children is the caregiving behavior of their parents, which
can be used as a predictive indicator of the security of their
environment. The resultant attachment patterns are trans-
mitted transgenerationally (39, 40). The degree of security
that is experienced during childhood sets development on
alternative pathways and adaptively shapes the individu-
al’s future reproductive strategy. A secure attachment will
result in a reproductive strategy that is based on late mat-
uration, a commitment to a long-term relationship, and a
large investment in parenting. In terms of evolutionary
developmental biology, which studies the developmental
mechanisms that control body shape and form and the
alterations in gene expression and function that lead to
changes in body shape and pattern (41), the expected re-
sponse to a secure environment will include investment in
largebody size (42,43).This exampleof transgenerational
phenotypic plasticity contrasts that of an insecure attach-
ment and a small parental investment that involves a large
number of children; the response is a compromise in body
size, early reproduction, and short-term mating.
Child growth and body composition display a vast
range of adaptive plasticity. Short-term plasticity in the
various child growth phases and transitions suggests that
epigenetic mechanisms determine the extent of adaptive
plasticity during growth in response to environmental
cues. In light of these new findings, this article considers
the utility of life-history theory and the links between epi-
genetics, developmental programming, and plasticity in
early growth and nutrition. Current research in child
health strives to identify mechanisms that underlie plas-
ticity in developmental programming and life-history
transitions. Developmental programming and life-history
transitions are purported to use nutritional or endocrine
cues for setting long-term biological strategies in response
to local ecological and/or social conditions (18, 23, 44).
Rapid changes in nutrition during one’s lifetime can then
lead to ‘‘mismatch”andmetabolic disease (20). It has been
further proposed that intergenerational influences on nu-
trition and growth stabilize the nutritional signals that are
received in utero to increase the reliability of an intrauter-
ine cue as apredictive signal (44). It is nowalsoknown that
the effects of hormones, stress, and drugs during embryo-
genesis can not only influence the subsequent behavioral
phenotype of the individual, but can also modify the in-
dividual’s response to adult experiences (2).
In his recent review on phenotypic plasticity and the
epigenetics of human disease, Feinberg (45) argues that
epigenetic changes are involved in normal development
and human disease.He proposes that the term “epigenetic
disease” be used to describe defects in the epigenome that
are known to lead to disease. These defects include
changes in the localized or global density of DNA meth-
ylation, incorrect histone modifications, or altered distri-
bution or function of chromatin-modifying proteins that,
in turn, lead to aberrant gene expression. According to
Feinberg, defects in phenotypic plasticity or the cell’s abil-
ity to change its behavior in response to internal or exter-
nal environmental cues are the underlying theme of epi-
genetic disease. Feinberg proposes that this theme can also
be applied to commondiseaseswith late-onset phenotypes
that involve interactions between the epigenome, the ge-
nome, and the environment.
The almost exponential expansion in our understand-
ing of epigenetic regulation now provides mechanistic in-
sights to developmental plasticity and the molecular rela-
tionships between the environment and the response of
genes. This article (45) proposes that phenotypic plasticity
is the manifestation of adaptive programming and that
“softly inherited” epigenetic mechanisms may underlie
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phenotypic plasticity and adaptive programming. The ar-
ticle also reviews the evolving idea of plasticity in devel-
opmental programmingwith respect to human life history
and transitions between life-history phases and proposes
that epigenetics provides a molecular mechanism for pro-
gramming that links genes, the prenatal environment, in-
trauterine growth, and subsequent susceptibility to dis-
ease. For this purpose, the epigenetic basis of plasticity is
reviewed in the setting of early nutritional experiences and
developmental programming. The notion that the pheno-
type of the placenta and its ability to support fetal growth
are established at the time of conception, or even implan-
tation, is also explored. This notion is further discussed in
the light of increasing knowledge that the placenta and the
fetus continue to adapt throughout pregnancy in response
to the prevailing environmental conditions.
II. Epigenetic Programming and
Developmental Plasticity
Epigenetics has evolved very quickly from the study of an
obscure collection of diverse phenomena to becomeone of
the most exciting topics in contemporary biology. It is a
rapidly expanding field of study in which the molecular
mechanisms of seemingly unrelated normal processes,
such as paramutation inmaize, position effect variegation
(PEV) in the fruit fly, and genomic imprinting andX-chro-
mosomal inactivation inmammals, are now recognized as
evolutionarily conserved epigenetic processes. In medi-
cine, epigenetics has become the new frontier.
The exact definition of epigenetics is controversial (46,
47), and discussion on its definition is beyond the scope of
this review. Irrespective of its definition, epigenetics is im-
portant for understanding gene function and expression
because expression profiles are influenced by epigenetic
modifications, and the epigenetic regulation of gene ex-
pression is essential for the normal growth, development,
and aging of higher organisms (45). Epigenetics also un-
derlies genomic imprinting, programming, and repro-
gramming in early life and the increased susceptibility to
disease in later life. In this section, we will describe the
epigenome and the epigenetic machinery to provide an
overview of the components of the epigenome and the
processes that the epigenetic machinery uses to influence
and/or modulate gene expression, programming, and dis-
ease susceptibility, which are topics that will be discussed
in detail in the various sections of this review.
The term “epigenetic landscape” is widely used when
discussing epigenetics (48). It describes the range of epi-
genetic marks that are acquired during the developmental
course of a cell, or an embryo, or its parts to take specific
trajectories that lead to different cellular or organismal
fates (lineage commitment) in response to the environ-
mental cues (49, 50). Initially, several possible pathways
are available because the cell is pluripotent, and early em-
bryonic cells follow one of these pathways. However, the
further a cell or embryo travels down any one develop-
mental pathway or trajectory, the more difficult it be-
comes for it tomove into an alternative one (canalization).
The choiceof adevelopmental trajectory canbe influenced
byexposureof themother toanenvironmental cue,which,
in turn, alters the nature of the mother-offspring interac-
tion and is capable of inducing a shift in the developmental
trajectory of the offspring (environmental programming).
Reprogramming between generations is a corollary of
Waddington’s (565) ideaand refers to the zygote regaining
its totipotency so that it can go down all the possible path-
ways as a new organism develops. This section will also
discuss these concepts, as well as presenting an overview
of the heritability of epigenetic change and the determi-
nation of phenotype.
A. The epigenome
Our genomes constitute more than just the DNA blue-
print. DNA is packaged as chromatin, and to fit within the
nucleus of the cell, DNA is very tightly coiled and bundled
into three-dimensional chromosomal structures. In eu-
karyotes, DNA is wrapped around an octamer of histone
proteins that consists of two copies of the core histones,
H2A, H2B, H3, and H4. These core particles or nucleo-
somes are the basic unit of chromatin, which can then be
assembled further into higher-order chromatin structures.
Thenucleosomecompacts theDNA-histone complex, and
the degree of compaction creates an added layer of regu-
latory control of the genome.
The compact histone-DNA configuration is main-
tained by electrostatic bonds between positively charged
histones and negatively charged DNA, and changes in the
patterns of these bonds regulate gene expression (51).
Nucleosomes also carry covalentmodifications on their core
histones and on the DNA. These epigenetic modifications
can determine whether parts of chromosomes are tightly or
loosely packaged, which in turn influenceswhether a gene is
switched “on” or “off.” It is now recognized that epigenetic
information is crucial for the dynamic interpretation of ge-
netic information so that the correct genes are expressed at
the right time during critical cell fate decisions.
The term “epigenome” refers to the global epigenetic
patterns that are characteristic of an organism.Changes in
epigenetic information during the life span can occur by
modifying the epigenetic marks on the DNA and/or his-
tone proteins without altering the underlying DNA se-
quence, whereas changes in genetic information occur by
altering the underlying DNA sequence. Epigenetic mech-
anisms of gene regulation are relevant throughout devel-
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opment from when the sperm first meets the egg, through
early lineage decisions, to fetal development andpostnatal
life. Epigenetic patterns that were acquired during devel-
opment are, in most cases, stable in somatic cells and dur-
ing adult life. However, somatic epigenetic patterns need
to be “reset” or “reprogrammed” in germ cells and also in
early embryos to achieve developmental pluripotency.Re-
programming normally results in differences in some epi-
genetic marks on chromosomes that are inherited from
eggs, when compared with those that are inherited from
sperm. The most striking example of such epigenetic
asymmetry is “genomic imprinting,” which occurs in
mammals. There are nearly 100 genes that are subject to
imprinting in humans and mice (52, 53). These genes are
marked epigenetically in the germ line, and this process
results in only one of the parental copies being expressed
after fertilization (discussed in Section IV.A). Epigenetic
regulation also underlies X-chromosome inactivation, a
phenomenon through which one of the two X-chromo-
somes is inactivated in every cell of the body, and in the
silencing of transposable elements, thereby preventing in-
sertional mutagenesis. X-inactivation and genomic im-
printing are discussed in detail in Section IV.C.
Almost all of the different cell types that make up an
organism share an identical genotype, yet each cell type
has well-defined, individual, and stable profiles of gene
expression. Subsets of the 20,000–25,000 genes of the
human genome are active in different tissues because of
their regulation by different sets of transcription factors
and epigenetic modifications (54, 55). Thus, the epige-
netic marks that accumulate in a differentiated cell will
differ from those in pluripotent cells and will also be
distinct from those of other differentiated lineages (Fig.
3). The set of epigenetic patterns, the “epigenotype,” is
specific to each cell type and influences its fate, irre-
spective of whether the cell is derived from the liver,
brain, or bone. Remarkably, during cell division, com-
mitted cells acquire the same epigenotype as their parent
cells. Therefore, epigenetic events create a memory of
cell identity to sustain genomic function that includes,
among others, maintenance of cell identity after differ-
entiation (Fig. 3) (56).
Epigenetic states, however, also have an inherent flex-
ibility because they can undergo regulated change in re-
sponse to particular stimuli to modulate gene expression
as the need arises. For example, this flexibility is evident
during the development of stem cells into particular organ
systems, reprogramming events in germ cells and early
embryo to restore pluripotency, and in the response to
external environmental factors, such as diet and environ-
FIG. 3. Top panel, DNA vs. chromatin. The genome is the invariant DNA sequence of an individual. The epigenome is the overall chromatin
composition, which indexes the entire genome in any given cell. It varies according to cell type and response to the internal and external signals
that it receives. Lower panel, Epigenome diversification occurs during development in multicellular organisms as differentiation proceeds from a
single stem cell (the fertilized embryo) to more committed cells. Reversal of differentiation or transdifferentiation requires the reprogramming of
the cell’s epigenome. [Fig. 3 and its legend have been reproduced with permission from C. D. Allis et al.: Epigenetics, Chap 3, Cold Spring Harbor
Laboratory Press, Woodbury, NY, 2007 (561). © 2007 CSHL Press.]
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mental chemicals.On the other hand, the functional states
of nondividing quiescent cells with a long lifetime, such as
neurons, require an epigenetic mechanism for their qui-
escence and longevity. If these naturally occurring epige-
netic processes occur improperly, major adverse health
and behaviors can ensue. Epigenetic modifications, there-
fore, can render the genome functionally flexible and
adaptable, but at the same time render it vulnerable in
many ways. The vulnerability of the genome and under-
lying epigenetic mechanisms of gene expression in various
settings are discussed in Section VIII.C–F.
B. The epigenetic marks
The traditional view of epigenetic modifications as
static on/off switches in the control of gene expression is
now being altered by the idea that these marks are dy-
namic. Because some environmental factors or cues can
act on the epigenetic machinery to bring about either
short-term or long-term outcomes, this next section will
briefly review the key features of the epigenetic marks and
associated machinery in the context of developmentally
regulatedgenes andplasticity throughoutmammalian life.
1. DNA methylation
The most comprehensively studied epigenetic mark is
DNAcytosinemethylation (m5C). Inmammals, nearly all
m5C is found at sites where cytosines are followed by
guanines (CpG dinucleotides) (57). The mammalian ge-
nome is greatly depleted of CpG dinucleotides, which ac-
counts foronlyabout1%ofallDNAbases (57).However,
the promoter regions of around 60% of all human genes
contain small stretches ofDNAwith a relatively highCpG
content (57). Although these promoter-region “CpG is-
lands” are largely unmethylated, promoter-region meth-
ylation of islands is frequently correlated with transcrip-
tional silencing (57–59). Cytosine methylation is required
for the allele-specific expression of imprinted genes, the
transcriptional repression of retrotransposons (mobile ge-
netic elements that are transposed through RNA interme-
diates) in germ cells and somatic cells, X-chromosome in-
activation in females, and stable silencing of some
pluripotency-associated genes during differentiation.
In the mammalian genome, methyl groups are placed
on DNA by a group of highly conserved proteins called
DNAmethyltransferases (DNMTs).ThedenovoDNMTs
(DNMT3A, DNMT3B, and their cofactor DNMT3-like)
establish methylation patterns early in development (60).
Although there is increasing evidence that DNMT3A and
DMNT3B are also involved in the maintenance of DNA
methylation (61), the activity of the maintenance DNMT,
DNMT1, ensures that DNAmethylation patterns are sta-
blymaintained during adult life. DNMT1preservesmeth-
ylation patterns throughout cell divisions by adding
methyl groups tohemimethylatedCpGdinucleotides (60).
However, widespread losses of DNAmethylation are ob-
served during the epigenetic “reprogramming” that oc-
curs in primordial germ cells (PGCs) and the early embryo
during particular developmental windows (Fig. 4) (62,
63). DNA methylation can be lost either passively by
blocking methylation of newly synthesized DNA during
DNA replication or actively by unknown mechanisms,
which possibly involve DNA repair (64). The erasure of
methylation marks at imprinted genes in the germ line is a
key developmental event so that gender-specific methyl-
ation is imposed subsequently during germ cell develop-
ment (65). Also crucial for development is the ability of
imprinted genes to maintain their methylation marks
throughout early embryo reprogramming to ensure the
inheritance of parental-specific epigenetic information
(Fig. 4) (66).
It is now recognized thatDNAmethylation contributes
to specifying cell fates and maintenance of cell identity.
Pluripotency transcription factors, such as OCT4 and
NANOG, are expressed in embryonic stem cells (ESCs)
but are silenced by DNA methylation and histone modi-
ficationsduring thedifferentiationof these cells (63).Con-
versely, the transcription factor gene, Elf5, is methylated
and silenced in the embryonic lineage but hypomethylated
and expressed in the trophoblast lineage (67). The func-
tion of this type of epigenetic marking of Elf5 is to rein-
force the trophoblast-specific transcriptional circuit and
fixation of the lineage fate (embryonic vs. extraembry-
onic) (68). Lastly, the results of several genome-wide stud-
ies have shown that methylation patterns differ between
tissues; a gene might be methylated in one tissue but un-
methylated in another, thereby constituting the so-called
tissue-specific differentially methylated regions (69–71).
Collectively, these examples support the notion that DNA
methylation plays a key role in tissue differentiation by
maintaining the transcriptional silence of genes whose ex-
pression is not required in specific cell lineages.
2. Histone modifications
Each core histone has an end-amino-terminal tail that
protrudes from the nucleosome and can be subjected to a
diverse array of covalent posttranslational modifications
(72). These modifications include acetylation of lysines,
methylation of lysines and arginines, ubiquitylation and
sumoylation (small ubiquitin-likemodification)of lysines,
and phosphorylation of serines and threonines. Histone
modifications recruit and bind critical DNA-regulatory
proteins, and these processes ultimately lead to changes in
DNA transcription, replication, recombination, and re-
pair.Histonemodifications constitute signals that are read
alone or in combination with other marks on the same or
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neighboring histones, and the resultant codes are referred
to as the “histone code.” Thus, histone modifications are
recruitment signals for protein effectors that exert a series
ofdiverse functional effectswith short-termand long-term
outcomes (Fig. 5).
Chromatin is generally compartmentalized into two
main domain types: heterochromatin, which is condensed
and gene-poor, and euchromatin, which is decondensed
and gene-rich (72). These domains have different patterns
of histone modifications and are associated with different
modes of nucleosome packaging, higher-order structure,
and nuclear organization. A link between heterochroma-
tin formationandgene silencinghasbeen inferred fromthe
loss of gene activity on the inactive X-chromosome (Xi)
and in PEV in Drosophila and other organisms. PEV oc-
curs when a gene that is normally “euchromatic” is jux-
taposed with heterochromatin by transposition or rear-
rangement; the resulting variegating phenotype indicates
that the gene has been silenced in a proportion of the cells.
In general, heterochromatin is associated with repressive
histonemarks andDNAmethylation,whereas euchroma-
tin is associated with active histone marks (72).
Histone acetylation is restricted to conserved lysines
across the core histones, despite being one of the most
prevalent of all the histone modifications (73). It is gen-
erally considered that a mark of open, active chromatin
domains corresponds to actively transcribed genes with
high levels of acetylation at their promoter regions, tran-
scription start sites, CpG islands, and functional regula-
tory elements (74). The levels of acetylation across chro-
matin are determined by histone acetyltransferases
(HATs), which catalyze the addition of acetyl moieties to
the lysine residues, and histone deacetylases (HDACs),
which remove the acetyl group from the lysine residues
(75). The balance of the activities of these two enzymes
determines the state of histone acetylation, which in turn
can influence the level of expression of the underlying
genes (73). When HDACs remove the acetyl groups from
histone lysines, a positive charge is restored to the lysine
residue, thereby condensing the structure of nucleosomes
(76). Nucleosomes that contain highly charged hypo-
acetylated histones bind tightly to the phosphate back-
bone of DNA, thereby inhibiting transcription, presum-
ably because transcription factors, regulatory complexes,
andRNApolymerase do not have access to theDNA.This
closed chromatin structure commonly precludes tran-
scription factor binding to DNA and underscores the im-
portance of enzymes that modify histone-DNA interac-
tions.On the other hand,HATs catalyze the acetylation of
selected positively charged amino acids, such as lysine, on
the protruding histone tails, of which histone H3 or H4 is
the most common. Acetylation of K9 residues on the end-
FIG. 4. Alterations in methylation status during development. During embryonic development and gonadal sex determination, primordial germ
cells undergo genome-wide demethylation, which erases previous parental-specific methylation marks that regulate imprinted gene expression. In
the male germ line, paternal methylation marks in imprinted genes are laid down in developing gonocytes that will develop into spermatogonia.
The female germ line establishes maternal methylation marks in imprinted genes at a later stage. After fertilization, the paternal genome is actively
demethylated, whereas the maternal genome undergoes passive demethylation (176). Genome-wide remethylation occurs on both parental
genomes before implantation. However, imprinted genes maintain their methylation marks throughout this reprogramming, allowing for the
inheritance of parental-specific monoallelic expression in somatic tissues throughout adulthood. [Reprinted with permission from R. L. Jirtle and
M. K. Skinner: Nat Rev Genet 8:253–262, 2007 (62). © 2007 Macmillan Publishers Ltd.]
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amino-terminal tails of H3 histones (H3K9ac), for exam-
ple, neutralizes the positive charge of the histone tail and
decreases histone’s affinity to negatively charged DNA,
and generates a more open DNA conformation. This re-
sults in “relaxing” of the DNA, which is wrapped around
the octamer of histone residues. Transcription factors and
the transcription apparatus can then access the DNA, and
expression of the corresponding genes is facilitated (77).
Importantly, many transcriptional regulators and factors
possess intrinsic HAT activity (73). Consistent with the
role of acetylation in transcriptional activation, deacety-
lation is generally associated with gene silencing. Indeed,
HDACs are generally considered as transcriptional core-
pressors (78).
Compared with histone acetylation, histone methyl-
ation is considerably more complex (79). It can occur on
conserved lysine and arginine residues and across all four
histone proteins. Up to three methyl moieties can be ap-
plied to the lysine amino group (monomethylation, di-
methylation, and trimethylation),whereas arginine can be
either monomethylated or dimethylated. Histone methyl-
transferases are the enzymes that are responsible for the
addition of methyl groups to either lysine or arginine res-
idues. Until recently, it was believed that histone methyl-
ation represented a more permanent, stable modification
because the global turnover of this mark was lower than
of thehighlydynamicacetylationmark (67).However, the
recent identification of enzymes that are capable of re-
moving methyl groups from histones has shown that this
mark may be equally dynamic (80). In contrast to acety-
lation that affects the charge of the residue, and thereby
directly impacts on histone-histone or histone-DNAbind-
ing, the role of methylation is likely to be solely orches-
trated through the recruitment of additional regulatory
factors. Therefore, methyl marks have the potential to in-
fluence gene expression in opposing ways that depend on
both the location and the timing of themark. For example,
trimethylation of lysine 4 on histone H3 (H3K4me3) is
generally perceived as an active modification and occurs
preferentially at active promoters,whereasmethylation of
H3K9 (H3K9me) is detected at the promoter of inactive
genes and yet is deposited in the coding regions of active
genes (81). H3K27me3 is strongly associated with gene
silencing via unique interactionswith the Polycomb group
(PcG) proteins, which are discussed in Section II.B.3.a.
The regulatory potential of histone modifications is
substantial in viewof the large number of different histone
modifications and the extensive cross-regulation thatmay
occur between certain histone marks. The cross talk be-
tween histone marks is a fundamental concept of the hi-
stone code hypothesis, which predicts that combinatorial
sets of histone marks act in concert to regulate the chro-
matin structure. There are various ways by which this
cross-regulation can occur. Different marks can antago-
nize each other on the same residue. For example, when a
lysine residue is acetylated, it cannot also be methylated,
and only one level of methylation (namely mono-, di-, or
trimethylation) can be present (82). Another level of cross
talk involves removal or recruitment of a protein complex
by an adjacent modification, as is the case for phosphor-
ylation of serine 10 on histone H3, which is necessary to
disrupt the binding of the heterochromatin protein 1
(HP1) to H3K9me3 (83). Alternatively, an enzyme com-
plex can be affected by multiple histone modifications:
H3K9ac andH3K14ac enhance the binding of the general
transcription factor TFIID to H3K4me3, and asymmetric
dimethylation of H3R2 prevents it (84). Cross talk can
also involve trans-histone effects, where modifications on
different histone proteins can regulate each other. For ex-
ample,monoubiquitylationofK120 is required for di- and
trimethylation of H3K4 (85, 86). Lastly, cross talk can
ultimately determine the final transcriptional output
through specific trans-acting effects of developmentally
regulated noncoding RNAs (ncRNAs) on transcription
FIG. 5. Histone modifications can generate both short-term and long-
term outcomes. The amino-terminal tails of all eight core histones
protrude through the DNA and are exposed on the nucleosome
surface, where they are subject to an enormous range of enzyme-
catalyzed modifications of specific amino-acid side chains, including
acetylation of lysines, methylation of lysines and arginines, and
phosphorylation of serines and threonines. Histone tail modifications
are put in place by modifying and demodifying enzymes whose
activities can be modulated by environmental and intrinsic signals.
Modifications may function in short-term, ongoing processes (such
as transcription, DNA replication, and repair) and in more long-term
functions (as determinants of chromatin conformation, for example
heterochromatin formation, or as heritable markers that both
predict and are necessary for future changes in transcription).
Short-term modifications are transient and show rapidly fluctuating
levels. Long-term, heritable modifications need not necessarily be
static; in theory, they still show enzyme-catalyzed turnover, but the
steady-state level must be relatively consistent. [Reprinted with
permission from B. M. Turner: Nat Cell Biol 9:2–6, 2007 (562).
© 2007 Macmillan Publishers Ltd.]
Endocrine Reviews, April 2011, 32(2):159–224 edrv.endojournals.org 169
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 03 March 2015. at 04:00 For personal use only. No other uses without permission. . All rights reserved.
wheremodifications on different histone proteins can reg-
ulate one another (87–89).
As we acquire more knowledge about histone marking
systems, the accepted concept of classifying histonemarks
as either active or inactive is being challenged. Indeed,
marks that were originally thought to be “active” can be
found within silent genes and vice versa; H3K9me3 is
found both in silent heterochromatin and at some active
genes (90). Therefore, it now seems prudent to consider
that a single typeofhistoneposttranslationalmodification
does not dictate a single outcome. Instead, it seems that a
combination and enrichment of histone posttranslational
modifications define different chromatin domains with
specific functional outcomes. Although it is widely ac-
cepted that chromatin has a crucial role in the inheritance
of transcriptional regulation, it is still unclear howhistone
modifications are reproduced after DNA replication and
are transmitted from one cell generation to the next. Sev-
eralmechanisms have been proposed bywhich “new”and
“old” histones, of which the latter carry their original
posttranslational modifications, are distributed after
DNA replication. These include random, semiconser-
vative, and asymmetric modes of histone distribution
(72, 91). The genome-wide epigenetic reprogramming
that occurs both in the germ line and embryo extends
beyond DNA methylation and also involves histone
marks, histone exchange, and the use of histone variants
(Fig. 4) (66, 68, 91–93). The mechanistic aspects of
reprogramming are under intense investigation and are
beyond the scope of this review [for further reading, see
Morgan et al. (94), Hayashi and Surani (95), Hem-
berger et al. (68), Popp et al. (96), Ray-Gallet and Al-
mouzni (97), and Xu et al. (98)].
3. Noncoding RNAs
Almost all of the genome is transcribed, yet only a small
proportion of it (1.2%) encodes proteins. One explana-
tion for this phenomenon is the existence of a large rep-
ertoire of short and long ncRNAs that includes many new
RNAs, in addition to the well-known groups of rRNAs,
small nuclear RNAs, and tRNAs. It has become clear that
these newly discoveredncRNAsare functional and central
to complex genetic phenomena in eukaryotes that include
transcriptional and posttranscriptional gene silencing, X-
inactivation, genomic imprinting, and germ cell repro-
gramming, all of which involve epigenetic processes.
a. Short ncRNAs.The fundamental biological role for short
regulatory RNAs was demonstrated in the late 1990s by
the discovery of RNA interference (RNAi) (99). RNAi is
a process through which exposure to double-stranded
RNA leads to silencing of homologous genes, most often
posttranscriptionally. This phenomenon was originally
thought to be restricted to exogenous double-stranded
RNAs, but it soon became clear that animals and plants
produce an array of small RNAs, which include endoge-
nous small interferingRNAs,microRNAs (miRNAs), and
P-element-inducedwimpy testes (PIWI)-interactingRNAs
(piRNAs), and this repertoire is continually increasing.
The three major small RNA silencing pathways identified
thus far seem to be involved in both posttranscriptional
gene silencing through RNA degradation or translation
arrest and chromatin-dependent gene-silencing pathways,
which in turn, also appear to occur through both tran-
scriptional and cotranscriptional gene silencing. A de-
tailed examination of the function and biogenesis of small
RNAs is beyond the scope of this review and has recently
been covered in detail in several excellent reviews by
Moazed (100) and Taft (101).
miRNAs are small ncRNAs that regulate gene expres-
sion at the posttranscriptional level by either degradation
or translational repression of a target mRNA (102). They
are generated from hairpin precursors by the successive
actions of the RNAse III enzymes, Drosha and Dicer,
which are located in the nucleus and cytoplasm, respec-
tively. Most miRNAs seem to act exclusively in the cyto-
plasm, where they mediate mRNA degradation or trans-
lational arrest. Some of the first miRNAs that were
discovered, such as the let-7 family ofmiRNAs, aremaster
regulators of developmental differentiation, both in early
embryos and adult tissues (103, 104). The let-7 targets are
“canonical,” in that the miRNA seed “sequence” (eight
nucleotides long) binds to target the3untranslated region
of mRNA and represses translation. The principal targets
of let-7 family members, of which there are 11 in verte-
brates, are cell cycle regulators, oncofetal genes, pluripo-
tency factors, and components of the miRNA biogenesis
pathway. Importantly, let-7 biogenesis and gene regula-
tion are characterized by a series of autoregulatory feed-
back loops (105). For example, let-7 targets the pluripo-
tency factor LIN28, which can in turn bind to the
conserved loopof the primary let-7 transcript (pri-let-7) to
directly inhibit the cleavage steps by the nuclear RNase,
Drosha. Consistent with the central role of let-7miRNAs
in developmental regulation, genetic variants of the
LIN28B locus have recently been associated with the tim-
ing of humanpubertal growth anddevelopment (106) (see
discussion in Section III.C).
In plants and in fission yeast, short regulatory ncRNAs
often work in concert with various components of the
cell’s chromatin and DNA methylation machinery to
achieve stable silencing (107).Althoughendogenous small
interfering RNAs or other classes of small RNAs that me-
diate transcriptional gene silencing have yet to be charac-
terized in mammals, the results of recent studies suggest
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that small RNA-directed epigenetic processes exist in
mammals. Indeed, human miRNAs have been found to
guide chromatin remodelingby inducingheterochromatin
formation at promoters (108, 109). For example, Kim et
al. (109) recently reported that miR-320, a conserved
miRNA, can direct the association of the RNAi protein,
Argonaute-1; the PcG protein, Ezh2; and H3K27me3 at
the promoter of the cell cycle gene, POLR3D. Further-
more, RNA-directed DNA methylation, which is a con-
servedmechanism for control of gene expression, has been
recently described in mammals, where it appears to be
restricted to germ cells (110). Members of the PIWI clade
of proteins and associated piRNAs are involved in the
repression of retrotransposons and are essential for ga-
metogenesis (111). Mutations in the mouse family mem-
bers of PIWI proteins, MIWI2 or MILI, result in demeth-
ylation of the LINE-1 retrotransposon and intracisternal
particle (IAP) transposable elements in the testis (112).
This finding suggests that piRNAs, directly or indirectly,
mediate changes in DNA methylation. However, the
mechanisms by which they trigger de novo methylation
are at present unclear, but this may involve demethylation
of H3K4 (60).
b. Long ncRNAs. It is estimated that at least 80% of tran-
scriptional activity in mammals corresponds to long
ncRNAs (lncRNAs) (113), which are generally more than
2 kb long, although some aremore than 100 kb. lncRNAs
are spliced RNAs that contain canonical polyadenylation
signals. Several lncRNAs have been found to be asso-
ciated with chromatin modifying complexes (89, 114).
A primary role of lncRNAs appears to be the regulation
of protein-coding gene expression through modulation
of chromatin states or through direct effects on gene
transcription. For example, Rinn et al. (115) recently
identified a 2.2-kb lncRNA, which they termed
HOTAIR, residing in the HOXC locus in an antisense
orientation. HOTAIR represses transcription across dif-
ferent chromosomes (in trans) bymaintaining a transcrip-
tional silent chromosomal domain that spans 40 kb of the
HOXD locus through PcG protein-mediated repressive
H3K27me3. In another study, Feng et al. (116) recently
demonstrated that the lncRNA Evf-2, which is partially
encodedby theDlx-5/6ultraconserved region, stably com-
plexes with the transcription factor Dlx-2 to increase the
transcriptional activity of the Dlx-5/6 enhancer, which in
turn regulates Dlx-5/6 expression. Of note, Evf-2-defi-
cientmice show reduced numbers ofGABAergic interneu-
rons in early postnatal hippocampus and dentate gyrus
and reduced synaptic inhibition in adulthood (117). From
these results, Bond et al. (117) suggested that ncRNA-
dependent balanced gene regulation in the embryonic
brain is critical for proper formation of GABA-dependent
neuronal circuitry in theadult brain. Such findingsprovide
additional evidence that lncRNAs are one ofmany critical
factors in the developing embryo that influence GABAe-
rgic interneuron function in adults (118). The findings
from these studies are relevant to the etiologies of adult
mental health disorders because these results show that
lncRNA-dependent processes are fundamental to the de-
velopment of the central nervous system. Moreover, the
findings suggest that adultmental disorders, in theabsence
of apparent physiological deficits, may be the result of
altered embryonicdevelopment, a topic that is discussed in
Section VIII.E.
lncRNAs are also associated with genomic imprint-
ing and X-chromosome inactivation (see Sections III.C
and IV.C). These two epigenetic phenomena have been
proposed to share some mechanistic features [see review
by Reik and Lewis (119)]. Several imprinted gene clusters
use lncRNAs as the main epigenetic mechanism to si-
lence their adjacent genes, possibly by establishing nu-
clear domains with repressive histone modifications
(120–122). Another lncRNA, X inactive-specific tran-
script gene (Xist), which is transcribed specifically from
the inactive X-chromosome, coats the chromosome in cis
to help create a repressive environment with recruitment
of histonemodifications andDNAmethylation (123) (see
also Section IV.C).
Disruption in the expression of small RNAs and
lncRNAs has been linked to human disease. For example,
miRNAs are frequently found aberrantly expressed in a
variety of cancers, central nervous system disorders, and
cardiovascular disease (101). Furthermore, microdele-
tions of the small nucleolar RNA clusters, HBII-85 and
HBII-52, on chromosome 15q11-q13 result in Prader-
Willi syndrome, an imprinting disorder that is character-
ized by hyperphagia, hypogonadism, and cognitive im-
pairment (124) (see Section III.C).
Dysregulation of lncRNAs is also a primary feature
in many cancer types, Alzheimer’s disease, spinocere-
bellar ataxia type 8, and the Beckwith-Wiedemann syn-
drome (BWS) (see Section III.C), among other diseases.
Interestingly, the results of genome-wide association
studies (GWAS) are beginning to identify ncRNAs as
novel disease loci (101). This is perhaps not surprising
because the genome is highly transcribed from inter-
genic regions and many disease variants map far from
genes; thus, the likelihood of interrupted lncRNAs is
high (101).
C. Reading the epigenetic marks and developmental and
physiological consequences
Epigenetic information is conveyed inmammalsby syn-
ergistic interaction between mitotically heritable patterns
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of DNA methylation, histone modifications, and various
DNA-binding proteins (49, 125). Cross talk between
DNA methylation and histone modifications occurs, and
this cross talk is mediated by methyl-binding or histone-
binding proteins (125), which decipher the regulatory in-
formation that is encoded in the DNA methylation and
histone marks. The methyl CpG-binding domain protein
family is a highly conserved family of DNA-binding pro-
teinswith a common sequencemotif (126, 127). This fam-
ily of proteins is widely believed to decode information
that is encoded in DNA methylation patterns into an ap-
propriate functional state by recruiting HDACs, for ex-
ample, to effect gene silencing (128, 129). As mentioned
previously, modified histones are recognition sites for ef-
fector proteins. For example, the spreading of repressive
chromatin can be achieved by H3K9me3, which is recog-
nized by HP1, to recruit the lysine methyltransferase
Suv39h1 and the DNMTs (129). This process facilitates
furtherH3K9me3marking,HP1binding, andDNAmeth-
ylation on the adjacent nucleosomes and results in the
spreading of chromatin domains.
PcG protein complexes are another group of proteins
that canmodifyhistones.ThePcGsystem,whichwasorig-
inally shown to repress developmentalHox genes inDro-
sophila melanogaster, is important for the stability of the
transcriptional program during development and mainte-
nance of stem cell pluripotency. PcG proteins are repres-
sors of target genes (130, 131). The catalytic component
of PRC (polycomb repressive complex) 2, Ezh2, catalyzes
the trimethylation of histoneH3K27 (H3K27me3),which
in turn recruits PRC1 via its chromodomain-containing
components and facilitates histone H2A ubiquitination
and chromatin condensation (132). In ESCs, PcG proteins
suppress cell fate-specific genes to keep stem cells in a
pluripotent state. Indeed, genes such asDlx, Pax, Six, and
Hox, which are required during development and for dif-
ferentiation, are held repressed in pluripotent ESCs by
induced H3K27 methylation (131, 133). Upon differen-
tiation, the reduced recruitment of PcG proteins activates
their target genes (134), and the trithorax group proteins
may be involved in this activation by substituting the PcG
proteins on the target genes (130).
Another prominent way by which histone modifica-
tions can influence developmental gene expression was
revealed from the results of epigenomic studies on murine
and human ESCs (133, 135). Using chromatin immuno-
precipitation, Bernstein et al. (135) showed that develop-
mental genes that are repressed in ESCs but are required
for later differentiation aremarkedbybivalent chromatin,
which contains both inactivating (H3K27me3) and acti-
vating (H3K4me3) marks (133, 135, 136). These bivalent
chromatin domains render genes poised for activation,
and therefore reflect the cell state and lineage potential
(135). Importantly, several genes that are not marked by
either H3K27me3 or H3K4me3 tend to be marked by
DNA methylation in a complementary mechanism to hi-
stonemodifications that ensures heritable gene repression
(137, 138).
Emerging evidence suggests that the distribution of
DNA methylation may be a major determinant of the
chromatin landscape by controlling histonemodifications
and histone variant deposition (138–140). In accordance
with this notion, H3K4me and DNA methylation have
been shown to be inversely correlated (138, 141). The
results of recent functional studies raise the possibility that
H3K4me needs to be removed by KDM1B lysine-demeth-
ylase so that some DNA methylation imprints can be es-
tablished in germ cells (142). This finding is consistent
with previous observations that DNMT3L recognizes hi-
stone H3 tails that are unmethylated at lysine 4 and in-
duces de novo DNA methylation by recruitment or acti-
vation of DNMT3A (139). In contrast to H4K4me,
H3K9me is found tobehighly coincidentwithDNAmeth-
ylation. Knockdowns of enzymes that catalyze thesemod-
ifications impact DNA methylation levels at defined loci,
and knockdown of DNMT1 results in altered levels of
these marks (143–145).
Many specialized sets of nuclearproteins,whicharenot
involved in chromatin modifications per se, are also crit-
ical for epigenetic regulation (146, 147). These include
chromatin remodeling complexes, which are thought to
modify chromatin accessibility by sliding or ejecting
nucleosomes, and enhancer-blocking insulator proteins,
such as CTCF, are thought to form a chromatin barrier
that protects a gene from neighboring transcriptional in-
fluences (148). In addition, specialized histone variants,
such as H3.3 and H2A.Z, introduce variation into the
chromatin template and often carry their own modifica-
tions (81, 149, 150).
The establishment of links between external signals and
the epigenetic machinery with specific physiological out-
comes is an area of increasing importance because of its
impact on developmental programming and child health.
The roles of histone demethylases in the context of whole
body physiology are now being uncovered. The histone
demethylase, Jhdm2a, for instance,was recently identified
as a crucial regulator of the genes that are involved in energy
expenditure and fat storage (151). This finding suggests
that Jhdm2a may be a key factor in obesity and metabolic
syndrome. Sirtuins also represent exciting new avenues of
research on developmental programming. Sirtuins are
proteins that possess either HDAC or monoribosyltrans-
ferase activity and are found in a variety of organisms that
range from bacteria to humans (152). Several sirtuins are
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class III NAD-dependent deacetylases with key roles as
metabolic sensors and mediators of survival for stressed
cells. They regulate chromatin structure and function by
targeting histones, in particularH4K16ac, aswell as other
nonhistone chromatin proteins (152, 153). Importantly,
their activity conveys information about the state of cel-
lular metabolism to chromatin as part of the adaptive re-
sponse to environmental stimuli. The underlying mecha-
nism of the signaling action of glucose, fatty acids, insulin,
and other metabolites and hormones to chromatin is a
fundamental question at the cellular level and is discussed
in several parts of Section VIII. Recently, a new mecha-
nism that links glucose metabolism to chromatin modifi-
cation and global transcriptional control via the enzyme
ATP-citrate lysate and production of acetyl-coenzyme A
was proposed (154). Acetyl-coenzyme Awas shown to be
a nuclear substrate for HATs, thereby providing addi-
tional evidence for a glucose-to-gene link (154–156).
D. Epigenetics as a molecular mechanism for
developmental origins of disease
There are three intriguing and fascinating facets about
the epigenetic state that are important to discuss in the
context of developmental programming and child health.
First, epigenetic states can be paradoxically both revers-
ible and heritable. Second, epigenetic states can be both
heritable across cell divisions in somatic cells and poten-
tially “inherited” across several generations. Third, epi-
genetic states can be both carriers of “memory” of early-
life experiences and “triggers” of disease susceptibility in
later life.
1. Heritability and reversibility
As previously discussed, it is well established that epi-
genetic marks are stably propagated during mitotic divi-
sions and contribute to cell lineage determination and dif-
ferentiation. Different cell types have their own “unique”
epigenotype as a result of distinct epigenetic programs that
are faithfullymaintained through cellular heritability. The
process by which cells acquire epigenetic marks that are
important for cell specification is generally referred to as
epigenetic programming.
We now know that epigenetic states can be switched
from being “stable” to being “flexible. The most striking
example of this flexibility is that which occurs during
“natural” epigenetic reprogramming, when epigenetic in-
formation is erased from the genome during periods of
development (see Sections II.E, IV.A, and VIII.F). To the
best of our knowledge, only germ cells and early embryos
have been shown to be able to “reset” or “reprogram” the
epigenetic marks on a genome-wide scale. Therefore, it is
reasonable to ask why reprogramming is needed and con-
fined to specific periods and embryonic types. Epigenetic
reprogramming in PGCs is important for the erasure of
genomic imprints and possibly for the control of trans-
poson silencing. Furthermore, it has the potential of eras-
ing “epimutations” that could otherwise be inherited
across generations, and reprogramming of PGCs could
also limit the amount of epigenetic information that is
passed onto subsequent generations. In general terms, the
global resetting of epigenetic marks is thought to achieve
developmental potency to allow the return of develop-
mental pluripotency to embryonic cells. It is thus not sur-
prising that the reprogramming that occurs in the early
embryo is crucial for erasing the gametic gene expression
programs and restoring totipotency to the zygote to form
an entire organism. Importantly, epigenetic reprogram-
ming can also occur in “artificial” experimental systems in
which differentiated cells are converted into inducible plu-
ripotent stem cells (157), and this reprogramming has im-
portant implications for the emerging field of regenerative
medicine.
Epigenetic information can pass over to the next gen-
eration (158) (see Section II.E). An important example is
that of IAP transposon insertions that can alter the ex-
pression of the neighboring endogenous genes depending
on themethylation status of the IAP. IAP elements seem to
resist methylation reprogramming in PGCs and during
preimplantation development, thereby potentially en-
abling the expression state of the associated genes to be
inherited across generations (159). Another mechanistic
example of “spillover” of epigenetic information is epige-
netic asymmetry between parental alleles at imprinted
loci. Indeed, some methylated DNA sequences at im-
printed genes in mature gametes are protected from de-
methylation at or after fertilization (Fig. 4) (160). As a
result, the transmission of epigenetic information to the
subsequent generations is made possible only when epi-
genetic states are not completely erased during the normal
reprogramming in germs cells and the early embryo. Epi-
genetic inheritance is relatively common in plants, but it is
still unclear howwidespread it is and whether it has a role
in phenotypic variation and evolution in mammals (see
Section II.E). Nonetheless, it is fascinating that it is im-
portant to erase epigenetic marks between generations,
while simultaneously having a need to maintain certain
epigenetic marks between generations, such as at certain
retrotransposons. Remarkably, there is growing evidence
that epigenetic marks may escape erasure between gener-
ations, thereby leading to multigenerational influences on
inheritance and phenotype (see Section II.E).
2. Defining epigenetic programming
Reprogramming is the most dramatic example of a dy-
namic epigenetic state.Asmentionedbefore, it refers to the
resetting of epigenetic marks to achieve developmental
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potency.Othermore “subtle” examples of epigenetic flex-
ibility are also seen at developmental genes (see Sections
II.C and IV.A). Indeed, the genes that are required later in
development are transiently held in a repressed state by
histone modifications, which are highly dynamic marks
and easily reversed when expression of these genes is
needed. This flexibility contrasts with long-term repres-
sion that is brought about by DNA methylation and as-
sociated histone modifications and is observed in genes
that are crucial for pluripotencyduringdifferentiationand
at imprinted genes and transposons.
An exciting topic for future research will be the full
characterization of the dynamic epigenome to establish
the “flexibility” of the epigenome beyond reprogramming
and the developmental program. As previously defined,
epigenetic programming is associated with acquisition of
marks that are important for cell specification and long-
term stability.DNAmethylation has long been considered
the most stable epigenetic mark and is thus critical for
epigenetic programming. However, it was recently re-
ported that certain promoters might be actively methyl-
ated and demethylated during transcriptional cycling in
differentiated somatic cells (161–163).
Therefore, it is tempting to speculate
that gene-specific resettingof epigenetic
marks (or “gene-specific reprogram-
ming”) may occur in particular cell
types, for example, in adult stem cells,
and in tissues with a high cellular turn-
over. It is also important to realize that
certain epigenetic marks can be re-
moved before a cell divides or within
few cell divisions (or short-term flexi-
bility), whereas others can be main-
tained for many divisions (long-term
stability) (Fig. 5). Short-term flexibility
of epigenetic marks is particularly im-
portant to allow appropriate responses
to acute environmental cues (Fig. 5).
As our knowledge about the flexibil-
ity of epigenetic mechanisms increases,
epigenetic programming should per-
haps be viewed as more than just the
acquisition of marks that define cell
types andmaintain cellularmemory. In-
stead, epigenetic programming should
be thought of as being inclusive: the dy-
namic epigenomic program that oper-
ates beyond the early embryo and
throughout the lifetime, from the estab-
lishment of epigenetic marks in the em-
bryo that specify lineages to the intrin-
sic responses to environmental factors
and aging. Therefore, this definition of epigenetic pro-
gramming will be used in the various discussions of this
review. Inherent in this definition is the concept of epige-
netic misprogramming, which refers to abnormal epige-
netic programming that canbe causedby either intrinsic or
extrinsic (environmental) factors.
3. Cellular memory of early-life experiences and
disease risk
TheDOHaD hypothesis proposes that some disorders,
suchasT2Dandcardiovasculardisease, can result froman
imbalance between the environments that are experienced
in utero, in early infancy, and later in life (Fig. 2). More
recently, it has been proposed that thememory of the fetal
history and adaptive responses in aging organs and cells
may be mediated through epigenetic mechanisms of gene
regulation (Fig. 6) (164, 165).Thekey featureof the“epig-
enotypemodel” ofDOHaD is largely based on the finding
that the environment can modulate epigenetic states. In-
deed, there is mounting evidence that links environmental
stimuli and the epigenome [reviewed by Jirtle and Skinner
(62) and Jaenisch and Bird (166)]. Examples include nor-
FIG. 6. The epigenotype model of developmental origins of disease. Environmental factors
acting in early life have consequences that become manifest as an altered disease risk in later
life. The period of life in which external factors can influence biology extends from
conception to the neonatal period and early infancy. It has been suggested that the baby
receives from its mother a forecast of the environment it will encounter after birth and
modifies its metabolism, whole body physiology, and growth trajectory appropriately to
maximize its chances of survival postnatally. However, these adaptations become detrimental
if the conditions after birth are not the same as the ones encountered during early life. These
adaptations include metabolic and endocrine changes that may lead to lifelong changes in
the function and structure of the body—a concept that has been termed programming. The
molecular mechanisms by which a phenomenon that occurs in utero has a phenotypic
consequence many years later are likely to involve epigenetic mechanisms of gene regulation.
Epigenetic marks can be modulated by environmental factors, are heritable, and perpetuate
gene-expression changes that underlie programming and may contribute to the onset of
disease in later life. Ac, Histone acetylation/active genes; CH3, DNA methylation/silent genes.
[Reprinted with permission from I. Sandovici et al.: Epigenetics, Horizon Scientific
Press/Caister Academic Press, Norfolk, UK, 2008 (563). © with permission from the publisher]
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mal physiological responses to cold exposure in plants,
behavioral programming bymaternal care in rats (see Sec-
tion VIII.D), and divergence between monozygotic (MZ)
twin pairs and between genetically identical inbred mice
(see Sections V and X). Furthermore, the results of several
studies have shown that environmental influences in early
life can induce permanent alterations in the epigenotype
and determine adult phenotypes and disease susceptibility
[reviewed by Skinner et al. (167)]. Such embryonic expo-
sures include suboptimal nutrition, glucocorticoids, and
EDCs, with transgenerational effects being reported in
some of these studies (168–170) (see also Sections VI.B
and VIII.C–F).
Epigeneticmisprogrammingmay occur throughout de-
velopment, during which particular developmental time
windows may be associated with specific outcomes. For
example, induced changes that affect reprogramming in
the germ line may alter the resetting of the normal chro-
matin state of the affected genes in subsequent generations
and result in transgenerational disease (see Section
VIII.F).Also, environmentally induced changes that affect
programming during early development, and especially
during cell differentiation,may have a greater,morewide-
spread effect than those that occur during less “plastic”
times in development. A still unanswered question is the
identity of those genes that are likely to be involved in the
enhanced susceptibility when they are epigenetically de-
regulated by environmental factors.Many approaches are
being followed to identify these genes using genome-wide
approaches in MZ and dizygotic (DZ) twins and inbred
mouse strains to study the environmental impact on the
chromosomemachinerywithout the confounding effect of
genetic variation.At this point in time, there are only a few
described examples of epigenetic targets of the environ-
ment, and they include transposable elements, metastable
epialleles, and a small number of developmental transcrip-
tion factors and imprinted genes (see Sections II.E, III.D,
and V). The outcome of the many ongoing epigenome
screens is eagerly awaited, in particular those that are try-
ing to look at the unexplored area of ncRNAs and how
they might impact on the programming of disease.
E. Heritability of epigenetic changes and the
determination of phenotype
The approximate composition of chromosomes is 50%
DNA and 50% protein (mainly histones). During the last
50 yr, most research effort has been directed toward in-
vestigating theDNAmolecule and its nucleotides. Inmore
recent times, the research effort has been directed toward
the protein content and function of DNA, and their roles
in epigenetic phenomena. The outbred nature of the hu-
man species poses challenges for the conduct of research
into epigenetic causes of phenotypic variation.Oneway to
overcome this problem is to studyMZ twins and look for
epigenetic marks that are variable between twins who are
discordant for disease (see Section V). These studies are
not easy to conduct becauseof theneed to recruit sufficient
numbers of MZ twin pairs to enable statistical validity.
Other barriers that need to be overcome include ethical
review, duration, cost, and, more importantly, the exact
interpretation of DNA methylation and other epigenetic
marks.
The epigenetic machinery, as described in Section II.B,
is mitotically heritable to establish cell type-specific gene
expression during development. Once established, epige-
netic marks are maintained, in most cases, with high fi-
delity as cells proliferate throughout life. However, some
epigenetic marks can sometimes be meiotically inherited.
Although it is obvious that reprogramming of the genome
in the sperm and oocyte cells is essential, some chromo-
somal components, such as telomeres, centromeres, and
transposable elements (retrotransposons), probably re-
main in their original state. Therefore, it is important to
know the extent of transgenerational transmission of epi-
genetic marks. Assuming a 10–15% loss of global DNA
methylation in a single life span (171), complete gene re-
pression or “epigenetic collapse”would occur after five to
10generations if therewas transgenerational transmission
of all epigenetic marks. Therefore, a repair or restorative
system is needed to erase epigenetic marks. In this regard,
Teixeira et al. (172) recently reported that genetically in-
duced epigenetic alterations can be transmitted to the next
generation in plants but are corrected in successive gen-
erations by posttranscriptional gene silencing and RNAi.
However, it should not be overlooked that reprogram-
ming could be life-threatening, or even lethal, for the de-
veloping organism. Lastly, it is also important to know
whether the transmission of epigenetic marks occurs on a
genome-wide scale, or whether only stable locus-specific
marks are transmitted.
The observed heritability of some epigenetic marks in
animals (173) andhumans (174, 175) raises the possibility
that part of the epigenotype can be transmitted from one
generation to the next generation. If this is true, how are
epigenetic signatures transmitted to the next generation?
One possibility is that the process depends on certain ge-
notypes that directly affect the epigenetic machinery, such
as the DMNTs. In this case, the epigenotype of the off-
spring would resemble that of the progenitors due to the
direct action of the epigenotype-associated inherited ge-
notype. The dependence on genotype is supported by the
association between methylation at the IGF2/H19 locus
with single nucleotide polymorphisms (SNPs) in cis in DZ
twins (174). Another possibility is that epigenetic marks
can be directly transmitted to the next generation. This
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idea is supported by the results of the study of Kaminsky
et al. (175) in which they found that epigenetic differences
between outbred mice were not significantly associated
with variation in the DNA sequence. Because MZ twins
develop from the same zygote and should possess similar
epigenomes at the timeof blastocyst splitting,Kaminsky et
al. (175) proposed that DZ twins have more epigenetic
differences than MZ twins because they originate from
different zygotes that carry two different epigenetic pro-
files. It is possible that genetic and direct transmission of
epigenetic marks occurs simultaneously (i.e., some DNA
regions are directed by one mechanism and others by a
differentmechanism).Themolecularmechanisms thatun-
derlie the heritability of epigenetic marks are still unclear.
Indeed, most genomic DNA methylation is erased during
embryonic development (62, 176), which implies that
other epigeneticmechanisms, in addition toDNAdemeth-
ylation, must participate in the reprogramming process.
The influence of environmental factors on the epige-
netic marking of genes and the heritability of epigenetic
marks are of particular interest to childhood growth and
development. Irrespective of the method of inheritance of
epigenetic phenomena and the problems of assessing epi-
genetic patterns in humans, there are some epidemiolog-
ical data that support the concept of transgenerational
inheritance of environmental effects. The results from the
Dutch famine birth cohort studies stand out because they
provide good evidence of this phenomenon (177–181).
The infants of pregnant women who experienced famine
due to the Dutch Hunger Winter during World War II
weighed less than expectedwhenmaternal undernutrition
occurred during the third trimester. This effect was passed
on to the second- and third-born infants in the second
generation (F2) from those who were exposed to the fam-
ine during the first trimester of pregnancy. The results of
these studies also showed that these children were more
susceptible to diabetes mellitus, obesity, cardiovascular
disease, and other health problems. Until very recently,
there was no molecular evidence of epigenetic correlates
with these phenomena. Heijmans et al. (182) recently re-
ported that individuals who were prenatally exposed to
Dutch famine have, six decades later, less DNA methyl-
ation of the imprinted IGF2 gene compared with their
unexposed, same-sex siblings. The association was spe-
cific for periconceptional exposure, thereby reinforcing
the notion that very early mammalian development is a
crucial period for establishing and maintaining epigenetic
marks. These data are the first to provide evidence that
early-life environmental conditions can cause epigenetic
changes in humans that persist throughout life.
Using data from the Overkalix and Avon Longitudinal
Studyof Parents andChildren (ALSPAC) cohort, Pembrey
et al. (35) supported the existence in humans of sex-spe-
cific, male-line transgenerational responses by showing
that smokingby the father during his childhood correlated
with a higher bodymass index (BMI) in hismale offspring.
Pembrey et al. (35) hypothesized that these transgenera-
tional transmissions were mediated by epigenetic events
on the Y-chromosome. In doing so, they added an entirely
new dimension to the study of gene-environment interac-
tions indevelopment andhealth. Suchdataare challenging
to interpret, and other mechanisms or even other expla-
nations are possible.
Some genes can be sensitive to environmental factors
because their activity is dependent on their epigenetic
state. Such alleles of mammalian genes with such charac-
teristics are termed “metastable epialleles” and are named
so as to distinguish them from traditional alleles [for clin-
ical examples, see review by Dolinoy et al. (183)]. These
alleles differ from SNPs in that they have epimutations,
rather than point mutations. The term “metastable” is
used to describe the state of permanency of the change:
they are not as stable as point mutations, and they can
change more rapidly. These alleles display more plasticity
than traditional alleles. At this stage, it is unclear how
common these alleles are, but an appreciation of their ex-
istence will aid in their identification. DNA methylation
often correlates with other regional chromatin features,
such as histone acetylation andmethylation. Accordingly,
DNAmethylation is used as an overall indicator of locus-
specific epigenetic alterations that regulate gene expres-
sion. Most genomic regions undergo developmentally
programmed establishment of epigenetic regulation and
show little interindividual variability in DNA methyl-
ation. Conversely, developmental establishment of DNA
methylation at metastable epialleles occurs probabilisti-
cally and results in dramatic interindividual differences in
epigenetic regulation (184).
Although the epigenetic states, once established, usu-
ally last for the lifetime of the individual, some can change
during that lifetime depending on genetic, environmental,
or stochastic factors (185) (see Section V). Therefore, the
epigenetic state is a record of the environmental history of
the individual. The epigenetic state is also labile (see Sec-
tion II.A), and phenotypic mosaicism exists between cells
(variegation) and between individuals (variable expressiv-
ity). The establishment of the epigenetic state that occurs
during early embryogenesis is a probabilistic event that in
some cases is influenced bywhether the allele is carried on
paternal or maternal alleles (see Sections III.C and IV.A
and D). In addition, the epigenetic state determines
whether these alleles are dominant. Some mammalian
genes display variable expressivity in the absence of ge-
netic heterogeneity. A litter of isogenic mice will display
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variable expressivity and variegation during early devel-
opment. This variegation occurs because daughter cells
remembered the epigenetic state of their founder cell. As-
suming that methylation of the gene promoter is the un-
derlying mechanism, one can speculate that methylation
of the promoter occurred during the early development of
the founder cell and was passed onto subsequent genera-
tions of offspring cells through cell division in clonal
patches.
Phenotypic variation among genetically identical indi-
viduals exists, evenwhen the environmental influences are
controlled, and is called “intangible variation” or “devel-
opmental noise” ingenetic textbooks. Intangible variation
results from the stochastic establishment of epigenetic
modifications to the DNA nucleotide sequence in early
development (54, 186). These modifications, which in-
volveDNAmethylation and chromatin remodeling, result
in alterations in gene expression that, in turn, affect the
phenotype of the organism. Random mutagenesis of the
genome can be used to identify genes that are involved in
epigenomic programming to understand the mechanisms
that underlie establishment of the epigenome and its re-
programming during development. Transgenes that are
known to variegate have been used to develop a mutagen-
esis screen to determine protein expression levels in red
blood cells using green fluorescent protein as the reporter
and fluorescence-activated cell sorting analysis (187). In
thisway, dominant and recessive screens can be developed
for identifying modifications in metastable epialleles. For
example, the PEV of eye color in Drosophila has been
extensively used to define genes when investigating epi-
genetic reprogramming (188).
Using this strategy,Whitelaw and colleagues (187) car-
ried out a “sensitized” N-ethyl-N-nitrosourea mutagene-
sis screen in mice that were carrying a variegating trans-
gene to identify genes that modify the epigenetic state.
They screened1000 first-generation (F1)mutantoffspring
for dominant mutations and identified 10 mutants or
modifiers of murine metastable epialleles (Mommes). In
most cases, they were homozygous lethal, and this finding
indicates the obligate requirement for those genes (187).
They have since characterized seven of the underlyingmu-
tations, of which two are novel (189, 190). The others
have been mapped to between 1- and 3-cM intervals. All
mutations that have been tested so far affect expression at
epigenetically sensitive loci and include the agouti viable
yellow allele. Interestingly, the mutations in a number of
cases showbothpaternal andmaternal effects; namely, the
wild-type offspring from heterozygous mutant parents
weredifferent from thewild-typeoffspring fromwild-type
parents (191). Heterozygosity for the mutations was as-
sociated withmild abnormalities in phenotypes. These re-
sults highlight the essential role of epigenetic reprogram-
ming in early development (189). These studies have been
extended, and another 12 Mommes have been identified
after screening of another 1000 F1 mice. This project has
the potential to identify many more novel genes involved
in epigenetic phenomena and to produce loss of function
(hypomorphs) and gain of function (hypermorphs) ver-
sions of knownmodifiers of the epigenetic state.Mice that
are haploinsufficient for such proteins show a range of
subtle phenotypes that include obesity and behavioral ab-
normalities. Viable mouse strains with mutations in epi-
geneticmodifier genes enable investigation into the role of
epigenetics inmaintaining genome stability. Thesemutant
lines are therefore a valuable resource to study the role of
epigenetics in gene/environment interactions. For exam-
ple, the risk of a poor outcome after a gestational exposure
to an environmental pollutant or anutrient deficiencymay
be greater for a MommeD heterozygous individual than
for a MommeD homozygous individual.
To summarize, we know that epigenetic regulation of
gene expression is essential for normal growth, develop-
ment, and the aging of higher organisms (45) and that
epigenetic dysregulation of gene expression is causally
linked with various pathologies, such as cancer (192). Re-
grettably, our current understanding of epigenetic marks
and the epigenetic machinery is incomplete. Understand-
ing the code of epigenetic marks and the underlying pro-
cesses of their writing, reading, and erasure is a “work in
progress.” The epigenome is not static, and we are now
beginning to appreciate that the epigenome is both stable
and labile. As wewill now discuss throughout this review,
the dynamic and heritable nature of the epigenome is im-
portant for understanding the underlying mechanisms of
metabolicprogramming,howprogramming influences in-
trauterine andpostnatal growth, and the origins of disease
in later life.
III. Human Growth and
Developmental Programming
A. Plasticity in human growth
Postnatal growth in body weight and stature can be
assessedby threemeasures: growthvelocity, attainedbody
size, and the timing or “tempo” of growth, which is a
measure of how rapidly an individual achieves its growth
potential. Human growth rates differ markedly between
individuals, particularly during the most rapid phases of
growth, which occur during infancy and adolescence
(193, 194).
Human growth demonstrates both “elasticity” and
“plasticity” (or long-term programming) during the dif-
ferent growth periods. The concepts of growth elasticity
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and plasticity arose from the results of studies in experi-
mental animals that date back to the 1960s in which the
influence of nutrition on growth was investigated. The
results of these studies demonstrated that there are critical
time windows in which the outcome of a programmed
growth trajectory can be changed. McCance and Wid-
dowson (195, 196) were the first to report this phenom-
enon when they showed that the exact timing of under-
nourishment in the growth phase can exert either a
permanent or transient effect on final body size.When rats
are transiently undernourished (food-restricted) in very
early postnatal life, they remained smaller throughout
later life than control rats that are not undernourished. In
contrast, rats that are transiently undernourished during
later growthphases showcatch-upgrowthafter theperiod
of undernutrition and attain the same adult weights as the
control rats.
Although human growth may be impacted by severe
acute or chronic diseases, there is growing awareness that
growth rates, and in particular the tempo of growth, may
have marked influences on the subsequent risks for mor-
bidityandmortality and,hence, reproductive fitness.Birth
weight is strongly correlated with perinatal mortality and
is the single strongest predictor of infant survival. Neo-
nates who are born at term and weigh between 1500 and
2500 g (10th percentile) have a 5- to 30-fold increase in
perinatal morbidity and mortality when compared with
neonates whose birth weights lie between the 10th and
90th percentiles. The strength of the correlation between
birth weight and perinatal mortality depends on gesta-
tional age (the lower the birth weight, the higher the rate
of neonatal mortality for the estimated gestational age)
(197) and also on factors that are unrelated to gestational
age. This low birth weight associationwith neonatal mor-
tality is echoed in adult life with the development of later
disease and mortality (15).
In postnatal life, there is growing evidence that the
“natural variations” in body size and growth rate may
have major relevance, not only on adult height but also
more importantly on infant and childhood survival and
reproductive fitness (198). Pygmies are an “extreme” ex-
ample of the interplay between postnatal growth and de-
velopment, survival, and reproductive fitness. Their char-
acteristic small adult size does not appear to have evolved
through any positive selection for short stature, but rather
as the result of a life-history trade-off between the fertility
benefits of large body size against the costs of late growth
cessation in a setting of extremely high childhood and
early adult mortality (199).
In Western settings, rapid weight gain during early
postnatal life is associatedwith increased risks for disease.
For example, Ong et al. (193) showed that children who
showed catch-up growth between birth and 2 yr of age
were fatter and had more central fat distribution at 5 yr
when compared with children with normal early growth.
Ekelund et al. (200) examined the independent associa-
tions betweenweight gain during infancy (0–6months) or
early childhood (3–6 yr) with components of the meta-
bolic syndrome in young adults in a prospective cohort
study in 128 individuals from birth to 17 yr. They con-
cluded that rapid weight gain during infancy (0–6
months), but not during early childhood (3–6 yr), pre-
dicted the clustered metabolic risk at age 17 yr.
Infant feeding type and feeding patterns can also influ-
ence growth trajectories and disease risk. Compared with
formula feeding, breast feeding is associated with slower
infant weight gain and lower later obesity risk. The results
of several meta-analyses suggest that breast feeding has a
protective effect, especially in SGA and preterm infants
(201). Experimental evidence from several randomized
control trials of nasogastric feeding of breast milk and
various nutrient formulae for 4 wk showed long-term dif-
ferences on adiposity levels and the later propensity to
cardiovascular disease (202–206). Precocious puberty
that is associated with rapid weight gain and growth, par-
ticularly during infancy, also has implications for future
life events. Ong et al. (207) have shown that an early age
of menarche confers increased risk for disease, such as
obesity, T2D, and hypertension, and death from cardio-
vascular disease and cancer in later life (208).
Finally, the mechanisms that signal and regulate early
catch-up growth in the postnatal period may mediate or
modify the associations between small size at birth and
risks for disease in adulthood. The combination of low
birth weight and a subsequent high BMI is related to the
increased incidence of T2D in later life. Using longitudinal
data that were collected from 8760 individuals who were
born in Helsinki between 1934 and 1944, Eriksson et al.
(209) reported that the large differences in the incidence of
T2D were associated with growth rates in utero, weight
gain in infancy, and the age at adiposity rebound. These
observations have implications for the early origins of
both obesity and cardiovascular disease, in that program-
mable windows of human obesity may exist during the
periods of greatest weight velocity. However, current ev-
idence has failed as yet to agree on the specific program-
mable windows during postnatal growth and develop-
ment for later disease risks (200, 202, 209).
B. Epigenetic regulation of human growth
If environment can influence long-term growth trajec-
tories in infants and children and their later life outcomes,
how do epigenetic changes influence growth at the mo-
lecular level? Human growth is highly heritable. The re-
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sults of twin studies estimate that genetic factors account
for 80% of the variations in adult height and approxi-
mately 80% of the variations in the timing of the adoles-
cent peak height velocity (210). Traditionally, pediatri-
cians and endocrinologists have had a hormone-centric
view of the regulation of growth and development.
Growth velocity is regulated by insulin, GH, IGF-I, and,
particularly during fetal life, IGF-II. The results of recent
studies (211–213) have described the BWS and the Silver-
Russell syndrome (SRS) as growth disorders due to defec-
tive IGF2 imprinting. The specific molecular defects and
consequent prenatal andpostnatal growth phenotypes are
discussed in detail in Section III.D. Rare mutations in the
genes that regulate the GH-IGF-I axis underlie some
causes of prenatal and postnatal growth failure and may
also retard intrauterine and subsequent growth. These
genes include theGHreceptor (GHR) gene (214, 215), the
STAT5Bgene (216, 217), IGF1 (218, 219), and the IGFIR
gene (220, 221). Although these growth factors and sex
steroids are the downstream factors that drive the growth
process, they do not convey messages of when the various
growth stages should start or stop, how such timings are
influenced by environmental factors, or how variations in
growth might be related to long-term disease risks.
Adult height is the summation of the velocity of child-
hood growth and also the duration of the various growth
phases, and it reflects the combined influence of multiple
genetic factors. The results of several recent GWAS have
begun to reveal the multitude of biological pathways that
contribute to thenormal variation in adult height.Amajor
surprise has been the absence of genes that are involved in
the traditional hormone regulatory pathways (222).
Rather, newly identified genetic loci for adult height high-
light several targets for let-7miRNAs, chromatin remod-
eling proteins, and Hedgehog signaling as important reg-
ulators of human stature (222). The expression of let-7
miRNAs is tightly correlated with the onset of adult de-
velopment inmany animals, and this relationship suggests
that let-7 miRNAs function as evolutionarily conserved
regulators of developmental timing (223) (see also Section
II.B.3.a).
Recently, the results of four GWAS identified that the
location of common genetic markers for the timing of
menarche in girls coincides with the height-related gene,
LIN28B (6q21) (106, 224–226), which is a potent and
specific regulator of let-7miRNA processing. This gene is
the first common variant to be associated with the timing
of human growth and maturation in both boys and girls
(106). Dysregulation of mRNA expression by the let-7
miRNAs is considered to be critical for the activity of
LIN28B in development; Viswanathan et al. (227) re-
ported that theLIN28Bprotein product selectively blocks
the processing of pri-let-7 miRNAs in embryonic cells by
blocking microprocessor-mediated cleavage of pri-let-7
miRNAs. More recent studies have described the roles of
let-7 miRNAs and the LIN-28 protein in controlling cell
self-renewal and cell differentiation (228). Collectively,
these findings indicate a remarkable parallel in the molec-
ular regulation of both cellular differentiation and whole
organism maturation. Further investigations are now
needed to explore how LIN28B and let-7miRNAs might
signal the effects of early-life environmental exposures on
subsequent height trajectory, the tempo of growth and
timing of puberty, and long-term disease risks (229).
C. Intrauterine growth and imprinted genes
Human growth is a complex event that requires the
programmed contribution and interaction of many oper-
ators. Key participants in the growth pathways are regu-
lated epigenetically to a certain extent, and correct
genomic imprinting is essential for mammalian ontogen-
esis. Somatic maintenance of imprints throughout devel-
opment is a highly complex process that involves not only
the allelic DNAmethylation at imprinting control regions
(ICRs), but also covalent histone modifications and non-
histone proteins (230–233) (see Sections II.B and III.A).
Errors in themechanisms for resetting andmaintaining
genomic imprints lead to imprinting defects with or with-
out nucleotide sequence abnormalities (234). In humans,
dysregulation of imprinting mechanisms has been linked
to fetal and postnatal growth, neurological development,
and behavior (21, 235). BWS (OMIM 130650) and SRS
(OMIM 180860) are two human growth disorders that
exhibit opposite phenotypes. BWS is characterized by pre-
and postnatal overgrowth, macroglossia, abnormal wall
defects, hemihyperplasia, and an increased risk of child-
hood tumors (236, 237). SRS, in contrast, first described
by Silver et al. (238) and Russell (239), is characterized by
pre- and postnatal growth retardation, a prominent fore-
head, relative macrocephaly, body asymmetry with hemi-
hypoplasia, feeding difficulties, and a BMI less than2 SD
score (213).
Both growth disorders are often caused by abnormal-
ities in DNA methylation at the 11p15 region, which en-
compasses many imprinted genes that encode key growth
regulators, such as the IGF2 gene. BWS has been reported
to result from loss of methylation (LOM) at the centro-
meric KCNQ1OT1 region on the maternal allele or gain
of methylation (GOM) at the telomeric IGF2/H19 region
on the maternal allele (236). Conversely, LOM at the te-
lomeric IGF2/H19 domain on the paternal allele has been
demonstrated in SRS (211, 213, 240–243) (Fig. 7). Ab-
errant imprinting at different loci and uniparental dis-
omies (the loss of one parental allele andduplicationof the
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opposite parental allele origin) are also the cause of several
other diseases. For example, aberrant LOM at imprinted
loci on chromosomes 6q24 and 11p15.5 has been de-
scribed in transient neonatal diabetes mellitus (244–248).
The recognition that disrupted imprinting underlies
these syndromes comes from the results of studies on Igf2-
knockout mice (65, 249–251). In humans, BWS and SRS
are caused by abnormal DNA methylation at the 11p15
region that encompasses many imprinted genes, including
the IGF2 gene (212, 252). As alreadymentioned, LOMat
the ICR of the KCNQ1 domain and GOM at the ICR of
the neighboring IGF2/H19 domain on the maternal allele
occur in individualswithBWS.The latter epigenetic defect
is associated with a high risk of cancer in such individuals
(236, 240, 253–257). Epigenetic changes in the 11p15
region also occur in individuals with SRS, and this syn-
drome could be perceived as a molecular mirror of BWS
(211–213). In these SRS patients, LOM
at the IGF2/H19 ICR occurs on the pa-
ternal allele. These human 11p15 im-
printing anomalies (LOM and GOM)
probably occur in the postfertilization
period because of the presence of mo-
saic patterns of imprinting abnormali-
ties andbecause such imprinting defects
are seen exclusively in the affected twin
within MZ twin pairs who are discor-
dant for these syndromes (211, 236).
D. Postnatal
developmental epigenomics
Realization that developmental plas-
ticity extends into the postnatal period
ledWaterland andGarza (164) in 1995
to propose “metabolic imprinting” as
the biological phenomenon that puta-
tively underlies the associations be-
tween nutritional experiences in early
life and later diseases. The term is in-
tended to encompass those adaptive re-
sponses to early-life nutritional chal-
lenges that are characterized by: 1) a
susceptibility that is limited to a critical
ontogenic window early in develop-
ment; 2) a persistent effect that lasts
through adulthood; 3) a specific and
measurable outcome (that may differ
quantitatively among individuals); and
4) a dose-response or threshold rela-
tion between a specific exposure and
outcome.
The mouse agouti gene encodes a
paracrine signaling molecule that pro-
motes follicular melanocytes to produce the yellow
pheomelanin pigment rather than black eumelanin pig-
ment. As a result, the hair coat in these mice is yellow.
There are several agouti gene mutations, such as lethal
yellow and viable yellow, in which the agouti gene is de-
regulatedandexpressed ectopically. In addition to causing
a yellow coat, deregulation of the agouti gene has pleio-
tropic effects that include adult-onset obesity, increased
tumor susceptibility, and premature infertility.Waterland
et al. (258, 259) have shown that food supplementation
with a methyl donor to female mice before and during
pregnancy permanently increases tissue-specific DNA
methylation at the agouti viable yellow (Avy) and axin-
fused (AxinFu) alleles in the offspring (the latter controls
dorsal-ventral axis development through the Wnt signal-
ing pathway, which describes a network of proteins that
FIG. 7. The two imprinted domains of the 11p15 chromosomal region are under the control
of two ICRs. The reciprocal imprinting of the maternally (mat) expressed H19 and the
paternally (pat) expressed IGF2 depends on an ICR1 located upstream from the H19 gene
that acts as an insulator. The repressor factor CTCF (CCCTC-binding factor) binds to the
unmethylated maternal copy of the ICR and prevents the IGF2 gene promoter from
interacting with enhancers downstream from the H19 gene. This results in transcriptional
silencing of the maternal IGF2 allele. On the paternal allele, the ICR is methylated, and CTCF
binding is prevented. This leads to IGF2 transcription on the paternal allele and silencing of
the H19 gene. The centromeric KCNQ1 domain produces a noncoding RNA (antisense
KCNQ1OT1 RNA) that silences many of the genes in this domain. Paternally expressed genes
are represented as white boxes, maternally expressed genes as black boxes, and
nonexpressed genes as gray boxes. BWS is associated with a variety of genetic and epigenetic
defects within the imprinted 11p15 region. Most patients (70%) exhibit an epigenetic defect.
Ten percent of BWS patients display an imprinting defect at the IGF2-H19 domain (aberrant
GOM at the maternal copy of the ICR), which results in silencing of the maternal H19 gene
and a biallelic expression of the IGF2 gene. The majority of the BWS patients exhibit a LOM at
the ICR of the KCNQ1 domain. Loss of methylation at this ICR results in activation of the
normally silent maternal allele of KCNQ1OT1 and CDKN1C silencing. In SRS, the mirror
phenotype of BWS, a loss of imprinting at the IGF2–H19 domain was identified: the paternal
allele switches to a maternal epigenotype, and this results in biallelic expression of H19 and
loss of IGF2 expression. Genetic and environmental factors could induce these epigenetic
anomalies.
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are involved in embryogenesis and cancer). This is an ex-
ample of an epigenetic effect within one generation be-
cause Waterland and his colleagues did not find evidence
of amemoryofmethyl donor supplementation across gen-
erations. Accordingly, they concluded that stochastic es-
tablishment of epigenotype at metastable epialleles is, in
general, labile to methyl donor nutrition, and such influ-
ences are not limited to early embryonic development.
Such findings inmicemayhavedirect relevance to thewide
variation of the human phenotype (see also Sections
VIII.C and F and IX.A).
Extensive data indicate that epigenetic dysregulation
can contribute to obesity (260). To test the hypothesis that
maternal obesity induces transgenerational amplification
of obesity, Waterland et al. (261) passed the Avy allele
through obese Avy/a females for three generations in two
separate, but contemporaneous populations of mice. One
population was fed a standard rat diet, and the second
population was fed a methyl-supplemented diet during
development to assess the cumulative effects on coat color
and body weight. They reported that the genetic tendency
for obesity in Avy mice was progressively exacerbated
when the Avy allele was passed through successive gener-
ations of obese Avy/a female mice, and this transgenera-
tional amplification of body weight was prevented by a
promethylation dietary supplement. Importantly, the ef-
fect of methyl supplementation on body weight was inde-
pendent of epigenetic changes at the Avy locus.
From these data,Waterland andMichels (55) proposed
two general mechanisms to explain the early postnatal
environmental influence on the developmental establish-
ment of DNA methylation: the supply of dietary methyl
donors and/or activity of DNAmethyltransferases can in-
duce either hyper- or hypomethylation at metastable epi-
alleles and alterations in transcriptional activity of specific
genes during ontogenic periodswhenDNAmethylation is
being established (Fig. 8).
To summarize, we are becoming increasingly aware
that epigenetic changes have important relevance to
growth. However, we do not yet know how these pro-
cesses interact with the hormonal axes or growth plates to
regulate the timing and extent of growth. We need to un-
derstand which specific types of epigenetic changes influ-
ence growth and the timing of postnatal development, as
well as the precise genetic loci in each tissue that these
epigenetic changes affect. With this kind of information,
one can begin to explore whether nutritional or other ex-
posures create or alter epigeneticmodifications duringkey
periods of growth and thereby exert their long-term pro-
gramming effects. Some of these concepts are discussed in
Section VIII.
IV. Genomic Imprinting, X-Inactivation, and
Childhood Disease
A. Epigenetic mechanisms in mammalian
genomic imprinting
Monoallelic gene expression is achieved by genomic
imprinting and X-inactivation, both of which are mech-
anisms that depend on DNA methylation and histone
modifications. Genomic imprinting refers to the differen-
tial expression where either the maternal or the paternal
FIG. 8. Potential mechanisms for environmental influences on
developmental establishment of DNA methylation. A, Nutritional or
other stimuli that affect either the efficiency of one-carbon metabolism
or the activity of DNMT1 could alter the developmental establishment
of DNA methylation at metastable epialleles. Flux through the
transmethylation/remethylation pathway is dependent upon nutrients
including folate, vitamins B12 and B6, choline, betaine, and methionine.
B, Transcriptional activity during critical developmental periods can
impair de novo methylation. Any nutritional or other environmental
exposure that activates gene transcription during periods of de novo
CpG methylation can permanently imprint transcriptional competence
by preventing hypermethylation. Methylated CpG sites are shown as
“filled lollipops.” Although a gene promoter region is shown here,
similar effects could occur at any genomic region contributing to
transcriptional regulation, such as a distal enhancer. 5CH3THF, 5-
Methyl tetrahydrofolate; SAH, S-adenosylhomocysteine; DMG,
dimethyl glycine. [Reprinted with permission from R. A. Waterland and
K. B. Michels: Annu Rev Nutr 27:363–388, 2007 (55). © Annual
Reviews.]
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copy of a gene is expressed (monoallelic expression or
functional hemizygosity) (65, 262). In genomic imprint-
ing, the activity of a gene is reversiblymodified, depending
on the sex of the parent that transmits it, and leads to
unequal expression of the maternal and paternal alleles in
the offspring (263). It is a form of non-Mendelian inher-
itance and is believed to have evolved in mammals to reg-
ulate, in part, the dosage of developmentally important
genes. Genomic imprints are established upon passage of
the genome through either the female or the male germ
line. They are fully acquired in sperm (paternal imprints)
and inmature oocytes (maternal imprints). After fertiliza-
tion, these parental imprints are maintained throughout
development in all somatic cells and tissues. The allelic
expression of imprinted genes that are mediated by the
parental imprints can be cell type- or tissue-specific
(66). In the developing PGCs of the embryo, imprints
are erased so that new imprints can be established at a
later developmental stage according to the sex of the
embryo (52). The expression of imprinted genes is made
additionally complex when, exceptionally, erasure and
resetting of the imprint are not entirely complete in a
single generation (234).
As mentioned earlier, more than 100 imprinted auto-
somal genes have been identified to date in mammals, and
many of these participate in the regulation of growth and
cellular proliferation, whereas others influence behavior
(52, 53). Imprinting is important inmammals because im-
printed genes affect intrauterine andpostnatal growth and
behavior, such as IGF2 (11p15) (242). There are two crit-
ical time periods in epigenetic reprogramming: gameto-
genesis and early preimplantation development. Early em-
bryonic maintenance is particularly critical because this
process is sensitive to environmental factors. Major re-
programming takes place in PGCs to erase parental im-
prints and restore totipotency. Imprint marks are then re-
established later during spermatogenesis or oogenesis.
Upon fertilization, genome-wide demethylation occurs
and is followed by awave of de novomethylation, both of
which are resisted by imprinted loci (Figs. 4, 8, and 9).
Almost all known imprinted genes are clustered in large
chromosomal domains whose organization is similar in
humans and mice. The parental allele-specific gene ex-
pression at these domains is mediated by ICRs, and the
parental imprints are established at these regions (Fig. 9).
The precise nature of these parental imprints is not yet
fully understood, but DNA methylation is a hallmark of
genomic imprinting at all ICRs. DNA methylation is not
the only epigenetic modification found at ICRs (52). Re-
sults from chromatin studies show that the chromatin is
compacted by repressive histone modifications on the
DNA-methylated allele. On the opposite parental allele,
where there is no DNA methylation, there are histone
modifications, which are typical for an open chromatin
structure. In this way, differential DNA methylation and
the associated chromatin features at ICRs convey the al-
lelic expression of imprinted genes at imprinted gene clus-
ters (52, 235, 252).
There are at least threeways throughwhich differential
DNAmethylation at ICRs can result in the silencing of one
of the two parental alleles at close-by genes (264). The
simplest way is through direct silencing of a promoter,
where the methylated allele is nontranscribed. One of the
best-studied imprinted genes is the IGF2 gene on human
chromosome 11p15.5. IGF2 is expressed from the pater-
nally inherited allele during fetal development and after
birth (52, 252). The allelic repression of this gene is reg-
ulated by an ICR that is located upstream of theH19 gene
and 90 kb from the IGF2 gene. This CpG-rich regulatory
region is marked by DNA methylation on its paternally
inherited copy only. This paternalmethylation is acquired
during spermatogenesis and is maintained during devel-
opment in all the somatic lineages. The mechanism of im-
printing at theH19 ICR involves formationof an insulator
on the unmethylated allele, which prevents the IGF2 pro-
moter from interacting with downstream enhancers and
consequently prevents IGF2 expression from thematernal
chromosome (265, 266). Another well-characterized
mechanism of imprinting is DNAmethylation-dependent
repression of a lncRNA transcript on one of the parental
alleles. Consequently, the ncRNA transcript is expressed
only from the unmethylated allele of the ICR. At some
FIG. 9. Parental imprints are established during oogenesis or
spermatogenesis at sequence elements that control the imprinted
expression (the ICRs). After fertilization of the egg by the sperm, these
imprints are maintained throughout development. DNA methylation
(lollipops) is the most consistent hallmark of imprints. Two examples of
ICRs are depicted: one with paternally derived (ICR1) and one with
maternally derived (ICR2) DNA methylation. [Reprinted from K. Delaval
and R. Feil: Curr Opin Genet Dev 14:188–195, 2004 (52), with
permission from Elsevier.]
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imprinted domains, the ncRNA recruits PcG proteins,
such asEZH2andEED, andhistonemethyltransferases to
the locus. Enrichment of repressive histone modifications
to the region consequently silences the surrounding genes.
Thismechanism is thought tobe involved in the imprinting
of both the KCNQ1 and IGF2R domains (267, 268). Im-
printed expression at these domains is tissue-specific, and
several of the genes are imprinted in the placenta only
(269). The ncRNA-mediated recruitment of PcG proteins
is important for this placenta-specific imprinting (270),
which also requires the histone methyltransferase G9a
(also called KMT1C) (120, 271). Not all genes of the
KCNQ1 domain are imprinted in the human placenta.
Monk et al. (270) reported that imprinting in the placenta
at the IGF2R domain in humans is polymorphic, thereby
potentially increasing the susceptibility of IGF2R locus to
the effects of epigenetic perturbation in some pregnancies.
Another example is the growth factor receptor-binding
protein 10 (GRB10), which is a potent growth inhibitor
(272). In the mouse, the Grb10 gene displays a complex
tissue-specific imprinting pattern that is controlled by dif-
ferent promoters. Some tissues show expression from the
maternal chromosome, and others show expression from
the paternal chromosome (273, 274). Whereas Grb10 is
expressed from the maternal allele in most tissues, its ex-
pression in the brain is only from the paternal allele, and
its maternal and paternal expressions are initiated from
different promoter regions (275). In addition, Sanz et al.
(275) have shown that the tissue differences in the im-
printed expressionof this gene inmice andhumans are due
not to the acquisition of an imprint mark, but rather to
differences in the reading of this mark. Specifically, this
ICR is methylated on the maternally inherited allele in
both humans and mice. Whereas this maternal imprint
in themouse conveysmaternal allele-specific expression in
manymesodermal and endodermal tissues that include the
placenta,maternal expression in humans is detected in the
villous trophoblast of the placenta only.However, in both
species, the ICR conveys paternal allele-specific expres-
sion in the brain (276).
B. Assisted reproductive technologies and
genomic imprinting
As described in the previous section, the somatic main-
tenance of imprints throughout development is a highly
complex process that not only involves the allelic DNA
methylation at ICRs but is also associated with covalent
histonemodifications and nonhistone proteins (231–233,
275). Different types of environmental stress, particularly
those that result from transferring cells and embryos from
their natural environment to in vitro conditions, can in-
terferewith the somaticmaintenance of imprints. Assisted
reproductive technology (ART) is a stressor of special in-
terest because in vitro culture of embryonic cells and em-
bryos can perturb the imprints at ICRs in different model
systems, thereby affecting fetal growth and development
(235, 277–284). Such findings have implications in hu-
mans because of the association between ART and in-
creased incidenceofBWS(231,281,285–287), SRS (288),
and Angelman syndrome, which is a severe neurodevel-
opmental condition characterized by microcephalus, ab-
sence of speech, severe mental retardation, and frequent
laughing (279, 289, 290).
In humans, it has been suggested that ART may favor
imprinting alterations at the imprinted KCNQ1 domain
[LOM at the maternally methylated ICR (281, 291) and
the IGF2/H19 ICR (211, 213, 288, 292)] in SRS. ARThas
alsobeenassociatedwith imprintinganomalies atmultiple
other loci (288, 293, 294). Therefore, it is presumed that
ART interfereswith the acquisitionormaintenance ofma-
ternal methylation marks and results in unfaithful main-
tenance of DNAmethylation marks after fertilization due
to dysregulation of trans-acting regulatory factors. It re-
mains to be discovered what precisely gives rise to the
altered DNA methylation patterns at ICRs (the “epimu-
tations”), but ART could possibly affect proteins that re-
cruit the DNAmethylation machinery to the ICRs during
each cell cycle. Because not all cells and tissues are affected
to the same extent, themosaic distribution of these human
epimutations suggests that imprinting is perturbed after
fertilization due to a failure to maintain the differential
methylation marks during preimplantation development
(281, 293).
In sheep and cattle, epigenetic changes have been
shown to be involved in large offspring syndrome (295).
Affected animals exhibit various phenotypes that include
large size at birth. In both species, the syndrome is caused
by the in vitro exposure of embryos to various unnatural
environments between fertilization and the blastocyst
stage. Large offspring syndrome is often related to the loss
of imprinting of the Igf2-receptor gene which ensures in-
ternalization and degradation of IGF2 and exerts an an-
tiproliferative function (296). In vitro preimplantation
procedures in mice are also responsible for fetal over-
growth due to the abnormal expression of various im-
printed genes, and in particular those genes that are lo-
cated at distal chromosome 7 (H19 and Igf2 genes), which
is orthologous to the human 11p15 region.
In the mouse, Kcnq1 domain paternal repression is
found at several genes in the placenta only. Interestingly,
the allelic repression does not involve acquisition of DNA
methylation at the promoters of these genes. Rather, the
paternal gene silencing in the placenta involves repressive
H3K9me and H3K27me (297, 298). This repressive his-
tone methylation becomes established on the paternal
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chromosome already during early development, a process
that requires a ncRNA, which is expressed from the ICR
on the paternal allele. This ncRNA recruits PCR2, which
methylates histone H3 tails at lysine 27 (297). Recently, it
was reported that repressive H3K9Me at theKCNQ1 do-
main and some other imprinted domains is controlled by
the histone methyltransferase G9a (Kmt1c) (271). Also,
this histone methyltransferase is recruited to the chroma-
tin by the same ncRNA (120).
Finally, based on the association between ART and the
increased incidence of BWS, Miles et al. (299) hypothe-
sized that subtle differences, whichmanifest as differences
in the phenotype and hormonal profiles in midchildhood,
may also exist in the previously underinvestigated in vitro
fertilization (IVF) population. After analyzing data from
69 IVF and 71 naturally conceived control children, they
reported that the prepubertal IVF children were taller
when adjusted for parents’ heights, had higher serum
IGF-II and IGF-I levels, had altered ratios between serum
IGF-II and IGF-binding protein 3 levels, and had a differ-
ent lipidprofilewhencomparedwith those in thenaturally
conceived children. Based on these preliminary findings,
they speculated that these differences in stature, serum
growth factors, and lipidmetabolismmay be due to subtle
epigenetic alterationof imprintedgenesand/orothergenes
that are involved in growth and development. This hy-
pothesis remains to be tested. Although ART in humans is
associated with exposure to multiple environmental fac-
tors, no specific aspect of the procedures has been impli-
cated as a unique cause of the alterations in genomic im-
printing and the risk of congenital abnormalities. This
inability to identify a unique cause of the alterations in
genomic imprinting is quite amazing, despite the birth of
approximatley 4 million IVF children worldwide and the
accumulation of substantial data frombirth registries. Fu-
ture studies should aim to identify the causal factor(s) and
emphasize the need to monitor the health of IVF children
through childhood into adulthood.
Important insights into the epigenetic changes that can
occur with ART have come from somatic cell nuclear
transfer (cloning) experiments in mice and domestic ani-
mals. Here, zygotes are cultured to the blastocyst stage
after introducing a nucleus of a somatic cell into an enu-
cleated oocyte and are then implanted into the uterus. This
in vitro culturing step frequently leads to altered DNA
methylation at ICRs and hence, perturbed imprinted gene
expression and phenotype when fetal calf serum is added
to the culture medium (278, 285, 300). In cloning exper-
iments in experimental animals, the uterine environment
is alsoan important factor that influences thedevelopment
of the cloned embryo until birth [reviewed in Loi et al.
(301)]. Importantly, results fromexperiments in cattle and
mice show that phenotypic alterations due to cloning be-
come corrected in the naturally conceived offspring of
cloned animals (302). This finding suggests that altered
DNAmethylationpatterns become largely correctedupon
transmission through the germ line and do not affect the
phenotype across multiple generations (303).
C. X-inactivation, imprinted genes, and the
Turner syndrome
In humans and other eutherians, sex is determined by
the X- and Y-chromosomes, which evolved from an or-
dinary pair of autosomes by the acquisition of a sex-de-
termining gene or mutation on one of the two autosomes.
Over time, the sex chromosomes divergedmore andmore
from each other by accumulating sex-linked mutations
and genes, and the only chromosomal part that is still
shared between the two sex chromosomes is the pseudo-
autosomal region. This chromosomal region is where
crossover in meiosis can occur between the different sex
chromosomes and recombination of the sex-specific re-
gion outside the pseudoautosomal region is suppressed
(304).
The lack of recombination between the X- and Y-chro-
mosomes led to the loss and differentiation of genes on the
Y-chromosome and a single copy of most X-linked genes
in males (305, 306). One outcome of the evolution of
genetic sex determination and distinct sex chromosomes
was an imbalance of gene dosage between autosomes and
sex chromosomes andbetweenmales and females.Topro-
tect the organism against the deleterious effects ofX-chro-
mosomemonosomy, twomechanisms of dosage compen-
sation evolved: X-chromosome up-regulation, which
equalizes the genedosagebetween theX-chromosomeand
the autosomes; and X-chromosome inactivation, which
silencesoneX-chromosome in females to equalize thegene
dosage between the sexes (305, 306).
The term“X-inactivation” is used to describe the initial
transition from a transcriptionally active to an inactive
state and also the subsequent stable maintenance of the
silent state (307). In female mammals, most genes in one
X-chromosome are silenced as a result of randomX-chro-
mosome. In X-inactivation of extraembryonic tissues in
the mouse, the paternal X-chromosome (Xp) is transcrip-
tionally silenced, and the maternal X-chromosome (Xm)
is transcriptionally active (306–308).
X-inactivation is a remarkable example of epigenetic
inheritance inwhich the silencing ofmore than1000genes
occurs by packaging DNA into transcriptionally inactive
chromatin through a process that is able to distinguish
between one of an essentially identical pair of chromo-
somes. The process of X-inactivation displays plasticity:
the Xi is reactivated during oogenesis, thereby permitting
inactivation in the next generation. One of the differences
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between Xi and the active X-chromosome (Xa) and au-
tosomes in differentiated cells is the unique combination
of epigenetic features of Xi that include histone modifica-
tions, DNA methylation, late replication timing, and a
peripheral nuclear location.
Critical for the inactivation process is the X-inactiva-
tion center (XIC), which is a multifunctional domain on
the X-chromosome to be inactivated, and its crucial com-
ponent, the Xist gene (308). The Xist gene is crucial for
both imprinted X-inactivation from either of the parental
chromosome and randomX-inactivation and gene silenc-
ing in eutherians because it encodes a nontranslated RNA
that coats Xi (see Section II.B.3.b). The mechanism of
choosing which X-chromosome will remain active and
which will be inactivated is complex and is regulated by
multiple elements in the XIC. Although Xist is able to
initiate inactivation, it does not appear to be sufficient for
recapitulating the entire X-inactivation process. The ele-
ments that are involved in the number of X-chromosomes
relative to autosomes (count) and the selection of the dip-
loid set that will remain active (choice) lie outside theXist
gene (309). Although the mechanism of count is currently
unclear,Morey et al. (309) proposed thatH3K4mewithin
Xist may be functionally implicated in the counting pro-
cess (see Section II.B.3.b).
Monoallelic expression ofmost of genes on theX-chro-
mosome in females is determined mostly by random X-
inactivation and partly by imprinted X-inactivation. X-
chromosome inactivation involves features that are
common to autosomal imprinted genes. However, it is
poorly understood how Xist RNA and other epigenetic
modifications are directed to sites along the inactive X-
chromosome and how inactivation spreads in cis over the
silenced X-chromosome (310). One critical unresolved
question on themechanism of imprinted X-inactivation is
the nature and origin of the imprinted gene(s). Is gene
imprinting established exclusively in the maternal or the
paternal germ line, or are the two different maternal and
paternal gene imprints necessary? At this stage, there are
no exact answers to these questions, but the results of
studies in mice suggest the existence of an epigenetic
switch at the XIC, which underlies the molecular aspects
of chromosome-wide silencing (306). In addition, the in-
heritance of imprinted epigenetic marks on Xp and the
imprinting of Xist on Xm appear to be linked to ensure
faithful imprinted X-inactivation (306).
The epigenetic mechanisms of X-inactivation are now
beginning tobeunderstood.Reik andLewis (119) recently
proposed that the processes of X-inactivation and
genomic imprinting are mechanistically similar and are
thought to have evolved together when the evolution of
the placenta exerted selective pressure to imprint growth-
related genes. These authors also proposed that ncRNAs
andhistonemodificationswereadopted for the imprinting
of growth suppressors on the X-chromosome and auto-
somes. The initiation of X-inactivation is thought to be
tightly correlated with early differentiation events during
development (311); Xp undergoes imprinted inactivation
from the cleavage stages onward, well before cellular dif-
ferentiation. In another study, Silva et al. (312) have
shown that the recruitment of PRCs to the Xi occurs in
both imprinted and randomX-inactivation, which occurs
in the embryo proper. Localization of these repressive
complexes to Xi occurs very early, at the onset of Xist
expression, but becomes less pronounced as differentia-
tion and development progress. In addition, the PcG com-
plex is required to establish H3K27me on Xi, which in
turn is required to stabilize the Xi chromatin structure.
Lastly, Patrat et al. (313) recently reported their findings
from a systematic, single-cell transcriptional analysis that
they performed to examine the activity of the Xp for a
panel ofX-linked genes throughout early preimplantation
development in the mouse. From the results of this anal-
ysis, they concluded that imprinted X-inactivation in
mice is far less concerted than previously thought and
highlighted the epigenetic diversity that underlies the
dosage compensation process during early mammalian
development.
Between 15 and 25% of female X-linked genes escape
X-inactivation, and these genes are potential contributors
to sexuallydimorphic traits, phenotypic variability among
females heterozygous forX-linked conditions, and clinical
abnormalities in patients with abnormal X-chromosomes
(310). There is a remarkable degree of expression heter-
ogeneity linked to the X-chromosome (310). This heter-
ogeneity has been attributed to: 1) the inactivation
“escape” of about 15%ofX-linked genes; 2) the dramatic
differences in the proportion of escape genes between dif-
ferent regions of the X-chromosome; and 3) variable pat-
terns of inactivation and expression of 10% of X-linked
genes from some inactive X-chromosomes.
Turner syndrome (TS) is thought to be caused by hap-
loinsufficiency of the escape genes and arises from a com-
plete and/or partial monosomy of the X-chromosome as a
result of loss of either part or all of a second X- or Y-chro-
mosome (314). Between 60 and 80% of TS individuals
have an intact Xm (45,Xm) (315–317). Because TS can
manifest in nonmosaic or mosaic forms with or without
the presence of a normal 46,XX karyotype, or occasion-
ally the 46,XY karyotype, its phenotypic spectrum is
broad, and it encompasses both physical and neurocog-
nitive features (318). Evidence exists for X-linked parent-
of-origin effects in TS individuals because phenotypic and
cognitive profiles differ between 45,Xm and 45,Xp indi-
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viduals. X-Imprinting effects in TS are found for cognitive
function and social cognition, statural growth, visceral
adiposity, and lipid metabolism (263, 317–323).
Individuals with TS have been used to investigate the
impact of putative X-linked imprinted genes on growth
and neurocognitive development. Whereas implementa-
tion and conduct of these studies in humans are difficult,
genetically engineered 39,XO mice have now been devel-
oped to study X-chromosome allele-specific expression
(Xa vs.Xi): theXpmouse (324), and theXmmouse (325–
328). Using such mice, Raefski and O’Neill (329) identi-
fied a cluster of X-linked genes that contains at least three
genes that show transcriptional repression of paternal al-
leles. They also established that the imprinting of these
three genes was independent of X-chromosome inactiva-
tion and has a dynamic and complex pattern of tissue and
stage specificity. In addition to these genetically engi-
neered mice, some nonanimal methods have been devel-
oped to study various aspects of X-chromosome allele-
specific expression. Fibroblasts fromwomen,where about
15% of X-linked genes escape inactivation, have been
used to study polymorphisms in genes of interest (310);
somatic mouse-human cell hybrids that contain either Xa
or Xi have been used to study transcription of genes of
interest, which are normalized to a known gene that al-
ways escapes inactivation (pseudoautosomal gene) (310);
and human ESCs have been used to study the early lethal-
ity of 45,X embryos (330).
Both human and murine data support the notion that
the TS phenotype could be modulated by imprinted loci,
particularly with respect to growth and neurocognition.
Nevertheless, conflicting data on the basis of TS in human
studies still exist due to unaccounted confounding vari-
ables, different test measures, small sample sizes, and sta-
tistical bias. Therefore, studies on TS in humans should
focus on quantifiable variables and on the underlying
physiological and genetic mechanisms. These studies
would complement future studies in the genetically engi-
neered mice and cell systems whose aims could be to in-
vestigate the underlying and diverse epigenetic mecha-
nisms that are associated with X-inactivation and the
variability of the TS phenotype.
V. The Role of Epigenetics in Aging
Understanding the links between epigenetics, theDOHaD
phenomenon, and age-related diseases has emerged as an
exciting research topic because epigenetic factors are now
known to mediate, at least in part, the relationship be-
tween the genome and the environment. Focusing specif-
ically on the relationship between epigenetics and aging,
an active role for epigenetics in aging must meet two prior
conditions: there must be specific epigenetic changes, and
the epigenetic changes must be functionally associated
with the aging phenotype. One of the theories of aging
claims that aging is the progressive decay of the potential
of adult stem cells tomaintain correct tissular homeostasis
(331, 332). The variation in the life span of a species seems
to be more strongly affected by the accumulation of mo-
lecular errors over time that compromise adult stem cell
function than by specific genetic programs (332, 333).
These molecular alterations can occur at both the genetic
and epigenetic levels, and age-dependent accumulation of
epigenetic marks depends on the genotype (intrinsic fac-
tors), the environment (extrinsic factors), and stochastic
factors (185). Young adult stem cells are pluripotent and
consequently participate in tissue regeneration. As these
cells grow older, their genome is marked epigenetically,
and this marking may be accompanied by a loss in their
ability to participate in tissue regeneration. Genotypes
with a low efficiency for repairing genetic and/or epige-
netic defects or maintaining epigenetic stability in re-
sponse toharmful environmental exposures canaccelerate
the accumulation of molecular alterations at the genetic
and epigenetic levels, which in turn can accelerate the ag-
ing process. In contrast, genotypeswith a high resilience to
genetic and/or epigenetic defects ormaintaining epigenetic
stability in response to harmful environmental exposures
can slow the accumulation of molecular alterations at the
genetic and epigenetic levels, which in turn can delay the
aging process (185).
Epigenetic variation, as illustrated by genomic methyl-
ationpatterns, is dynamicbecause it changesover timeand
during the aging process. Time-associated epigenetic vari-
ationwas first observedmore than 40 yr ago byBerdyshev
et al. (334), who reported that spawning humpbacked
salmon showed a global decrease in 5-methyldeoxycyt-
idine levels with age. In a more detailed follow-up study,
Vanyushin et al. (335) reported a global loss of m5C in
DNA in the brain, heart, and spleen; no m5C changes in
the liver and lungs; and modest m5C increases in the kid-
neys of rats with aging. Based on these results, Vanyushin
et al. (335) proposed thatDNAmethylationmaybe one of
the regulatory mechanisms of gene activity and the ob-
servedchanges inm5Ccouldbe responsible for theprocess
of aging. These early findings were confirmed by Wilson
et al. (336), who reported gradual loss of DNA methyl-
ation with aging in different mouse tissues and human
bronchial epithelial cells. Wilson et al. (336, 337) also
provided convincing evidence that the reduction in DNA
methylation was unrelated to the proliferation rate of the
cells and could not be ascribed to the dilution effect of cell
division. Age-dependent global hypomethylation has
since been demonstrated in humans and other mammals
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(338, 339). In addition, specific loci are known to become
hypermethylated during aging in mammals. Examples in-
clude hypermethylated clusters of ribosomal DNA in the
liver and germ cells of old rats (340) and hypermethylated
CpG islands in the promoters of tumor suppressor genes,
lysyl oxidase, p16INK4a, runt-related transcription fac-
tor, and tumor promotor TPA-inducible gene 1 in various
human tissues (171). Intriguingly, global DNA hypom-
ethylation and aberrant promoter hypermethylation also
occur in cancer (192, 341). Such findings lend support to
thenotionof age-related lossofnormal epigenetic patterns
as a mechanism for the late onset of many human diseases
(342).
The relative importanceof genetic andnongenetic com-
ponents in aging can be estimated from the results of twin
studies (174, 175, 339, 343). The underlying rationale of
twin studies is that MZ twins are identical genetically,
whereas DZ twins on average share 50% of their segre-
gating genes and are as genetically different or similar as
ordinary siblings (344). Despite being genetically identi-
cal, MZ twin pairs vary in a wide range of anthropomor-
phic features and also in their susceptibility to disease
(344). The cause of phenotypic discordance in MZ twins
has been traditionally attributed to unique exposure to
postnatal environmental factors of each sibling, namely
thenonshared environment.Nevertheless, there is increas-
ing evidence that postzygotic genetic, epigenetic, and pre-
natal environmental factors may contribute to the pheno-
typic discordance in MZ twins (344). In fact, MZ twins
display numerous epigenetic differences, and in some
cases, these differences are associated with specific behav-
ioral and physical features (344). Recently, Fraga et al.
(343) analyzed the global epigenetic differences in differ-
ent-aged MZ twins and showed that elderly MZ twin
pairs, who lived apart from their own families, exhibited
numerousphenotypic differences.Moreover, these elderly
MZ twin pairs have more epigenetic differences than
young and phenotypically similar MZ twin pairs who
lived in the same household with their parents. In agree-
ment with other reports (345–347), Fraga et al. (343) also
found that MZ twins have significantly different gene-
expression phenotypes, although most of the epigenetic
changes occurred in nonfunctional and repetitive DNA
elements. Overall, the results from these different-aged
MZ twin studies suggest that intraindividual epigenetic
changes do occur over time.
This notion has been recently corroborated by the re-
sults of a longitudinal study inwhich successiveDNAsam-
ples were collected more than 10 yr apart in two popula-
tions, each with more than 100 individuals (339). In this
study, Bjornsson et al. (339) measured global DNAmeth-
ylation in two samples that were collected, on average, 11
yr apart from 111 individuals of an Icelandic cohort and,
on average, 16 yr apart from 126 individuals of a Utah
cohort. They reported that the change in DNA methyl-
ation over time was greater than 10% in 29% of the
Icelandic individuals. The family-based Utah sample
also displayed similar intraindividual changes in DNA
methylation over time, as well as familial clustering of the
methylation change. In addition, families that showed the
greatest global DNAmethylation loss also have the great-
est loss of gene-specific methylation. From these results,
the authors concluded that changes in DNA methylation
occur over time and proposed that the maintenance of
DNA methylation may be under genetic control. The re-
sults of other studies provide further support for the ex-
istence of epigenetic differences between twin pairs. For
example, DZ twins havemore differences in genome-wide
(175) and locus-specific (174)DNAmethylation thanMZ
twins. Collectively, these findings suggest that the main-
tenance of epigenetic marks with aging is genetically
regulated.
Environmental exposures affect time-associated epige-
netic variation [reviewed by Feinberg (45)]. Using smok-
ing as an example, Belinsky et al. (348) determined the
prevalence of aberrant promotermethylation of thep16, the
O(6)-methylguanine DNAmethyltransferase, the death-as-
sociated protein (DAP) kinase, and the Ras effector ho-
molog (RASSFIA) genes in nonmalignant bronchial epi-
thelial cells fromcurrent and former smokers in ahospital-
based, case control study of lung cancer. They also
determined the relationship between loss of heterozygos-
ity at 9p and p16methylation in bronchial epithelium and
the prevalence for methylation of these four genes in spu-
tum from cancer-free, current, and former smokers. From
their results, Belinsky et al. (348) concluded that aberrant
promoter hypermethylation of the p16 gene, and to a
lesser extent theDAPkinase gene, frequently occurs in the
bronchial epithelium of lung cancer patients and cancer-
free controls and persists after smoking cessation. More-
over, the strong association between methylation of the
p16 gene in the bronchial epithelium and the correspond-
ing primary tumor led them to suggest that inactivation of
the p16 gene, although itself is not transforming, is likely
to be permissive for the acquisition of additional genetic
and epigenetic changes that lead to lung cancer.
Genetic or environmental effects cannot explain all the
epigenetic changes, such as the differences in DNA meth-
ylation, that have been reported in isogenic animals that
live under the same environmental conditions (349). Iso-
genic laboratory animals that are maintained under iden-
tical environmental conditions also exhibit marked phe-
notypic differences (350), of which life span is one (351).
Such phenotypic variability is thought to be due to sto-
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chastic factors, which are independent of the environment
and can contribute to randombiological variability (350).
Hereditary, environmental, and stochastic factors de-
termine the accumulation of epigenetic variation over
time, but their relative contribution to the phenotypic out-
come is unclear because little data are available. For ex-
ample, Ronn et al. (352) reported that age influences the
extent of DNA methylation and the expression of OX-
PHOS genes, a set of genes that influence oxidative phos-
phorylation in muscles. However, they were unable to
determine whether the age-associated changes in DNA
methylation were due to hereditary, environmental,
and/or stochastic factors.
The finding of concordance of some psychological ap-
titudes betweenMZ twins that were reared either apart or
together (353) suggests that stochastic events are more
important than hereditary or environmental factors if
these aptitudes depend on epigenetic factors. In contrast,
results from studies of large cohorts of MZ twins that are
discordant for cancer, which is one of the best known
epigenetic-dependent diseases (354), have shown that en-
vironmental factors have an important role in the etiology
of this disease (355). It is possible that the influence of one
factor, be it environmental, genetic, or stochastic, is dif-
ferent in different genomic regions, such as the coding
elements and repeated sequences. Consistent with this no-
tion, most of the environment-related changes in pheno-
typic expressionbetweenMZtwins preferentially occur in
heterochromatic, gene-poor regions (346, 347), which are
the regions where most epigenetic differences are found
in environmentally dependent, phenotypically discor-
dant MZ twins (343). In contrast, the IGF2/H19 locus,
whose epigenetic variation depends primarily on ge-
netic factors, is resistant to age-related changes in DNA
methylation (174).
The functional role of epigenetic alterations that occur
over time depends on the genomic region that is affected
by these changes. Although genome-wide (175, 343) ap-
proaches suggest that epigenetic differences between MZ
twins occur frequently outside the functional coding ele-
ments, the discordant expression phenotypes ofMZ twins
(347) and the relationship between environmentally de-
pendent epigeneticmarks and cancer (45) suggest that epi-
genetic differences can have significant functional impli-
cations. In this regard, Mill et al. (356) assessed the
methylation statusof twoCpGsites in thepromoter region
of the COMT gene in 12 MZ twin-pairs who were dis-
cordant for birth weight but were clinically normal. They
found that the extent ofDNAmethylation at the twoCpG
sites was highly correlated, but there was considerable
variation in the concordance of methylation levels be-
tweenMZ twin-pairs, which explains the incomplete phe-
notypic concordance. Differences in DNA methylation
have also been found inMZ twins discordant for the cau-
dal duplication syndrome, which is a rare family of devel-
opmental defects inwhich structures derived from the em-
bryogenic cloaca and notochord are variously duplicated
at the AXIN1 gene, which has been implicated in this
syndrome (357). In addition, differential methylation of
theX-chromosomehas beenproposed as a possible source
of discordance among femaleMZ twin-pairs with a bipo-
lar disorder (358).
In conclusion, epigenetic states can change over time,
and this epigenetic variation depends on hereditary, envi-
ronmental, and stochastic factors (Fig. 10). Future studies
are now needed to: 1) quantify the contributions of each
component to epigenetic variation over time; 2) determine
the molecular mechanism involved in the transmission of
epigenetic patterns between generations; and 3) assess
their functional role and the DNA regions in which they
occur. The application of the new technologies of ultra-
deep sequencing to large cohorts of accurately phenotyp-
ically annotated MZ and DZ twins should generate
enough epigenome-wide information to gain insights into
the functional relevance of the epigenetic changes that oc-
cur during aging and to determine the contributions of the
genetic, environmental, and stochastic factors to their
establishment.
VI. Tissue-Specific Epigenetic Changes
There is nowmuch evidence that tissue-specific epigenetic
patterns exist across chromosomal regions.Thesepatterns
are conserved across individuals because patterns in the
same tissue from different donors are strongly correlated.
Indeed, DNA methylation profiles of the same tissue cor-
relate better across individuals than those of different tis-
sues from the same individual (359). Interestingly, the
DNA methylation profiles across various regions of the
brain are strongly correlated. This strong correlation sug-
gests that the shared methylation pattern of these tissues
was established in a common precursor cell type, and that
the functions of these cells are sufficiently similar to be
reflected in a similar pattern of epigenetic modifications.
Over the past 30 yr, research has established that type
1 diabetes mellitus (T1D) is a family of disorders in which
glucose homeostasis is disrupteddue to loss of tolerance to
-cell autoantigens. As a result, progressive and selective
destruction of insulin-secreting -cells of the islets of
Langerhans occurs by a multigenic process in which nu-
merous immune and -cell defects associate to drive the
diabetogenic process. This process has been extensively
studied in the nonobese diabetic mouse, a spontaneous
modelofT1D.Findings fromthenonobesediabeticmouse
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and other genetically engineered T1D mice have been in-
strumental in understanding the complexity of this disease
and deciphering its autoimmune basis. From these stud-
ies, proinsulin, glutamic acid decarboxylase, phogrin (1A-
2), IA-2, carboxypeptidase E, and many other -cell au-
toantigenshavebeen identified as targets of autoimmunity
in T1D. The results of other studies have established that
the thymus also contributes to the development of T1D
autoimmunity (360, 361).
Recently, Concannon et al. (362) reviewed the genetic
basis forT1D,whose complexpolygenic etiologyhas been
gradually teased out. The combination of heritability es-
timates from family studies and the specific results of link-
age studies and GWAS clearly reveals that T1D suscepti-
bility has a major genetic basis. A recent GWAS meta-
analysis identified at least 40 loci that are associated with
the risk of T1D in humans (363). The concordance rates
for T1D in MZ twin pairs are around 30–35%, and such
figures have been used to simply allocate the contributions
of genetic vs. environmental factors (362, 364). However,
disease onset can occur at different ages in each of the
twins and sometimes with a 30- to 40-yr interval (365).
This longperiodbeforediseaseonset inMZtwinswas also
found by Redondo et al. (366), who investigated the ap-
parent discordance of T1D in MZ twins. They reported
that 65%of the discordant unaffected twins do eventually
develop the disease. Epigenetic mechanisms could, there-
fore, be relevant inmediating the effectsof environmenton
disease risk and also on the timing of disease onset.
Nontraditional, apparently epigenetic inheritance does
occur in T1D, but its basis is still unknown. Akesson et al.
(367) recently suggested that not only the inherited hap-
lotypes, but also the noninherited haplotypes, may influ-
ence the risk of the disease. They investigated the risk of
T1D in 563 childrenwith the disease and 286 nondiabetic
children according to the human leukocyte antigen (HLA)
haplotypes, which can be classified as noninherited from
either the maternal side (NIMA) or paternal side (NIPA).
They found no difference in the frequency of the positively
associated haplotypes between the NIMA and NIPA in-
dividuals. They also reported that NIMA, but not NIPA,
was associated with the risk of T1D.
The notion that maternal microchimerism (maternal
cells in the circulation and tissues of her offspring) might
affect growth and development, or may contribute to dis-
ease or tissue repair in the progeny and persist into adult
life in healthy subjects, arises from observations in chil-
dren with severe combined immunodeficiency. Maternal
microchimerism as a mechanism of nontraditional inher-
itance of T1Dhas been investigated byNelson et al. (368).
To identify and quantify maternal microchimerism, they
first developed a panel of quantitative PCR assays that
targeted nontransmitted, nonshared maternal-specific
HLA alleles. They then assayedmaternal microchimerism
FIG. 10. A model of how genetic and epigenetic factors can affect aging. Young adult stem cells present no alterations in either the genetic or
epigenetic levels, and so there is proper stem cell function and, consequently, tissue regeneration. Genotypes of low efficiency in repairing genetic
or epigenetic (represented as lollipops over the structure of the DNA) defects or in maintaining epigenetic stability accompanied by harmful
environmental exposures can accelerate the accumulation of molecular alterations at the genetic and the epigenetic levels, which in turn can
accelerate the aging process. On the other hand, genotypes that are highly efficient in repairing genetic and epigenetic defects and in maintaining
epigenetic stability accompanied by harmless environmental exposures can slow the accumulation of molecular alterations at the genetic and
epigenetic levels, which, in turn, can delay the aging process. [Reprinted from F. M. Fraga: Curr Opin Immunol 21:446–453, 2009 (185). © with
permission from Elsevier.]
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levels, whichwere expressed as the genome equivalent per
100,000 tested cells, in the peripheral blood from 172
individuals, of which 94 had T1D, 54 were unaffected
siblings, and 24were unrelated healthy subjects.Maternal
microchimerism levels were significantly higher in the
T1D individuals than those in the unaffected siblings and
healthy subjects. The differences between the groups were
evident, irrespective of HLA genotypes. However, for in-
dividuals with the T1D-associated haplotype, maternal
microchimerism was found more often when the haplo-
type was transmitted paternally (70%), when compared
with that found when transmitted maternally (14%).
From these results, they concluded that maternal micro-
chimerism may contribute to islet -cell autoimmunity in
a mother’s progeny because T1D individuals have higher
levels of maternal microchimerism in their circulation
than unaffected siblings and healthy individuals.
Given the variable heritability of T1D, investigation
has now shifted to environmental causes to explain the
heterogeneous phenotype of the disease. Viruses (congen-
ital rubella, Coxsackie B, mumps, echovirus, cytomega-
lovirus, Epstein-Barr virus, retrovirus, rotavirus, parvovi-
rus B19), bacteria in the gut microbiota (369), diet [cow’s
milk; decreased vitamin C, D, and E intake; early intro-
duction of cereals (370), potatoes, carrots, fruit, berries,
N-nitroso compounds, and increased caloric intake], and
psychosocial factors have all been implicated as environ-
mental causes (371).
Miao et al. (372) examined histone methylation pat-
terns in blood cells from T1D individuals and found sig-
nificant increases in H3K9me2 patterns in a subset of
genes in lymphocytes, but not in monocytes. They also
found increased H3K9me2 in the promoter of one of the
candidate T1D susceptibility genes, CLTA4, and two
high-scoring networks of genes. Many genes in the two
high-scoring networks have been previously identified as
known T1D candidate genes and are associated with sev-
eral autoimmune and inflammation-related processes and
molecules, suchasTGF-, nuclear factor-B (NF-B), p38
MAPK, Toll-like receptors, and IL-6 (372). In another
study, El-Osta et al. (373) reported transient hyperglyce-
mia-induced long-lasting epigenetic changes in the pro-
moter of theNF-B subunit p65 in aortic endothelial cells,
both in vitro and in nondiabetic mice. Furthermore, El-
Osta et al. (373) reported that the epigenetic and gene
expression changes persisted for at least 6 d of subsequent
normal glycemia, as did the NF-B-induced increases in
the expressions of monocyte chemoattractant protein 1
and vascular cell adhesionmolecule 1. The results of these
two studies show that even hyperglycemia has epigenetic
consequences.
One known epigenetic mechanism in transient neona-
tal diabetes, a rare form of nonpermanent diabetes melli-
tus in newborns, is LOM at the TNDM locus on chromo-
some6q24.Lossof this epigeneticmark in themesodermal
lineage leads to the prune belly sequence, which is a syn-
drome of abdominal muscle hypoplasia, urinary tract ab-
normalities, andcryptorchidism(244).Laborie et al. (374)
investigated a family with transient neonatal diabetes and
prune belly sequence that included one set of MZ twins.
The twin with both transient neonatal diabetes and prune
belly sequence had extensive LOMat theTNDM locus, as
well as at the IGF2R, DIRAS3, and PEG1 loci, whereas
the healthy MZ twin and other family members had nor-
mal methylation. Therefore, the LOM at the loci that are
associated with both transient neonatal diabetes and
prune belly sequence may indicate a generalized maternal
hypomethylation syndrome.
Apotential for inducing epigeneticmodifications in cell
therapy for T1D has been raised by the finding that en-
docrine pancreatic cell lineages can be prompted to be-
come endocrine cells by treatment with HDAC inhibitors
(375, 376). This approach as a treatment for T1D clearly
merits further investigation, and epigenetic drug therapy is
discussed in Section IX.A of this review.
VII. Sexual Dimorphism of Gene Expression
and Epigenetics
Many tissues exhibit sexual dimorphism for a substantial
proportion of the genes that they express (377, 378). Sex-
ual dimorphism has been explained traditionally by the
regulatory pathways that underlie sexual development of
the gonads, brain, and other organs, and the impact of
lifelong fluctuations in the circulating level of sex hor-
mones. Sensitivity to specific environmental challenges for
each sex also exists during gametogenesis and develop-
mental programming and throughout the individual’s life
(378). Because environmental factors can influence epige-
netic marking during particular spatiotemporal windows
of life in a sex-relatedmanner, it is therefore not surprising
that the sexes differ in their sensitivity to environmental
challenges throughout an individual’s life. There aremany
examples of sex differences on the effects of prenatal and
early postnatal life exposures and the risks of subsequent
metabolic disease (378–384). These sex differences could
beattributed to theproperties of the sex chromosomes, the
different regulatory pathways that underlie the sexual de-
velopment of most organs, and the lifelong fluctuating
impact of sex hormones. In fact, sex-specific gene expres-
sion appears to be under the control of sex-specific epi-
genetic marks. For example, modifications of histone H3
are sexually dimorphic in the developingmouse brain, and
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patterns of acetylation, but not methylation, are mascu-
linized in females by testosterone in utero (385).
A. Sex chromosomes and the hormonal basis of
sexual dimorphism
Mammalian sex determination is initiated by the pres-
ence or absence of the testis-determining SRY gene on the
Y-chromosome and is expressed only in Sertoli cells in a
very narrow spatiotemporalwindow, namely between the
sixth and seventh week of gestation. This male factor in-
duces thedifferentiationof testes and the secretionof those
hormones that are responsible for male secondary sexual
differentiation (386). This does not mean that female de-
velopment occurs by default; the results of recent studies
suggest the existence of both X and Y sex-chromosomal
mechanisms of sex determination (387). In addition, sex-
determining genes on the sex chromosomes are thought to
contribute to the development of nongonadal organs in
secondary sexual development and to the development
of organs beyond the reproductive system, such as the
brain (387).
All male cells possess a single X-chromosome of ma-
ternal origin and a Y-chromosome of paternal origin. Fe-
male cells comprise two X-chromosomes, one of which is
silenced by X-inactivation. This can be either the Xm or
the Xp, thereby defining two populations of cells in fe-
males. In about half of the female cells, Xm is inactivated,
whereas Xp is inactivated in the other female cells. Over-
all, gene expression in a given female tissue is approxi-
mately the sumof the gene expression profiles of these two
cell populations. Several classes of genesmay be expressed
in a sexually dimorphicmanner, depending on their origin
and location on the X- and Y-chromosomes. Y-chromo-
some-encoded genes are expressed solely in males, and
those X-chromosome-encoded genes that escape (or par-
tially escape)X-inactivationwill bemore highly expressed
in females. In addition, some genes on the X-chromosome
can be imprinted in such amanner that either thematernal
or the paternal copy is expressed. This expression is inde-
pendent from the randomX-inactivation mechanism that
controls the allelic repression ofmostX-linked genes. This
can generate differences in expression levels between
males and females. For instance,X-linked imprinted genes
that are expressed from Xp will be expressed solely in
females because males have only an Xm.
It has been proposed that the dimorphism between
male and female fetuses could start before the formation
of the gonads (387). Recently, it was found that the re-
sponse of male and female cells to chemical exposure to
either ethanol or camptothecin was sexually dimorphic.
These sexually dimorphic responses apparently occurred
at fetal stages that preceded the production of sex hor-
mones and could therefore be directly attributed to a sex
chromosome effect (388). Thus, cells can differ according
to sex, irrespective of their history of exposure to sex hor-
mones. From the results of this experiment, one can con-
clude that sex chromosomes are crucial for establishing
sexual dimorphism.
B. Sexual dimorphism of gene expression in the liver
Gene expression in somatic cells and tissues can be in-
fluenced by external factors, such as the extracellular hor-
monal milieu. A good example of hormonal regulation is
the effect of GH on gene expression in the liver, which
leads to sex differences in manymetabolic processes, such
as steroid and fatty acid metabolism, cholesterol homeo-
stasis, and drug metabolism (389). Important sex differ-
ences also characterize responses to various hepatic
stresses in both rodent models and humans. For example,
alcohol-induced liver fibrosis is more prevalent in women
than in men, whereas sepsis- and hepatitis virus-induced
liver fibrosis, hepatic ischemia/reperfusion injury, and
hepatocellular carcinoma are more prevalent in men than
in women; and these sex differences are, at least, in part
due to hormonal factors (389, 390).
Liver sex differences are best studied for the major he-
patic steroid- and drug-metabolizing cytochrome P450
enzymes (CYPs), wheremale-female differences in the lev-
els of individual CYP mRNAs range from about 2-fold to
as high as 1000-fold in both rats and mice (389). Sex dif-
ferences in the expression of CYPs and other enzymes of
steroid and drug metabolism are much smaller in the hu-
man liver, but nevertheless can have substantial impact on
physiological and pathophysiological processes (389). In
rats, liver sexdifferences emerge at pubertywhen theonset
of a pulsatile pattern of pituitary GH secretion first ap-
pears in males and a near-continuous pattern of GH se-
cretion emerges in females (391–393). These sex differ-
ences in plasma GH patterns are programmed by the
action of gonadal hormones on the hypothalamus during
the early neonatal period; they are first seen at puberty,
continue into adulthood, and then declinewith senescence
(394). The sex-dependent patterns of pituitary GH secre-
tion, in turn, dictate the sex differences in the expression
ofmany liver-expressed genes (395, 396). PlasmaGHpat-
terns are also gonadal hormone-regulated and sex-depen-
dent in humans (397, 398). These plasma GH patterns
regulate the sex differences in liver gene expression at the
level of initiation of gene transcription (399, 400).
The results from mouse knockout studies have identi-
fied two nuclear factors that are required for the observed
sex differences in liver gene expression: signal transducer
and activator of transcription 5b (STAT5b), and hepato-
cyte nuclear factor (HNF) 4 (401, 402). STAT5b protein
is rapidly activated by each incoming plasma GH pulse in
the adult male rat liver; this in turn gives rise to a pulsatile
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pattern of nuclear STAT5b activity that parallels the pul-
satile pattern of plasma GH stimulation. In contrast,
STAT5b activity in the adult female liver is maintained at
a low, but persistent, level by themore continuous plasma
GH pattern (403–405). Thus, although there are no sex
differences in liver STAT5bmRNA or protein levels, liver
STAT5b DNA-binding activity shows major sex differ-
ences. These findings led to the proposal byWaxman et al.
(403) that STAT5b maintains male liver gene expression
through its stimulatory effects. As revealed by microarray
analysis of STAT5b-deficient mouse liver, these stimula-
tory effects were shown to impact approximately 90% of
the genes in the mouse liver that show male-predominant
expression (389). On the other hand, STAT5b exerts its
inhibitory effects on approximately 60%of the genes that
show female-predominant expression in the mouse liver
(389). Indeed, STAT5b deficiency inmalemouse liver pri-
marily, but not exclusively, affects those genes that show
sex differences in expression in wild-type mice. Further
support for this model is provided by the results of recent
studies that have shown that STAT5 protein (primarily
STAT5b) binds dynamically to its chromatin binding sites
in the liver, cycling on and off with each plasmaGHpulse,
with marked sex differences in STAT5 DNA binding oc-
curring at low-affinity, but not at high-affinity, STAT5
sites (406).
A second nuclear factor, HNF4, is a liver-enriched
transcription factor that is required for hepatic expression
of many of the same sex-dependent genes that are targets
ofGHand STAT5b.However, it is not precisely clear how
HNF4 contributes to sexual dimorphism of the liver in-
sofar as it also regulates many liver-expressed genes that
do not show sex differences in their expression. One pos-
siblemechanism is suggestedby thediscovery thatHNF4
and GH-activated STAT5b are both required for the ex-
pression of several other transcription factors, whose ex-
pression shows sexdifferences inmouse and rat liver (407)
and might, in turn, control the expression of downstream
sex-dependent target genes via a GH-regulated transcrip-
tional regulatory network (407).
Support for the involvement of chromatin features in
the regulation of genes that show sex differences in the
liver comes from the discovery of short genomic regions
that show sex-dependent andGH-regulated differences in
chromatin accessibility (“hypersensitivity sites”) in liver
tissue, as probed using the enzymeDNAnuclease (DNase)
I. Thus, increased hypersensitivity to DNase I cleavage in
the male liver tissue, compared with that of female liver
tissue, is seen in the promoter regions of twomale-specific
genes, C4a/Slp, sex-limited protein, and Cyp2c11, which
catalyzes testosterone hydroxylation (408, 409). Corre-
spondingly, female-specific DNase I hypersensitivity sites
have been identified adjacent to the female-specific
Cyp2c12, a steroid sulfate hydroxylase (410) (Fig. 11).
DNase hypersensitive chromosomal regions, such as
these, have increased access to transcription factors and
other DNA-binding proteins and include promoters, en-
hancers, silencers, and insulators. These findings of sex
differences in DNase hypersensitivity are indicative of a
sex-specific liver chromatin organization, which is pre-
sumably established and/or maintained by the sexually
dimorphic patterns of pituitary GH secretion that emerge
at puberty and through their downstreamsignaling,which
leads directly to the sex-dependent patterns of nuclear
STAT5b activity (403–405). Further studies are now
needed to determinewhether theseGH- and sex-regulated
differences in chromatin accessibility are a general char-
acteristic of sex-specific genes in mammalian liver and
how these sex differences in the epigenome are function-
ally linked to the sexual dimorphism of liver gene expres-
sion. Differential factors that regulate liver GH respon-
siveness are also indicated by the finding that intrinsic sex
differences in early GH pulse responsiveness characterize
45 individual genes that show male-predominant expres-
sion; these genes are rapidly inducedbyGH(within30–90
min) in the livers of hypophysectomized male mice, but
not in the livers of hypophysectomized female mice
(411). The persistence of these sex differences in GH
responsiveness several weeks after hypophysectomy
could be the result of epigenetic programming, which
could be mediated by hormonal exposure at an earlier
point in time, i.e., before hypophysectomy.
FIG. 11. Epigenetic regulation of sex-specific CYPs. Female-specific
Cyp genes are proposed to be repressed in the male liver, and male-
specific Cyp genes are proposed to be repressed in the female liver by
packaging in heterochromatin. Continuous GH is proposed to activate
female-specific genes, such as Cyp3a genes, by a mechanism that
involves the local conversion of heterochromatin to euchromatin,
which enables the binding of transcription factors (TF) that activate
CYP gene expression. This process could involve the loss of DNA CpG
methylation and/or loss of chromatin marks that are associated with
repressed chromatin, such as histone H3 lysine 27 trimethylation,
which is typically found in genes in a compact chromatin structure and
is associated with a stable, inactive heterochromatic state. [Reprinted
from D. J. Waxman and M. G. Holloway: Mol Pharmacol 76:215–228,
2009 (389), with permission from the publisher.]
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VIII. Phenotypic Plasticity and
Environmental Programming
A. Epigenetics and environmental programming
As noted earlier, there is now a large body of evidence
indicating that epigenetic events mediate developmental
plasticity and that chromatin modifications may be trans-
mitted transgenerationally to influence the development
and behavior of subsequent generations, especially when
they are acquired during development and transitions be-
tween life-history phases. Indeed, the initial data that gave
support to the DOHaD phenomenon were gathered by
experimental replication (412, 413). Only a few environ-
mental influences have been shown to cause DNA se-
quence changes that could explain altered gene expression
or increases in disease frequency in a particular region
(414). Evidence is also accumulating that different envi-
ronments are able to alter gene expression and change the
phenotype by modifying the epigenome [see review by
Gluckman et al. (8)]. Such findings add further support for
the likely role of epigenetic mechanisms in developmental
plasticity. Moreover, when environmentally induced epi-
genetic adaptations occur at crucial stages of life, they can
potentially change behavior, disease susceptibility, and
survival (62). For example, Barber et al. (415) showed that
radiation could induce transgenerational germ-line insta-
bility in mice that persisted for at least two generations.
This finding raises important issues of risk evaluation in
humans and highlights the existence of an alternate path-
way for disease etiology that does not involve a change in
the DNA sequence.
Jirtle and Skinner (62) proposed that three kinds
of genomic targets are susceptible to gene-expression
changes owing to environmental perturbations of epigenetic
marks: the promoter regions of certain housekeeping genes,
transposable elements that lie adjacent to genes with meta-
stable epialleles, and regulatory elements of imprinted genes.
BothDNAmethylationandhistonemodifications aremark-
edly altered in the promoter regions of tumor suppressor
genes and oncogenes in human cancer. The importance of
epigenetics in the etiologyof cancer is notwithin the scopeof
this review but has been discussed extensively elsewhere [for
example, see Esteller (192)]. The second genomic target is
genes with metastable epialleles, which are loci that can be
epigenetically modified in a variable and reversible manner
such that a distribution of phenotypes occurs from geneti-
cally identical cells (seeSections II.Band IV.D).Asdiscussed
in Section IV.A, the allelic expression of the third genomic
target, imprinted genes in the present generation, may de-
pend on the parental environment in which these genes re-
sided in the previous generation.
It is therefore not surprising that the influence of envi-
ronmental factors on the epigenetic marking of genes and
the heritability of epigenetic marks are of particular inter-
est to childhood growth and development. The resultant
alterations in gene expression could have consequences
for cellular function and health of the individual through-
out the life span. Diet, hormones, and social and lifestyle
factors (all of which will be discussed in this section) have
all been shown to influence the epigenotype andmay exert
profound effects onmany aspects of child and adult health
and disease susceptibility in later life (62, 167, 416). In
animals, chromatin transitions at genes have been linked
to: 1) circadian, sleep-wake, and rest-activity rhythms; 2)
the hunger-satiety cycles; and 3) the major components of
energy homeostasis and thermogenesis (383). Because
chromatin modifications are both dynamic and labile (see
Section II.B), epigenetic modulation or modification of
gene expression is possible because epigenetic plasticity
extends beyond birth. For example, maternal nutrition
can influence gene expression of the growing fetus in utero
and in the developing progeny after its birth (170, 382,
417, 418), and DNA methylation can be prenatally ma-
nipulated by hormonal stimuli (168). Diet also can affect
the gene expression by altering the extent of DNA meth-
ylation in gene promoters and histone acetylation in the
chromatin structure (286, 419). Epigenetic marks that ac-
cumulate during aging can lead to dysregulation of gene
expression, which are important in tumorigenesis and the
onset of age-related diseases (420–422).Maternal behav-
ior has long-term effects on the methylation of the gluco-
corticoid receptor (GR) gene in the hippocampus of the
offspring (423). Lastly, EDCs can exert transgenerational
effects (TGEs) on gene expression and DNA methylation
patterns in the progeny that can last for as long as four
generations (62, 168, 424, 425) and are discussed in Sec-
tion VIII.F. The flexibility of epigenetic marks makes it
possible for all these above-mentioned influences to alter
existing DNA methylation patterns, create new histone
marks, or modify the chromatin structure during a par-
ticular spatiotemporal window, sometimes in a sex-spe-
cific manner (377, 426).
B. Environmental factors and epigenetic processes
Awide range of environmental factors and compounds
may influence long-term disease risks, despite only tran-
sient exposures at specific earlier periods of development
[reviewed by Gluckman and Hanson (24)]. Epigenetic
modifications have been proposed as a plausible link be-
tween the alterations in gene expression, environment,
and disease phenotypes and susceptibilities (62). Epige-
netic mechanisms result in stable regulation of gene ex-
pression without alterations to the DNA sequence and
trigger initiation and/or maintenance of cell-specific tran-
scriptional profiles. Indeed, the precise control of tran-
scription is achieved by modulating the chromatin struc-
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ture and three-dimensional organization of the nuclear
architecture and genome (see Section II). Because epige-
netic programming and reprogramming can lead to stable
changes in lineage specification, deviation of cell-type de-
terminationby either amplifyingordecreasing thenumber
of specific cell subtypes in early life can lead to disease
and/or changes in disease susceptibility in adulthood
(375), and this process can be potentially manipulated or
even reversed by appropriate epigenetic drugs (427) (see
Section IX.A).
Abnormal maternal behavior, inadequate maternal
feeding, and exposure to deleterious environmental com-
pounds during critical periods of life (periconception and
fetal and infant development) can change developmental
trajectories. Some epigenetic marks may originate from a
previous generational experience and increase disease sus-
ceptibility in the offspring (62). Epigenetic changes that
failed to be erased in the germ line or early embryomay be
transmitted to thenext generation in a sex-specificmanner
and exert a TGE (186, 428–433) (Fig. 12). The results of
early studies on TGEs assumed that theywere the result of
the epigenetic malprogramming of somatic processes.
However, paternal or maternal germ line epigenetic in-
heritance couldalsoaccount for theTGEs (168, 184, 434).
Moreover, both somatic and germ line effects may be sex-
ually dimorphic and can affect both mitochondrial and
nuclear DNA through the maternal line (435) (Fig. 12).
Therefore, the phenotype of an individual is the result of
lifelong remodeling of the epigenome due to a complex
interaction between the genotype and the ancestral and
current environments.
There are at least three signaling pathways that can
transduce signals from the extracellular environment to
the epigenetic machinery (378, 436). These include the
traditional membrane receptor signaling cascade, ligand
activation of nuclear receptors (NRs) by small lipophilic
molecules, and metabolic activators and inhibitors of the
epigenetic machinery. The consequences of stimulating
each of these pathways can lead to altered tissue-, stage-,
sex-, and age-specific epigenetic landscapes (Fig. 13).
Chemical andnonchemical environmental factors, such as
drugs, food, toxins, social cues, and cultural factors can
have specific impacts on the epigenetic machinery that
depend on their access to chromatin (Fig. 13).
In the first signaling pathway, specific environmental
factors, the aging process, and the actions of sex hormones
may influence the chromatin modifying enzymes (437,
438). After their passive or active entry across the cell
membrane, exogenous and/or endogenous substrates un-
dergo cell-specific metabolism. Folates and methionine
are precursors for the biosynthesis of S-adenosyl methio-
nine (SAM), which is the principal methyl donor for DNA
and histonemethylation. Thus, agents that modulate one-
carbon metabolism or directly affect the intracellular
and/or nuclear levels of SAM can affect epigenetic pro-
gramming (439). Such agents, including some bioactive
constituents in foods, such as sulforaphane (SFN) in broc-
coli, and beverages, such as resveratrol in red wine, or
drugs, such as valproic acid and trichostatin A, areHDAC
inhibitors (see Section IX.A). Surprisingly, some drugs
havebeen shown to causeDNAdemethylation, even in the
presence of the DNA methylation inhibitor 5-azaC, thus
illustrating the complex relationship between histone
modifications andDNAmethylation processes (440) (dis-
cussed in Section II). Thus, endogenous or exogenous
compoundsmay lead to the alteration of a critical balance
of the chromatin remodeling enzymes, notonly for specific
sets of dysregulated genes, but also at the whole genome
level.
In the second pathway, some compounds specifically
bind toNRs, which provide direct links between signaling
molecules, epigenetic remodeling, and transcriptional re-
sponse. Their action involves several mechanisms (441).
NRs may be present in the nucleus or cytoplasm where
they bind to their ligand. When this binding occurs in the
cytoplasm, theymayundergo severalmodificationsbefore
being translocated to the nucleus where they bind to their
specific response elements (REs). Some environmental
compounds, such as EDCs, may bind to estrogen and tes-
tosterone receptors to cause the same (or slightly different)
effect as the natural ligand (see Section VIII.F). Other
FIG. 12. Sexual dimorphism in the modes of transmission and its
effects on the offspring in successive generations. The sex specificity of
these effects operates at three different levels: 1) the maternal
transmission during pregnancy and postnatal periods; 2) the sex of the
parent who transmits the consequences of a stimulus exposure via the
germline; and 3) the sex of the offspring who displays the maternal
effect or paternal and/or maternal germline TGEs. [Reprinted from A.
Gabory et al.: Mol Cell Endocrinol 304:8–18, 2009 (378), with
permission from Elsevier.]
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NRs, such as peroxisome proliferator-activated receptors
(PPARs) and RXRs (retinoid X receptors), are already
dimerized in the nucleus on their RE at the promoter of
target genes. Their binding to a complex of corepressors
and HDACs prevents transcription of these genes in the
absence of PPARorRXR ligands.Uponbindingwith their
natural polyunsaturated fatty acid ligandsordrugs suchas
fibrates, allosteric rearrangement leads to the recruitment
of coactivators and chromatin remodeling factors to form
a transcription-prone chromatin complex that activates or
inhibits chromatin-modifying enzymes. Appropriate
modifications of the epigeneticmarks at PPARorRXRRE
in target gene promotersmodulate the expression of genes
in a tissue-specific manner depending on the presence of
the appropriate cofactor(s) (442).
The third pathway comprises traditionalmembrane re-
ceptor signaling cascades (443, 444). The basic idea,
which was proposed by Szyf (440) and co-workers, is that
behavioral exposures stimulate signaling pathways in the
brain, which in turn activates sequence-specific factors
that recruit or directHATs to specific targets that enhance
the probability ofDNAdemethylation. Such amechanism
provides a conduit through which both social and behav-
ioral experiences, as well as endogenous and environmen-
tal chemicals, could affect the epigenome, and thus gene
expression and function. It is possible, depending on the
type of ligand or spatiotemporal conditions, that different
pathways could be activated. The maintenance of DNA
methylation patterns is dependent on the preservation of
thebalanceof several factors, such asDNMTs,DNAdem-
ethylases, HATs, HDACs, histone methyltransferases,
andhistonedemethylases. Extra- or intracellular signaling
pathways could trigger the activation or suppression of
one or some of these enzymes, which, for example, could
change loci-specifichistoneacetylationand tilt thebalance
toward DNA demethylation and a change in the expres-
sion state of a particular gene.
C. Nutrition, epigenetics, and programming in early life
The placenta evolved in eutherianmammals to provide
nutrients to the developing fetus, and fetal growth and
survival depend on its integrity (445). To fulfill this phys-
iological role as a nutrient sensor and supplier, the pla-
centa follows a carefully orchestrated developmental pro-
gram during gestation.
Many of the detrimental events that occur in the fetus
are “secondary” phenomena due to a wide range of
causes, which include preeclampsia and other hyperten-
sive disorders, abnormal development of the placenta and
its vasculature, and viral infections (50). IUGR is a term
that is used to describe slow fetal growth and has many
causes [see Section I.A and reviews byGluckman and oth-
ers (19, 20, 22)]. IUGR is closely linked to placental de-
velopment and function, and undernutrition during preg-
nancy reduces birth weight and programs the adult
phenotype for growth and body composition, with con-
sequences for morbidity and life expectancy (446, 447)
(see also Sections I.A and II). In fact, placental insuffi-
ciency and an abnormal uterine environment are two of
the known environmental factors that predispose the de-
veloping fetus to epigenetic misprogramming, which in
FIG. 13. The three signaling pathways transduce environmental signals from the cell membrane to the chromatin structure in epigenetic
programming of the genome: 1) activation or inhibition of the chromatin epigenetic machinery by metabolites of these substrates; 2) activation of
nuclear receptors by ligands; and 3) traditional membrane receptor signaling cascades. [Reprinted from A. Gabory et al.: Mol Cell Endocrinol 304:
8–18, 2009 (378), with permission from Elsevier.]
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turn increases susceptibility of the offspring to disease in
later life (16, 382, 433, 448–450) (see Section II.D).
Several concepts are now emerging to explain the con-
sequences of IUGR, and these conceptswere recently sum-
marized by Borowicz and Reynolds (446). The first con-
cept, whichwill be discussed in this section, is the idea that
the placenta can be epigenetically programmed in re-
sponse to a maternal stressor, such as maternal nutrient
restriction, and that epigenetic programming in the pla-
centa can lead in turn to altered nutrient transport to the
fetus, and hence to fetal growth restriction. The second
concept is the idea that a compensatory increase in pla-
cental function, such as an increase in nutrient transport,
occurs in response to undernutrition during pregnancy.
The third concept is the idea that the placental response to
maternal stress is variable and complex because the re-
sponse depends on the type of stressor, such as the mater-
nal age and thematernal environmental stress. The fourth
concept is that altered placental angiogenesis, which can
include a compensatory increase in vascularity in some
cases, is also an important component of placental pro-
gramming. Of these four concepts, the first concept, epi-
genetic programming in the placenta, will be discussed in
the next two sections, and it focuses on the effects of di-
etary modifications and hormones on the phenotype and
gene expression in early life. In these two sections, the
discussion on the role of epigenetics in the plasticity and
epigenetic regulation of human growth will be an exten-
sion of the discussions in Section III.A of this review.
There are basically two causes of epigenetic program-
ming in theplacenta: nutritionalprogramming (whichwas
introduced in Section III.D and will be discussed in this
subsection and Sections VIII.F and IX.A), and endocrine
programming (whichwill be discussed in Section VIII.D).
Epigenetic programming of the placenta (placental pro-
gramming) can result in structural and functional changes
in genes, cells, tissues, and evenwhole organs (451). These
changes may be isolated or widespread events with either
discrete or cumulative effects on development depending
on the nature and timing of the programming stimulus
(21). The consequences of placental programming depend
on whether the developmental deficit is the inadvertent
outcome of an insult that acts as mutagen or a specific
adaptation to an environmental challenge that is designed
tomaximize survival to reproductive age (8, 22, 23).With
mutagenesis, the structural and functional deficits are per-
manent and invariably detrimental to long-term survival.
In contrast, the physiological adaptations made in re-
sponse to suboptimal intrauterine conditions may im-
prove viability in the short tomedium term, but at the risk
of later morbidity (discussed in Section I). Placental pro-
gramming also has consequences for the next generation,
and this topic is discussed in Section VIII.F.
Focusing on the effects of nutrition on placental pro-
gramming, the effects are mediated through changes in
placental gene expression,which includes imprinted genes
(447, 452). As already discussed in Section IV.A, im-
printed genes are expressed monoallelically according to
their parental origin. Although not well understood, im-
printedgenes seem tohave adisproportionately important
influence on placental development (453–455). For ex-
ample, Coan et al. (447) recently reported that undernu-
trition of pregnant mice resulted in decreased expression
of the placental-specific transcript of the Igf2 gene, al-
thoughmethylation of its promoterwas unaffected. There
is also increasing evidence that nonimprinted genes can be
nutritionally programmed in utero. This programming in-
volves changes inDNAmodifications, particularly at pro-
moter regions,whichare related toalteredgene expression
in adulthood (456, 457). Whether these changes in gene
expression are mediated through alterations in the pla-
centa is unknown because it has also been shown that
feeding a protein-restricted diet to pregnant mice during
the first 3.5 d of the pregnancy before blastocyst implan-
tation can induce nutritional programming and an altered
phenotype of the offspring (458).
Lillycrop and colleagues (459–461) fed either a control
or a protein-restricted diet to pregnant rats and mice and
then measured the hepatic expressions of the GR and
PPAR, as well as other markers of glucose homeostasis
and -oxidation in the offspring at different times after
birth. GR and PPAR are NR proteins (whose signaling
pathway to chromatin was discussed in Section VIII.B)
and play key roles in glucose and lipid metabolism, two
processes that are dysregulated in the offspring of protein-
restricted mothers. The results of these experiments
showed that modest changes to maternal intake of ma-
cronutrients during pregnancy induce stable changes to
the epigenetic regulation ofGR and PPAR in the livers of
the juvenile (459, 461) and adult offspring (460). Mater-
nal protein restriction also induced the down-regulation
of the maintenance DNMT, DNMT1 (462). This finding
suggested that hypomethylation of the PPAR and GR
promoters may result from the decreased expression of
DNMT1, and hence the progressive loss of methyl groups
from CpG dinucleotides after mitosis, rather than active
demethylation. Thus, altered gene methylation may pro-
vide a causal mechanism to explain howmaternal diet can
induce stable changes in gene expression within the off-
spring and may represent a fundamental mechanism for
altering the phenotype.
The finding that maternal protein restriction induces
down-regulation of DNMT1 and the hypomethylation of
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the GR110 promoter suggests that DNMT1 mRNA ex-
pression may be related to the level of methylation of the
hepaticGRpromoter. To determinewhetherDNMT1 ex-
pression was also related to the level of methylation of the
GR1-CTotal promoter, which shows 70.6% homology
with the rat GR110 promoter (463), in fetal human tissue,
Lillycrop et al. (462) investigated DNA methylation and
DNMT expression in human umbilical cords that were
collected from 15 term infants whose birth weights were
within the normal range. They found that DNMT1 ex-
pression significantly predicted 49% of the variation in
GR1-CTotal methylation, whereas DNMT3A expression
was not related to GR1-CTotal methylation (462). Thus,
methylation of human GR appears to be associated with
the capacity of DNMT1 to maintain methylation of CpG
dinucleotides, rather than the capacity for DNA methyl-
ation de novo. These findings are consistent not only with
findings in rats, but also with the hypothesis that the in-
duction of different phenotypes in humans by prenatal
nutrition may involve variations in DNMT1 expression
and, in turn, DNA methylation. These findings lend sup-
port to the notion that there are critical periods during
embryogenesis and early postnatal life when epigenetic
processes are susceptible to perturbations by maternal
nutrition.
There are studies that explored the“rescue”of aberrant
phenotypes in utero or the reversibility of induced pheno-
typic effects (see Section III.D). Lillycrop et al. (459)
showed that supplementationof theprotein-restricteddiet
with folic acid, amethyl donor cofactor, during pregnancy
prevented changes to themethylation status of theGRand
PPAR promoters and led to the normalization ofGRand
PPAR expression. Their result is consistent with those of
Jackson et al. (464) and Brawley et al. (465), who were
also able to prevent induction of an alteredmetabolic phe-
notype in the offspring of rats who had been fed either a
folic acid- or glycine-enriched protein-restricted diet. In
addition, Burdge et al. recently reported that folic acid
supplementation in the peripubertal period did not nor-
malize the effect of the maternal protein-restricted diet on
thephenotypeor epigenotypeof theoffspring (466).These
findings imply that the timing of the nutritional interven-
tion is an important factor for determining the phenotypic
outcome. The apparently contrasting effects of increased
folic acid exposure before birth or after weaning may re-
flect differences in the supply of folate to the offspring.
Before birth,maternal physiologymay buffer ormodulate
supply of folate to the offspring. After weaning, the off-
spring receive folic acid directly, and so the exposure of the
juvenile animalsmaybegreater than fetuses. Furthermore,
the results of the postweaning folic acid supplementation
study showed that the juvenile-pubertal period is another
period of plasticity when specific nutrient intakes may al-
ter the phenotype of the offspring through epigenetic
changes in specific genes. Folic acid supplementation in
the juvenile-pubertal period may therefore provide a win-
dow of opportunity for appropriate nutritional interven-
tions to reverse the effects of a poor prenatal environment.
There are now also several published reports on atten-
uation, and even reversal of the adverse effects of high-fat,
high-carbohydrate (HC), or low-protein diets on the neo-
natal phenotype by maternal nutritional interventions in
rodents (467). Srinivasan and colleagues (468, 469)
showed that artificial rearing of female rat pups on a HC
milk formula resulted in chronic hyperinsulinemia and
adult-onset obesity (HC phenotype), and that the mater-
nalHCphenotypewas transmitted to their progeny.Using
this model, Srinivasan et al. (470) then tested the idea that
the fetal adaptations that predisposed the progeny for the
expression of the HC phenotype in adulthood and the
transfer of the HC phenotype to the progeny could be
reversed by maternal food restriction. For this purpose,
they modified the intrauterine environment of HC rats by
pair-feeding pregnant rats the identical amount of food
that was consumed by age-matched control rats from the
time of their weaning. This mild dietary restriction re-
versed the HC phenotype and also prevented the devel-
opment of the HC phenotype in the progeny. From these
results, they concluded that: 1) malprogramming of the
progeny of hyperinsulinemic-obeseHC female rats for the
expression of the HC phenotype is initiated in utero; and
2) normalization of the maternal environment by mild
food restriction in HC female rats resulted in a normal
phenotype in their progeny.
Junien and colleagues (382) investigatedwhether alter-
ing fat intake in mothers during the periconceptual, ges-
tational, and lactational periodsby feeding themahigh-fat
diet (HFD) that induced obesity could be used to modify
fetal/neonatal metabolic programming to prevent the de-
velopment of the postnatal metabolic phenotype. To this
end, they crossedF1obese femalemicewithT2Dmice that
were fed a HFD with F1 lean males that had been fed a
normal rodent chow. The HFD of these F1 females was
then switched to the normal chow before mating and dur-
ing the gestational and lactational periods, and all second-
generation (F2) mice were fed a HFD for 5 months. Sen-
sitivity or resistance to the HFD differed significantly
between generations and sexes. The proportions of the F1
and F2 males that developed hyperphagia, obesity, and
T2Dwere similar. In contrast, the proportion of F2 female
mice thatwere hyperphagic andobese anddevelopedT2D
was significantly lower than that of the F1 (57 vs. 83%).
In other words, the proportion of the F2 female offspring
that were resistant to the effects of the HFD was signifi-
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cantly higher than that of the F1 (43 vs. 17%). Despite
having free access to theHFD, these “resistant” F2 female
mice displayed a “satiety phenotype”; they were lean, no
longer hyperphagic, and hadnormal plasma glucose levels
and insulin sensitivity, despite being mildly hypercholes-
terolemic and glucose intolerant (382). These results sug-
gest that feeding rats a diet with an appropriate fatty acid
profile before mating and during the gestational and lac-
tational periods in the setting of maternal obesity inter-
feredwith fetal or neonatal programming of themetabolic
syndrome.
In another study, Howie et al. (418) reported recently
on the long-term impact of a moderately HFD during pre-
conception and/or pregnancy and lactation on postnatal
growth and metabolism of the rats from birth to adult-
hood. The major findings of this study were: 1) the off-
spring of dams that were fed aHFDduring pregnancy and
lactation were smaller than normal; 2) a postweaning
HFD increased adiposity in all treatment groups, but the
offspring whose dams were fed a HFD during pregnancy
and lactation had elevated adiposity compared with con-
trols regardless of postweaning diet; 3) this increased ad-
iposity was accompanied by hyperinsulinemia and hyper-
leptinemia; and 4) maternal preconceptual diet did not
impact offspring adiposity. From these results, the authors
suggested that the diet in pregnancy and lactation, but not
preconception, is an important influence on the long-term
health of the offspring.
Lastly, Mao et al. (471) recently reported contrasting
effects of different maternal diets on sexually dimorphic
gene expression in themurineplacenta. In their study, they
examined the impact of diet and fetal sexonplacental gene
expression in mice that were fed a very high-fat, low-fat,
or chow diet of intermediate caloric density, and then ex-
tracted and analyzed placental RNA by microarray on
embryonic day (E) 12.5. First, they found that the changes
in the expression of 1972 genes were more than 2-fold in
at least one of the three treatment groups. Second, they
reported that the placentae that were attached to female
pups (female placentae) demonstrated more striking al-
terations in gene expression in response to the maternal
diet than that found in the placentae that were attached to
male pups (male placentae). Third, they reported that each
diet provided a distinctive signature of sexually dimorphic
genes; the expressionof the sexually dimorphic genes from
female placentae was generally higher than those from
male placentae. Fourth, they found that the expression of
other genes, which are normally considered as character-
istic of kidney function,were affected by diet and included
genes that regulated ion balance and chemoreception.
Fifth, they found that transcript levels of many known
olfactory receptor genes in the placenta, which may allow
the placenta to sense odorant molecules and other minor
dietary component genes, were influenced by diet and the
sex of the fetus. From these results, they concluded that
gene expression in the murine placenta is adaptive and
could be influenced by the maternal diet. Moreover, they
found that the placenta exhibits pronounced sexual di-
morphism; the female placentae were more sensitive to
nutritional perturbations than the male placentae.
The results of the rodent studies in which the maternal
diet was manipulated and induced the metabolic pheno-
type and its underlying epigenetic changes in the offspring
may have implications for humans. From these results, it
is also now evident that future studies should investigate
the effects of maternal nutrition on the epigenetic regula-
tion of gene expression in placental programming to un-
derstandhow thematernal diet influences the health of the
resultingoffspringduring the life span.Themetabolicphe-
notype, which includes obesity, T2D, and othermetabolic
disorders, belongs to the group of the fastest-growing
health problems worldwide, and a substantial body of
evidence indicates that lifestyle factors contribute to the
increasedprevalenceof obesity andT2D.The riskof spon-
taneous abortions and congenital malformations of neo-
nates is higher in diabetic women than nondiabetic
women, and poor diabetic control increases these risks
(209, 472). As a result, a vicious cycle develops; prenatal
development in a diabetic milieu favors the development
of T2D in the offspring in later life (473). In the context of
a worldwide epidemic of obesity, the increasing preva-
lence of excessive body weight and obesity due to imbal-
anced nutrition (25% of women in France and 50% of
women in the United States) creates an abnormal uterine
environment in women of childbearing age. Therefore,
making pregnant women, especially overweight pregnant
women, aware of 1) their diet and/or nutrition and their
importance during pregnancy; 2) their body composition
and the consequences of excessive weight; and 3) the sub-
sequent effects of diet, nutrition, body composition, and
weight on the phenotype and health of their babies may
help disrupt the vicious cycle of the mother-offspring
transmission of adult metabolic phenotype.
D. The effect of hormones on epigenetic gene
regulation in early life
Hormones have an important role in regulating normal
growthanddevelopment inutero.Undernutrition, hypox-
emia, and stress can alter both maternal and fetal concen-
trationsofmanyhormones that includeGH, IGFs, insulin,
glucocorticoids, catecholamines, leptin, thyroid hor-
mones, placental eicosanoids, sex steroids, and placental
lactogen. Some of the epigenetic effects of these hormones
have already been discussed in this review. The epigenetic
regulation of imprinted genes that are important for
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growth regulation, such as IGF2, and the role of let-7
miRNAshave been discussed in Sections III.B and IV.Aof
this review. In addition, the consequencesof dysregulation
of imprinting mechanisms at the 11p15 region that en-
compasses many imprinted genes and underlies the devel-
opment of BWS and SRS in humans have been discussed
in Section IV.B of this review. In addition, IGF2 and its
epigenetic regulation have been recently reviewed in depth
[for example, see reviews by Gicquel and Le Bouc (242,
252) and Chao and D’Amore (474)]. From the results of
studies using Igf2 knockout mice, evidence is emerging
that imprinted genes and hormones have central roles in
controlling both the fetal demand for and the placental
supply of maternal nutrients during mammalian develop-
ment [see reviews by Reik, Constancia, and others (269,
452, 453, 475, 476)]. We also refer readers to several
recent reviews on the epigenetic effects of other pregnan-
cy-related hormones by Fowden and Forhead (477, 478)
and Pasca and Penn (479).
In view of these referrals to other sections of the review
and published reviews, the discussion of this section will
focus on the epigenetic effects of glucocorticoids, which
have widespread programming effects in utero and medi-
ate the programming effects of nutritional and other en-
vironmental challenges during pregnancy (480–482).
Specifically, glucocorticoids act at cellular and molecular
levels and can induce changes in tissue accretion and dif-
ferentiation by direct and indirect mechanisms. Many of
these effects are mediated by genes, and comprehensive
lists of the genes that are influenced by glucocorticoids can
be found in the various reviews of Fowden and colleagues
(451, 455, 481, 483–487).
The epigenetic effects of glucocorticoids have been re-
ported. Thomassin et al. (488) reported that glucocorti-
coid administration caused DNA demethylation associ-
ated with increased gene expression of a hepatic
aminotransferase in rats during the perinatal period. In
another study, Drake et al. (489) showed that fetal expo-
sure to the synthetic glucocorticoid, dexamethasone, dur-
ing the last quarter of pregnancy in rats exerted a TGE on
the key hepatic gluconeogenic enzyme, phosphoenolpy-
ruvate carboxylase, and the subsequent development of
hyperinsulinemia and hyperglycemia that persisted into
the F2 without further treatment of the F1 animals. In
another study, Weaver (490) reported that the levels of
methylation at the 5-end of the GR gene promoter in the
hippocampus were inversely proportional to the extent to
which rat pups were licked, groomed, and nursed by their
mothers, and that the reduced level of methylation at the
GR promoter correlated with higher GR transcription.
Collectively, the results of such studies provide support for
the notion that glucocorticoids are intimately linked with
fetal programming of adult pathophysiology (482) (see
also Section VIII.E).
Although a complete understanding of the epigenetic
actions of glucocorticoids on the placental and fetal ge-
nome and its TGE on the hypothalamic-pituitary-adrenal
(HPA) axis, and the fetal “programming” of adult patho-
physiology is still required, antenatal glucocorticoid ad-
ministration has significant implications in humans be-
cause multiple courses of synthetic glucocorticoids are
currently recommended for various conditions. Preterm
delivery occurs in approximately 10% of all pregnancies,
and prenatal exposure to synthetic glucocorticoids is very
efficacious in reducing the incidence of respiratory distress
syndrome in these babies. Despite the beneficial therapeu-
tic effect of antenatally administered synthetic glucocor-
ticoids, its TGE is different in males and females with re-
spect to the risk of developing cardiovascular disease and
themetabolic phenotype in later life (482, 489, 491–493).
Moreover, the sex differences of the TGEs that occur in
later life after the antenatally administered synthetic glu-
cocorticoids are exacerbated by the type of synthetic glu-
cocorticoid and the timing of their administration (494).
From the results of such studies, there is nowmore aware-
ness of the potential consequences of repeated antenatal
administration of glucocorticoids on the health of male
and female infants. This increased awareness is echoed in
a recent article by Newnham and Jobe (495) who wrote,
“Unless further evidence of both benefit and safety of re-
peated courses is provided, it would be prudent for clini-
cians at this time to confine their use of antenatal corti-
costeroids to single-course treatment.”
E. Epigenetics of mental health and behavior
Following on from the discussion in Section II.B.3.b,
which presented evidence on the relationship between epi-
genetics and mental health disease, the discussion in this
section will present information on the role of the post-
natal environment in generating vulnerabilities to chronic
mental disease (496–498) and behavior (499, 500). The
long-term effects ofmaternal behavior in the rat, aswell as
othermammals, on the stress responsiveness and behavior
of the offspring during adulthood are well documented
(501–503). The results of these studies have shown that
early handling and deprivation can exert effects on spon-
taneous open-field behavior, acoustic startle, and the
endocrine stress response when they become adults. In
addition, these adult rats exhibited enhanced active
avoidance and their stress hormone responses were re-
duced. Permanent changes in emotional and neuroendo-
crine reactivity have been observed in rodents after a va-
riety of experiences, even minor ones, during postnatal
life. In addition, it is well documented that stressful events
that occur prenatally, and even at preimplantation, can
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have permanent consequences on behavior in later life
(504–508).
Epigenetic programming occurs in response to rat ma-
ternal care, and the epigenetic programming of DNA
methylation and histone acetylation is different in the low
and high maternal care offspring (509, 510). Specifically,
the nature and amount of care that a pup receives from its
mother modulates its reaction to stress later in life largely
through effects on the GR in the hippocampus (509). This
maternal effect is transgenerational or heritable only in-
sofar as its manifestation depends upon the pup’s experi-
ence in the first week of life.
Maternal behavior also triggers a signaling pathway
that involves the serotonin receptor, an increase in cAMP,
and recruitment of the transcription factor nerve growth
factor-inducible factorA. In turn, theHATCREB-binding
protein, and the methylated DNA binding protein, meth-
yl-CpG-bindingdomain2, are recruited toactivate theGR
gene promoter (511). Using this pathway to study the epi-
genetic consequences of maternal care in rats, Weaver et
al. (511)demonstrated thatDNAmethylationpatternsare
dynamic: the methylation and demethylation of genes
could be reversed during adulthood, althoughDNAmeth-
ylation was established early in life. They observed differ-
ences in DNA methylation and histone acetylation in the
regulatory regions of the GR exon 17 promoter in the
hippocampus of the offspring from high- and low-caring
nursing rats. They also showed differences in DNAmeth-
ylation and histone acetylation that appeared to cover
wide regions of chromosome 18 in adult rats that had
experienced high and low maternal care when they were
pups. In adult rats, they also reported that hippocampal
gene expression was significantly altered and that the ex-
tent of the changewas a function of the early-lifematernal
care that they had received. Therefore, differences in hip-
pocampal gene expression due to early-life experiences
determined the HPA stress response in the developing off-
spring and were maintained throughout their lives (510–
513). They also reported that high maternal care resulted
in hypomethylation in somebrain regions andhypermeth-
ylation in other regions and was reversed by inhibiting
histone acetylation (513). When an HDAC inhibitor was
injected into the brains of adult offspring of low-caring
mothers, they reported reversal of the epigenetic program-
ming of the hippocampal GR promoter. Moreover, the
treatment reestablished stress responsivity and open field
behaviors that were indistinguishable from the adult off-
spring of high-caringmothers.Whenmethionine,which is
also an inhibitor of active demethylation (514), was in-
jected into the brains of adult offspring of high-caring
mothers, they reported: 1) DNA methylation; 2) down-
regulation ofGR; 3) heightened stress responsivity; and 4)
open field behaviors that were indistinguishable from the
adult offspring of low-caringmothers. These findings sug-
gest that variations in maternal behavior can directly pro-
gram the rudimentary defensive responses to stress
through epigenetic mechanisms. These findings are sup-
ported by results of recent studies in which Miller et al.
(515, 516) reported that the dynamic response of DNA
methylation in neurons is involved in fear conditioning.
These challenging findings in rats have been extended
to humans by identifying an association between early
childhoodadversity andepigeneticmarks in later life (423,
517, 518). McGowan et al. (518) investigated the extent
of DNA methylation in the promoter of genes that en-
coded rRNA genes in the brains of suicide victims. Suicide
victims who had experienced childhood abuse had higher
overall rRNA gene methylation and expressed less rRNA
than other victims with no history of child abuse. From
these results, the authors concluded that the difference
in methylation was driven by an environmental factor,
namely child abuse, rather than by a genetic variation
(518). More recently, McGowan et al. (518) compared
theGR exon 1f promoter of suicide victims whowere or
were not abused as children. They report site-specific
differences in DNA methylation in the GR exon be-
tween suicide victims who experienced or did not ex-
perience social adversity in early life. These differences
in DNA methylation were associated with reduced ex-
pression of the GR gene (423).
These data are the first demonstration of differences in
DNAmethylation states thatwerepossibly triggeredbyan
early-life exposure to social adversity. Moreover, these
epigenetic imprints have functional consequences that re-
sult in reduced expression of a key regulator of the HPA
stress response. Thus, early-life adversity might have last-
ing impact on gene regulation and results in susceptibility
to mental health problems in later life.Moreover, the idea
that epigenetic processes are involved in mental health
disease adds a new dimension to the impact of early-life
experience on disease susceptibility in later life and points
to the possibilities of prediction, early diagnosis, and new
therapeutic approaches to treating these diseases.
F. Transgenerational actions of
endocrine-disrupting chemicals
EDCs are exogenous environmental chemicals that
mimic or block the actions of endogenous hormones (2).
To date, the vast majority of known EDCs are those that
activate the parts of the endocrine system that are associ-
ated with the steroid/retinoid/thyroid superfamily of re-
ceptors, and within this superfamily, receptors that are
related to the hormone estrogen are usually stimulated.
We are becoming increasingly aware of the role of en-
vironmental factors in disease susceptibility. Because the
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genome is evolutionarily and chemically stable, these en-
vironmental influences regulate genome activity indepen-
dent of DNA sequence changes. An additional consider-
ation for environmental influences on disease etiology is
the developmental stage of exposure. Exposures during
a crucial time of development can alter genome activity
associatedwith the differentiation-linked programming
of cells or organ systems. This altered program and gene
expression profile can then promote an abnormal phys-
iology and disease at the later adult stage of develop-
ment (167).
Exposure of the germ cells during this critical period to
environmental toxicants, such as EDCs, can reprogram
the germ line (168, 519), and an epigenetic transgenera-
tional phenotype can develop. When postnatal and/or
adult exposures to environmental toxicants occur, game-
togenesis can be affectedwith potential reprogramming of
the germ line. Although epigenetic effects on gametogen-
esis have been described (520–523), no TGEs have been
observed. In contrast, the transmission of a permanently
altered germ line epigenome can promote a transgenera-
tional inheritance of corresponding phenotypes to subse-
quent generations and progeny (168).
Muchofourknowledgeon theTGEsofEDCshas come
from the studies of Skinner and colleagues (168, 424, 425,
519, 524–528). They used rodents to examine the TGEs
of two chemical pesticides with endocrine disruptor ac-
tivity, namely vinclozolin, which is a fungicide with anti-
androgenic properties, and methoxychlor, a replacement
for dichlorodiphenyltrichloroethane, whose metabolites
have estrogenic, antiestrogenic, and antiandrogenic activ-
ities. They reported that transiently exposing pregnant
rats between E8 and E15 to either methoxychlor or vin-
clozolin promoted a spermatogenic defect that was char-
acterized by increased apoptosis and decreased cell num-
ber and motility in the adult F1 (168). They also reported
that this spermatogenic defect was carried over four gen-
erations. The preliminary data suggest that this defect is
linked to altered DNA methylation of the male germ line
and the inductionofnew imprinted-likeDNAmethylation
sites. This altered sperm epigenome also impacted on the
genome activity of other developing tissues and cell types
through the paternal genome (528). Interestingly, the ex-
pression of over 200 genes was altered in the embryonic
testis, and this altered transcriptome was present in gen-
erations F1-F3. Altered transgenerational transcriptomes
were also identified in several other tissues and cell types,
with each tissue and cell type having a unique set of dif-
ferentially expressed genes. The next step in understand-
ing this TGE is to establish the functional relationships
between the differential DNA methylation and transcrip-
tome effects (2). In addition to detecting the male testis
disorder, Skinner and colleagues (424, 527) also reported
a TGE on the development of other disease states as the
animals aged, such as tumor development, prostate dis-
ease, kidneydisease, and immune abnormalities, aswell as
on thepregnancies and theonsetofdisease in female adults
(425). In fact, the phenotype of the young adult rats re-
sembled one of an aged animal, which suggests that vin-
clozolin accelerated the aging process (528). Skinner and
colleagues (528, 529) also recently reported TGEs on be-
haviors, such as sexual selection and anxiety, due to vin-
clozolin exposure.
Based on these results, two potential epigenetic mech-
anisms of action for EDCs have been proposed (62) (Fig.
14). The first mode occurs during active development of a
specific organ when the epigenome and transcriptome are
progressing through a cascade of developmental stages to
establish the adult organ transcriptome and physiology.
The second mode occurs during reprogramming of the
epigenome of the germ line and promotes an abnormal
epigenome (168, 424, 519). In both mechanisms, the
transgenerational epigenetic mechanism of action of an
EDC occurs at the time of sex determination to cause al-
tered epigenetic programming of the germ line. As a result,
the transcriptomes of developing organs are altered in
such a way as to induce various adult disease states
transgenerationally.
Other EDCs of potential importance include phytoes-
trogens, which are naturally occurring estrogenic chemi-
cals, and are present in high levels in plant-based diets.
One such phytoestrogen is genistein, an isoflavone that is
found mainly in soybeans and is widely consumed world-
wide (see also Sections IV.D and VIII.C). Concern has
been raised over the potential estrogenic effects of
genistein in soy-based infant milk formulae on fetal de-
velopment and the long-term consequences on female re-
productive performance, adiposity, and cancer risk (530,
531). These concerns originate from the results of studies
ofMcLachlanandcolleagues (2, 532–534),whoproposed
that developmental reprogramming by early-life estro-
genic exposures may be linked to cancer in later life due to
altered epigenetic memory. At the heart of this concern is
the lifetime isoflavone exposure profile, despite the low
and variable potency of soy isoflavones to bind and acti-
vate estrogen receptors, and their ability to act as selective
estrogen receptor modulators.
Jirtle and colleagues (530) reported that maternal di-
etary genistein supplementation of mice during gestation,
at levels comparable with humans consuming high-soy
diets, shifted the coat color of heterozygous viable yellow
agouti (Avy/a) offspring toward pseudo-agouti. This
marked phenotypic change was significantly associated
with increased cytosine methylation at a retrotransposon
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upstream of the transcription start site of theAgouti gene.
Because the extents of DNA methylation were similar in
endodermal, mesodermal, and ectodermal tissues, they
concluded that genistein acts during early embryonic de-
velopment. They also concluded that in utero dietary
genistein protected the offspring from obesity because
genistein-induced hypermethylation persisted into adult-
hood. Since the publication of this study, other studies,
such as those of Cederroth et al. (535, 536), have con-
firmed the beneficial effects of soy and/or genistein on
adiposity and body composition. For example, Cederroth
et al. (535, 536) reported that male mice fed from con-
ception to adulthood with a high soy-containing diet had
reduced bodyweight and adiposity and decreased glucose
intolerance. In a recent follow-up study, they showed that
eating a high soy-containing diet during gestation, lacta-
tion, or after weaning could alter body composition, glu-
cose tolerance, and blood pressure in adult individuals
independently of adipose gain (537). In addition to these
animal studies, the Arkansas Children’s Nutrition Center
conducted aprospective longitudinal study that compared
the growth, development, and health of breastfed children
and soy formula-fed children from birth to age 6 yr (531).
After 5 yr, the growth of soy formula-fed children was
normal. Although this study reported that no adverse ef-
fects occurred with eating high levels of soybean, further
studies with longer follow-up andwider assessment of the
outcomes after consuming high-soy diets are needed.
Although the actions of most EDCs will likely involve
alterations in the somatic cell epigenome andwill not pro-
mote a transgenerational phenotype, one can speculate
that some component of adult-onset disease will involve
the actions of EDCs on the germ line to promote trans-
generational inheritance. The suggestion that EDCs can
reprogram the germ line and induce epigenetic transgen-
erational disease is a new paradigm and should be con-
sidered in disease states that have a familial inheritance
that does not follow normal genetic mechanisms (2).
IX. Perspectives in Clinical Epigenetics
Epidemiological evidence provides strong support that en-
vironmental exposures early in development may influ-
ence susceptibility to disease in later life. Furthermore,
some of these environmental effects could rarely be passed
on to subsequent generations. In this review (Section
VIII.C–F), we have described the experimental evidence
FIG. 14. A model for endocrine-disruptor-induced epigenetic transgenerational disease. Endocrine-disruptor action reprograms the epigenome of
the developing germ cell during embryonic sex determination, leading to genes and other DNA sequences with altered DNA methylation. These
changes are proposed to alter the transcriptomes of the testis and other organs, thereby promoting adult pathologies, some of which are inherited
transgenerationally. Epigenetic mechanisms might therefore have a role in the induction of adult-onset disease through environmental exposures
early in development. [Reprinted with permission from R. L. Jirtle and M. K. Skinner: Nat Rev Genet 8:253–262, 2007 (62). © 2007 Macmillan
Publishers Ltd.]
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from animal studies that supports the notion that epige-
netic modifications provide a plausible link between the
environment and alterations in gene expression thatmight
lead to disease phenotypes. Although differences between
humans and other species in regard to epigenomic regu-
lation and, most importantly, imprinting require caution
in extrapolating the findings from one species to another,
there is an increasingbodyof evidence fromanimal studies
that supports a role of environmental epigenetics in dis-
ease susceptibility (62, 167). In this review, we have also
emphasized that the growing fetus has “environmentally
sensitive” periods for building the epigenome. In this sec-
tion,wewill discuss therapeutic targeting of the epigenetic
mechanisms of these sensitive periods and the potential
use of epigenetic biomarkers to identify fetuses at risk for
developing an abnormal physiology or phenotype anddis-
ease at the later adult stage of development.
A. Drug and dietary targeting of epigenetic mechanisms
As discussed in Sections II.B and C, genomic program-
ming is accomplishedbyDNAmethylationand changes to
the chromatin architecture during cellular differentiation,
and critical periods of gestation and early life is a highly
organized process. The resultant epigenetic patterns are
dynamic, and the epigenome is sculpted continuously by
the complex chromatin machineries throughout life in re-
sponse to external cues. In contrast to genetic information,
which is highly stable, epigenetic information is flexible
and therefore potentially reversible. Therefore, if one
couldmodify epigenetic patterns pharmacologically or by
nonpharmacological means, it would be possible to alter
deleterious gene expression programs (440). The idea that
epigenetic states could be prevented or reversed has im-
mensely important implications for the potential of inter-
ventions to override the effects of early-life adversity on
health and behavior.
Selective DNA methylation inhibitors and DNMT1
modulators are available experimentally but are not in
clinical use. However, there are drugs in current clinical
use that influence DNA demethylation. Procainamide is a
widely used antiarrhythmic drug that inhibits DNMT ac-
tivity and promotes DNAhypomethylation. Hydralazine,
a peripheral vasodilator that is used to treat some types of
hypertension, and valproic acid, a widely used antiepilep-
tic and mood stabilizer, are now known to cause DNA
demethylation. Because an effect on DNA methylation is
one of the actions of these drugs, concerns that other drugs
in current clinical use might also affect DNAmethylation
patterns have been raised. Accordingly, it has been sug-
gested that future drug safety tests should now include
measures of DNA demethylation (440, 538).
The DOHaD hypothesis has been much discussed in
this review. Acceptance of this hypothesis has been the
main reason for advocating maternal supplementation
with the dietarymethyl donors and cofactors, such as folic
acid, vitamin B12, betaine, and choline, to optimize DNA
methylation and gene expression (55) (see Sections III.D
and VIII.C). However, it is now known that eating cru-
ciferous vegetables is also associatedwith epigeneticmod-
ifications because naturally occurring HDAC inhibitors
are normal constituents in these foods. For example, di-
allyl disulfide in garlic and SFN in broccoli are class I and
class IIHDAC inhibitors (419, 539).There aremanyother
known or putative diet-derived HDAC inhibitors, such as
butyrate, which is derived from the fermentation of di-
etary fiber and is the primary metabolic fuel for colonic
epithelial cells. Of interest are the results of the study of
Myzak et al. (540), who measured the level of HDAC
inhibition in peripheral blood mononuclear cells in
healthy volunteers after ingestion of a single dose of SFN-
rich broccoli sprouts. Each participant consumed 68 g (1
cup) of broccoli sprouts, and blood was collected over the
next 48 h. They reported that HDAC activity was inhib-
ited as early as 3 h after broccoli sprout intake and re-
turned to normal after 24 h. Therewas strong induction of
histone H3 and H4 acetylation coincident with HDAC
inhibition at 3 and 6 h, and histone hyperacetylation was
evident for at least 48 h. Overall, the level of HDAC in-
hibition and histone hyperacetylation was equal to or
greater than that achieved with the clinically used HDAC
inhibitor, vorinostat. Other dietary constituents can alter
HDAC activity through other mechanisms. For example,
resveratrol, a polyphenol constituent of red wine, can
activate human SIRT1, which is member of the family
of sirtuin proteins that are essential for gene silencing
(541) (see Section II.C). Lastly, the major polyphenol in
green tea, epigallocatechin-3-gallate, has been reported
to inhibit DNMT and reactivate methylation-silenced
genes in human esophageal squamous cell carcinoma
cell lines (542).
To summarize, much research is still required to “con-
nect the dots” between diet, epigenetically altered genes,
child growth and development, and adult disease. With
increasing attentionnowbeingput on the effect of diet and
nutritional supplements on the placental and fetal epig-
enome in pregnancy, we should begin to pay more atten-
tion to the constituents of the maternal diet and their po-
tential effects on these two epigenomes. Optimizing the
nutritional environment towhich an individual is exposed
during development has the potential to improve the
health of the global population. On the assumption that
nutraceuticals (a food or naturally occurring food supple-
ment thought to have a beneficial effect on human health)
and food andbeverage constituents can cross the placental
barrier and/or be secreted unchanged intomilk, the saying
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that “you arewhat you eat” still holds true, but it now has
the following caveat “you are what your mother ate and
did when she was pregnant with or nursing you.”
B. Epigenetic biomarkers
Biomarkers are biometric measurements that provide
information about the biological condition of the subject
that is being tested and provide varied information de-
pending on the category of interest. Accordingly, bio-
markers fall into several categories, and there are now
biomarkers of exposure, biomarkers of susceptibility, and
biomarkers of response (543). The clinical potential of a
biomarker must satisfy three criteria: ease of clinical mea-
surement, provision of new information, and therapeutic
value and utility (544). To these ends, biomarkers have
been used as a screen for the presence of a disease, an
indicator of the disease process and its clinical course, a
measure of disease severity, and a method of confirming
thediagnosis. Biomarkershavealsobeenused todetect the
predisposition to disease, as well as to predict clinical re-
sponses to therapies. The ideal biomarker should have the
following characteristics: 1) highly sensitive; 2) highly spe-
cific; 3) cost effective, rapid, and simple; 4) noninvasive;
and 5) accurate, with a standard reference range (545).
The epigenetic consequences of placental and fetal pro-
gramming create a potential opportunity for the develop-
ment of epigenetic biomarkers for use in child and adult
health and practice. Such epigenetic biomarkers could
be used for early diagnosis of disease, identification of
individuals at high risk of diseases, and the monitoring
of responses to preventive or curative interventions
(546–548).
As shown in Fig. 8, allele-specific CpG methylation is
the most comprehensively studied epigenetic mark and
one of the hallmarks of genomic imprinting. Accordingly,
patterns of DNAmethylation and histonemodification of
imprinted genes that are associatedwith development also
have potential clinical use. Methylation-specific amplifi-
cation (MSA) can identify genes that are differentially
methylated in cancers and novel tumor suppressor and
drug resistance genes (549, 550). Shen et al. (59) recently
advanced this technique by combining MSA with oligo-
based microarray hybridization for rapid methylation
profiling and genome-wide analysis of CpG methylation.
Based on these techniques, Tycko and colleagues (551)
developed a SNP chip-basedmethod for combined genetic
and epigenetic profiling, which they called a methylation-
sensitive SNP array for identifying sequence-dependent
allele-specific DNA methylation. SNP arrays are used for
methylation profiling to produce bar code readouts of the
methylation status at thousands of SNP-tagged loci (552).
Using this method, they surveyed DNA from 12 normal
tissue samples that included peripheral blood leukocytes,
kidney, brain, lung, placenta, and buccal cells at 50 and
250K resolution. Based on their results, they claimed that
the recurrent phenomenon of sequence-dependent allele-
specific methylation (ASM) has practical implications for
mapping and interpreting associations of noncoding SNPs
and haplotypes with human phenotypes.
As noted in Section VIII.D, the epigenetic lability of
imprinted genes underlies placental programming. Tycko
et al. (553) used ASM to develop a method for measuring
DNA methylation patterns in placental tissue. They were
able to distinguish specific patterns of DNA methylation
in the human placenta from other human organs and un-
covered other differences that distinguish normal placen-
tal tissue fromhydatidiformmoles. Theirmethod seems to
be unique because it revealed not only net gains and losses
inDNAmethylationwhen comparing twobiological sam-
ples, but also differences in ASM.
Fetal DNA circulates in maternal plasma, and this dis-
covery has enabled new approaches for noninvasive pre-
natal diagnosis of disease and monitoring using maternal
blood samples (554). Although still in its infancy, the mo-
lecular characterization of plasma nucleic acids for dis-
tinguishing Y-chromosomal DNA sequences from the
background maternal plasma DNA shows great potential
in prenatal diagnosis. Using this approach, Chim et al.
(555) investigated the potential clinical utility of themas-
pin (SERPINB5) tumor suppressor gene, a gene that is
expressed in the placenta, for the noninvasive prenatal
assessment of the developing fetus. They used bisulfite
DNA sequencing to determine the methylation status of
the maspin gene promoter in placental tissues and paired
maternal blood cells from pregnant women. They found
that the maspin gene promoter was hypomethylated in
placental tissues and densely methylated in maternal
blood cells. Using real-time quantitative methylation-spe-
cific PCR, they reported that the unmethylated maspin
sequences that were detected in maternal plasma in all
three trimesters of pregnancy were cleared within 24 h
after delivery. Of particular interest, the maternal plasma
concentration of unmethylated maspin sequences was el-
evated almost 6-fold in preeclampsia, when compared
with non-preeclamptic pregnancies. From these results,
Chim et al. (555) proposed that hypomethylatedmaspin
DNA could be used as a universal marker for fetal DNA
in maternal plasma to diagnose pregnancy-associated
disorders, irrespective of fetal gender and genetic
polymorphisms.
The future clinical utility of epigenetic biomarkers and
techniques, such asmethylation specific amplificationmi-
croarray, in routine clinical practice will require rapid,
quantitative, accurate, and cost-effective techniques and
objective criteria for selection of the suitable genes. An
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additional consideration is the choice of tissue; epigenetic
marks are cell- and tissue-specific, although preliminary
evidence suggests that some conclusions can be drawn
from the results of studies in germ and blood cells. Not-
withstanding the social, ethical, and regulatory aspects on
the use of epigenetic biomarkers for prenatal diagnosis,
there can be little doubt that the introduction of epigenetic
biomarkers will have considerable impact on prenatal di-
agnosis and the management of the developing fetus. The
speed at which these biomarkers will become clinically
useful tools depends on our rate of acquiring knowledge
on the relationship between epigenetic marks and the
linked consequences on placental and environmental pro-
gramming on the fetal phenotype. Until such knowledge is
acquired through research, epigenetic biomarkers are not
yet appropriate for routine clinical use.
X. Future Directions: Identifying the Needs
and Opportunities for Advancing Epigenetic
Research in Child Health
Theend-target of translational research is thepatient,with
the goal to improve medical care. Traditionally, transla-
tional research has followed a one-dimensional sequence
of events: discovery of a new mechanism and a potential
target in an experimental or basic research setting; devel-
opment of a biomarker; validation of its utility in the clin-
ical setting; and its eventual introduction into clinical
practice. Translational epigenetic research in child health
must be seen as a reiterative process that ranges from re-
search in the basic sciences to preclinical research and pe-
diatric clinical research.Wide knowledge gaps still exist in
our current understanding of the epigenetic machinery,
despite the increasing use of numerous experimental sys-
tems. As a result, we still do not knowwhether some of the
epigenetic mechanisms that have been identified thus far
using these experimental systems are operative in humans
and other eutherians. For example, the short ncRNAs of-
ten work in concert with various components of the cell’s
chromatin and DNA methylation machinery to achieve
stable silencing in fission yeast and plants (107) (see Sec-
tion II.B.3.a).
Hereditary, environmental, and stochastic factors de-
termine the accumulation of epigenetic variation over
time, but their relative contribution to the phenotypic out-
come and the extent of stochastic epigenetic reprogram-
ming that is required to alter human phenotypes is not
known because few data are available (see Sections II.E
and V). Although we do not also fully understand the
underlying mechanism of programming and reprogram-
ming, a reasonable hypothesis would be that an inade-
quate set of epigenetic modifiers increases the risk of so-
matic epimutations, or mutations, or both.
If the environment (epigenetic events) can influence
growth and developmental trajectories during preadult
life-history stages and later life outcomes, how do epige-
netic events influence the transition from one life-history
stage to the next, growth, and puberty at the molecular
level? Growth and puberty are regulated by insulin, GH,
the IGFs, and the sex hormones. These hormones drive the
rate of growth and development, but it is unclear what
determines the timing of the different phases of develop-
mental events and the quantity of growth. At the target
tissues for these hormones, we need to first identify the
specific types of epigenetic changes that occur in each tis-
sue, aswell as the precise genetic loci in each tissue that are
affected by these epigenetic changes. The cell type speci-
ficity and tissue specificity of chromatin regulation are
great challenges for future human studies into epigenetic
regulation of gene expression and the role of epigenetics in
disease susceptibility.
Epigenetic mechanisms potentially play an important
role in the DOHaD phenomenon. Environmental influ-
ences during embryonic and early-life development can
permanently alter epigenetic gene regulation, which in
turn can result in imprinting and reprogramming of the
epigenome and influence disease susceptibility in later life.
Themechanisms bywhich cues about nutrient availability
in the uterus andpostnatal environment are transmitted to
the offspring and bywhich different stable phenotypes are
induced are still unknown. The genetic control of the reg-
ulation of placental supply and fetal demand for maternal
nutrients is not fully understood, and many of the detri-
mental events that occur in the fetus could possibly be due
to epigenetic misprogramming.
As stated in Section VIII.F, epigenetic transgenera-
tional disease is a new paradigm in disease etiology that
has not been considered previously. In fact, research into
epigenetic transgenerational disease is nowone of the new
topics that is undertaken to understand the etiology of
disease states that have a familial inheritance but do not
follow normal genetic mechanisms. Epigenetic epidemi-
ology provides a basis for future studies into the relation-
ships between early-life exposures, epigenetic mecha-
nisms, and adult disease, and epigenomics will accelerate
the discovery of human loci atwhich epigenetic regulation
is correlated with early environmental exposures.
Whereas it is generally held that the mouse is neuro-
logically immature at birth, relative to the human, it is
possible that the timing of specific developmental mech-
anisms is conserved from mouse to human (556). Almost
all current epigenetic research is conducted in laboratory
animals or cell systems. Finding the most appropriate
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animalmodels to study the epigeneticmachinery is critical
to advancing our knowledge for child health. For this pur-
pose, inbred mice can be very useful to allow the investi-
gator to control for genetic factors and the environment.
Inbred littermates are a powerful tool to study epigenetics
because theyarehomozygousat everyallele.Anyobserved
phenotypic change in these mice is epigenetic because ge-
netic noise has been eliminated by definition. Therefore, a
litter of inbred mice is similar to a set of MZ twins. By
manipulating the genetics of the mouse in a controlled
environment, gene-environment interactions and trans-
generational epigenetic inheritance can be studied. More-
over, the mice can be used to seek explanations for com-
plex and sporadic disease. In this regard, work from a
number of laboratories suggests that the establishment of
epigenetic states can be influenced by the environment,
and epigenetic states are involved in the developmental
origins of some disease states. Agouti viable yellow mice
are particularly useful because changes in their coat color
can be used to quantify phenotypic variation among in-
bred littermates. For example, alterations in the DNA
methylation levels havenowbeen reported inagouti viable
yellowmice, which were given 10% alcohol before fertil-
ization and during early pregnancy (557). Because specific
loci on the epigenome of these mice are particularly sen-
sitive to nutritional influences, these findings underscore
the role of epigenetic mechanisms in the development of
fetal alcohol syndrome.
Because no other animal has a similar preadult life his-
tory to that of humans, an obvious question iswhether the
findings from any experimental animal can be extrapo-
lated to humans. Many tissues can be sampled in humans
by noninvasive and minimally invasive methods, includ-
ing red blood cells, T cells, sperm, placentae, umbilical
tissue and blood, and fetal cells and/or fetal DNA in the
maternal circulation, foreskin, urine, cord blood, nails,
and hair. Obviously, the lineage of the specimens is highly
important when studying epigenetic mechanisms. For ex-
ample, foreskin derives from endoderm and cord blood
from the mesoderm. Appropriate specimen collection in-
cludes the need for robust protocols for sample prepara-
tion, storage, and retrieval. In addition, accurate pheno-
typing of the donor is crucial to ensure the reliability of the
data from any past, current, or future cohort studies. Fi-
nally, the available options for noninvasive sample col-
lection overcome some, but not all, of the stringent ethical
requirements for conducting experiments in humans.
As described in Section II of this review, the epigenetic
machinery is complex, and our appreciation of its com-
plexity continues to growwith our increasing knowledge.
Future studies are now needed to: 1) establish the contri-
bution of each component to epigenetic variation over
time; 2) determine the molecular mechanism involved in
the possible transmission of epigenetic patterns between
generations; and 3) assess their functional role and the
DNA regions in which they occur. The burgeoning com-
plexity of the epigenetic machinery leads to two issues:
selection of genetic locus to study an epigenetic mecha-
nism, and the validity and interpretation of the resultant
epigenetic mark. Although this review has not discussed
chromatin techniques in detail, readers should be aware of
the development of next-generation sequencing vs. themi-
croarray in epigenetic research for ultimate clinical use in
humans (558).
Focusing specifically on the needs and opportunities in
child health, we need better phenotypic assessments than
those currently available to define study populations and,
in particular, to distinguish between IUGR infants and
other SGA infants. The SGA infant embraces twodifferent
phenotypes: first, a small infantwhohas been a small fetus
throughout pregnancy with a normal fetal growth rate;
and second, an IUGR infant with reduced fetal growth
rate. To distinguish between these two phenotypes, an
accurate classification for identifying each phenotype is
critical for the clinician to: 1) reduce avoidable perinatal
morbidity andmortality; and2)more accurately assess the
risk of developing disease in later life. Although birth
weight and length are easily obtainable, they are inade-
quate indices to fully phenotype SGA and IUGR infants,
even with additional information on ethnicity, sex, and
parental size. Birth weight and length are sometimes
crudely used as indicators of fetal growth and nutrition
but are measures of attained size, rather than measures of
fetal growth rate. Epigenetic biomarkers have the poten-
tial to greatly improve the phenotyping of these subsets of
infants, and this is an example of the need for such a bio-
marker in child health. Animal models will clearly inform
the identification of suitable candidate biomarkers and
selection of the most appropriate animal model of IUGR.
Nijland et al. (559) used a nonhuman primate model of
IUGR to investigate epigeneticmodifications in gluconeo-
genesis in response to fetal malnutrition. They induced
maternal nutrient restriction in pregnant baboons by lim-
iting their caloric intake to 70% of controls’ ad libitum
intake. Although this difference in caloric intake did not
significantly lower fetal weight at 0.9 of gestation, fetuses
from the nutrient-restricted mothers were thinner. In ad-
dition, fetuses from the nutrient-restrictedmothers had an
increase in hepatic phosphoenolpyruvate carboxylase 1 in
both expression and immunoreactive protein and hypom-
ethylation of the promoter in their liver. These data em-
phasize that analysis of fetal weight may not be sufficient
to fully classify IUGR or the fetal response to intrauterine
nutrient deprivation, and more refined measures are
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needed to classify the pathological process of IUGR, such
as morphological asymmetry or genetic profiling assays
(560). Although nonhuman primates were used by Ni-
jland et al. (559), most investigations on the effects of ma-
ternal nutrient restriction on the fetus have been done in
rodents for ethical reasons and cost, amongothers.Choice
of the IUGR model is also crucial when rodents are used
as themodel, as demonstrated by the recent publicationby
Shahkhalili et al. (467),who compared two rodentmodels
of IUGR, maternal food restriction and dexamethasone
exposure, for early postnatal catch-up growth and later
development of glucose intolerance and obesity. Their
finding that prenatal food restriction is a more sensitive
model than the dexamethasone-exposed model to study
the consequences of IUGRshould alsobe considered in the
light of the discussion on placental programming by glu-
cocorticoids, which was covered in Section VIII.D.
Epigenetic information also has the potential to help in
all phases of the developing individual during his/her life
history (Fig. 1). Epigenetic information could be used to
indicate the fetus’ experience of prenatal nutrition and
maternal health. It could also be used to monitor infant
nutrition and the role of supplementary vitamins and di-
etary methyl donors (folic acid), and the quality of bond-
ing and attachment, and possibly help to predict the ef-
fectiveness ofGH treatment or other interventions in SGA
infants who remain short.
The topics that have been discussed and ideas that have
been presented in this review indicate that the epigenetic
program that is established early in life in response to
certain maternal behaviors has the potential to be manip-
ulated or even potentially reversed by social and cognitive
interventions, drugs, anddiet. Epigenetic information that
is collected during childhood could potentially represent a
stable indicator of the child’s psychological and behav-
ioral experiences that include neglect or even abuse and
might provide insights into risks for mental and physical
health. These results are very intriguing because they hint
of the existence of an epigenetic link between nurture and
nature.
Lastly, epigenetic information that is collected during
the transition to juvenility could potentially be used to
inform the prevention of obesity and the metabolic phe-
notype. The focus of many studies in prenatal program-
ming of adult health is restricted to specific narrow win-
dowsof embryonic developmentor, at themost, to a single
life-history stage. As a result, these studies have not con-
sidered the cumulative nature of critical experiences
throughout life history. To incorporate these consider-
ations, careful thought must be given on ways to include
anadditionaldimension,namely the social environment in
which the individual lives and which itself has a genetic
basis. This type of research, as an adjunct to existing ep-
idemiological methods, requires future close collabora-
tion between epigeneticists and clinical scientists.
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